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Pseudomonas aeruginosa is an opportunistic human pathogen responsible for a large 
proportion of drug-resistant, hospital-acquired infections worldwide. These infections are 
notoriously difficult to treat due to P. aeruginosa’s many intrinsic and acquired resistance 
mechanisms. Despite the critical need for new antibiotics against P. aeruginosa, the current pipeline 
is unable to meet the demand for treating these infections. P. aeruginosa can thrive in diverse 
infection scenarios by rewiring its central metabolism, and an example of this is in the lungs of 
cystic fibrosis patients, where this bacterium metabolises fatty acids into acetyl coenzyme A for 
biomass production via the glyoxylate shunt. The glyoxylate shunt is comprised of two enzymes: 
isocitrate lyase and malate synthase G, and allows the synthesis of cellular constituents from C2 
nutrient sources, bypassing the decarboxylation steps of the citric acid cycle when glucose is not 
available. The glyoxylate shunt has potential as a new antibacterial target in P. aeruginosa as there is 
evidence to support that, besides carbon fixation, the glyoxylate shunt is implicated in virulence 
and is essential for establishing pulmonary infections.  
In this dissertation, the glyoxylate shunt was investigated as an antibacterial target in 
Pseudomonas aeruginosa. The biochemical characterisation of malate synthase G resulted in the first 
reported crystal structure solved to 1.6 Å resolution. Computational evaluation of the crystal 
structure revealed two promising binding sites suitable for future in silico drug design, which 
confirmed malate synthase as an apt drug target. Two 2-aminopyridine derivatives were found that 
displayed dual inhibition of the glyoxylate shunt enzyme activities as well as P. aeruginosa growth 
with low micromolar potencies. Insights into the different mechanisms of action on the target 
enzymes were explored using kinetic analysis and isothermal titration calorimetry. Hit to lead 
optimisation experiments of the hit compounds provided awareness of their potential for any 
future development as antibacterial agents. Although the compounds showed promising efficacies, 
in vitro drug metabolism and safety profiles, I also found that they displayed possible "off-target" 
effects and had issues in chemical stability. Together, these data indicate that the compounds 
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1. Introduction  
1.1 Drug-resistant bacterial infections are a global crisis 
 
Hospital-acquired infections (HAIs) are the most frequent adverse events in healthcare 
worldwide.1 More than 720,000 HAIs in the United States and 300,000 HAIs in England are 
reported every year.2,3 HAIs are a risk for vulnerable patient populations including the elderly, the 
immunocompromised, and the chronically ill.4 One of the main risk factors associated with 
obtaining HAIs is being hospitalised longer than two days, while the risk of developing drug-
resistant HAIs is associated with hospitalisations longer than five days.5  
The main culprit behind HAIs is the “ESKAPE” panel of multidrug-resistant bacteria; a 
group of six pathogens that exhibit widespread resistance to clinical antibiotics including; 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter species.6,7 The ESKAPE pathogens already cause serious infections, but 
treating these infections is a growing challenge in the face of multidrug resistance. Four out of the 
six ESKAPE pathogens are Gram-negative bacteria, which represent the greatest unmet clinical 
need in drug-resistant HAIs.8 
An estimated 700,000 deaths are attributed to drug-resistant infections (DRIs) globally 
every year.9,10 In the United States, more than two million cases of DRIs and 23,000 deaths are 
reported each year.11 In Europe, 700,000 DRIs resulting in 33,000 deaths were reported in 2015.12 
Across Asia, the collective occurrence of DRIs is estimated to be more than double that of the 
United States and Europe combined, with particularly alarming rates of multidrug resistance 
developing in countries like India.13 A report commissioned by the UK government predicted that 
by 2050, more people will die from drug-resistant bacterial infections than from cancer, which is 
currently estimated at 10 million per year.14 DRIs not only prolong hospitalisations and increase 
unnecessary deaths, but also escalate the costs of healthcare. It is projected that by 2050, DRIs will 
add an economic burden of $100 trillion to the world’s economy.10  
The discovery of antibiotics in the first half of the 20th century revolutionised modern 
medicine and drastically improved the quality of human life. Antibiotics have increased the average 
person’s life expectancy by 30 years in developed nations and have been essential in supporting 
medical advancements, such as neonatal care, surgical procedures and cancer treatments.15,16 
Despite these successes, antibiotics are among the only types of medicines that lose their 
effectiveness and value over time. As a result, we are now in a time where resistance to every 
antibiotic class used clinically has been observed.17,18 Antibiotics are also different from other types 
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of drugs, unfortunately, in that the negative effects of resistance extend far beyond individual 
patients. 
1.1.1 The rise of antibiotic resistance 
The first antibiotic, penicillin, was discovered serendipitously by Alexander Fleming 90 
years ago.19 Antibiotics usage has intensified since their introduction into society in the early 1940s, 
and a rising trend of resistance has swiftly followed.20 Clinical resistance actually pre-dates 
penicillin, where the first resistance to the antibacterial drugi, Salvarsan (used to treat syphilis before 
penicillin), was reported in 1924.21,22  
It seems as though antibiotic resistance is a modern phenomenon in response to human 
consumption, but this is just one (anthropocentric) interpretation of history. Investigations have 
shown the prevalence of genetic operons encoding the synthesis of antibiotics in bacteria, 
alongside several self-protection measures against said antibiotics, and that these antibiotic-
producing gene clusters are ancient.23–25 This suggests that the capacity for resistance should be as 
old as the capacity for producing antibiotics. Indeed, an analysis of 30,000-year-old DNA from 
permafrost sediments in the Canadian Yukon detected resistance genes to modern antibiotic 
classes, such as β-lactam, tetracycline and vancomycin.26 These findings establish that bacteria have 
attained the tools needed to cultivate, acquire and spread resistance genes long ago without human 
influence.27  
Antibiotic resistance mechanisms, once developed, remain among bacteria even if the 
selective pressure to survive subsides as the antibiotic concentration decreases.28 Instead, resistance 
elements are integrated into the antibiotic resistome, a shared reservoir of resistance that has 
developed over the last 3.5 billion years that is accessible by all bacteria—pathogenic or non-
pathogenic.29,30 Its discovery highlighted the enormous diversity of resistance elements in 
environmental bacteria, and a large fraction of the resistome is believed to be comprised of silent 
and proto-resistant genes, which are present in the genome, but a mutation or mobilisation is 
required to express a resistant phenotype.31–33 While antibiotic resistance is a natural and primordial 
process, human usage of antibiotics over the last century has been artificially imposed on the 
process, accelerating the capture of resistance from the resistome by providing Darwinian selective 
pressures.34 Our antibiotic consumption has been the single largest driver behind the antibiotic 
resistance crisis.11  
                                                 
 
i
The distinction between antibiotic and antibacterial drug refers to the compound’s source. A compound isolated from 
nature is an antibiotic, and a compound discovered by chemical synthesis is an antibacterial agent or drug. However, 




Most antibiotic usage has been deemed improper; i.e. overused or inappropriately used in 
clinical medicine and agricultural practice.35 In the United States, analyses revealed that 22 standard 
doses (e.g. a pill or capsule) were prescribed per person per year, but that this inpatient antibiotic 
usage only represented 39% of the total US antibiotic market.36,37 Data from China show an 
antibiotic prescription rate twice that of the World Health Organization’s recommended rate for 
a middle-income country.38 Antibiotics prescribed by physicians are largely driven by patient 
treatment expectations, coupled with diagnostic uncertainties, and incentives to overprescribe for 
drug reimbursements.39 Improvements in manufacturing over time have also provided less 
expensive drugs that embolden non-prescription and off-label uses.40 It is estimated that non-
prescription use accounts for anywhere from 19-100% of antibiotic use outside of Europe and 
North America, which is aggravated by the lack of regulations.41 Public misconception about 
antibiotics has also led to their overuse. A recent survey revealed that only a slim majority (56%) 
of people in the European Union understand that antibiotics do not kill viruses.42  
Antibiotic underuse is another contributing factor to the crisis, which refers to bacterial 
exposure to sub-lethal concentrations of antibiotics as they are recycled from hospitals, clinics, 
farms, and manufacturing plants into the environment.43 An estimation of 20-80% of antibiotics 
excreted by humans and animals are in their chemically stable and active forms, which contaminate 
environmental reservoirs such as rivers, lakes and soil, where they can remain for months or years 
at sub-therapeutic levels.44  
Inappropriate use is characterised by improper treatment regimens prescribed by clinicians, 
such as the extensive use of broad-spectrum antibiotics as monotherapies. Even more egregious 
is the use of antibiotics for non-curative purposes by the food industry. It has been estimated in 
the United States that in the early 2000s, 11.2 million kilograms of antibiotic doses were given to 
livestock for non-therapeutic purposes, compared with only 900,000 kilograms given for 
therapeutic purposes.45 Examples of non-curative uses include prophylaxis, such as spraying 
antibiotics on fruit and vegetable crops or using antibiotics to promote animal growth.46  
It is clear that how we have used antibiotics historically has resulted in accelerated bacterial 
resistance to all of the current classes in our arsenal.47 The rise and dissemination of antibiotic 
resistance over the past several decades have led to multidrug resistant (MDR), and extensively 
drug-resistant (XDR) strains of bacteria that are responsible for severe infections, especially in 
hospitals. An example is the New Delhi metallo-β-lactamase-containing bacteria (NDM-1), 
identified in India in 2009, that display broad resistance to carbapenems.48 Five years later, NDM-
1 was detected on every habitable continent.49 Moreover, bacterial strains have been isolated from 
hospitals that exhibit pan-drug resistance (PDR) to all antibiotics, such as Mycobacterium tuberculosis, 
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Pseudomonas aeruginosa, and Klebsiella pneumoniae.50–53 The potential for the rapid, global transmission 
of these PDR strains and their extreme resistance profiles warrants close patient monitoring and 
prudent antibiotic administration in hospitals. 
 
 
Figure 1. Timeline of antibiotic innovations. This graph shows the years when all major 
antibiotic classes were discovered, introduced into the clinic, and resistances were first observed. 
All instances of resistance have been seen within ten years of discovery or introduction into the 
market, except the polymyxins, which were used sparingly due to toxicity issues. A dotted black 
line indicates the end of the golden era of antibiotic drug discovery (1960). Data obtained from 
Lewis, 2013.47 
 
1.1.2 Bacterial resistance mechanisms 
Beyond the basic cellular requirements for survival and proliferation, bacteria harbour 
intrinsic genetic determinants of resistance.54 This allows bacteria to escape the detrimental effects 
of certain antibiotics over others. An example is that Gram-negative bacteria are intrinsically less 
permeable to many antibiotics than Gram-positive bacteria, which is due to the presence of the 
lipopolysaccharide outer membrane. The outer membrane encapsulates the periplasm and filters 
out large, hydrophobic molecules.55 An example of intrinsic resistance is to the glycopeptide 
antibiotics, like vancomycin, which cannot pass the outer membrane and are thus not effective 
against most Gram-negative species.56 Intrinsic resistance unquestionably prompts careful 
consideration of appropriate treatments by clinicians and complicates infection outcomes; 
however, the crux of the present resistance crisis is attributed to the continuous development and 
acquisition of resistance mechanisms between all bacteria.57 Resistance is acquired (figure 2A) 
through resistance genes in portable DNA sequences, such as plasmids or transposons, spreading 
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from one bacteria to another through horizontal gene transfer (HGT) in a process known as 
conjugation.58,59 HGT accomplished through bacteriophages is known as transduction.60 
Chromosomal genes can also be transmitted to a bacterium by the uptake of naked DNA released 




Figure 2. Overview of antibacterial targets and resistance mechanisms. A) Resistance to 
antibiotics is acquired through processes including horizontal gene transfers and point mutations 
in chromosomal DNA. B) Primary antibiotic resistance mechanisms include decreasing 
intracellular drug concentration, reducing drug penetration, or by circumventing drug inhibition 
through alterations in the biological target structure, target necessity, or target abundance. C) 
Approved antibiotic classes act upon relatively few bacterial targets, meaning that once resistance 
arises, it affects multiple classes with shared mechanisms of action. Figure created from 
information from Coates, 2002.79 
 
Antibiotic resistance occurs through three general mechanisms, as shown in figure 2B. 
These include altering the structure, abundance or necessity of the drug target,62 lowering the 
intracellular drug concentration,63,64 and decreasing drug entry into the cell.65,66 First, altering the 
target structure can be achieved through single nucleotide polymorphisms, or point mutations, 
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which result in amino acid substitutions that lower the target’s affinity for the drug without 
compromising the target’s function.67 A common clinical example is point mutations in DNA 
gyrase that yield quinolone resistance.68 Increasing a drug target’s abundance from upstream point 
mutations, promoter acquisitions or gene amplification can also render a drug ineffective.69 As a 
last line of defence, bacteria can employ functional homologues in metabolic pathways acquired 
through HGT or de novo genome changes that supersede the original target.70 A notable example 
of this is in methicillin-resistant S. aureus, in which the β-lactam-insensitive protein, PBP2a, enables 
cell wall synthesis to occur as the β-lactam inhibits the native PBP.71 
Second, to lower the intracellular drug concentration, bacteria exploit mechanisms to alter 
or destroy the drug. A classic example is the hydrolysis of β-lactam antibiotics by β-lactamase 
enzymes.72 Aminoglycosides are also susceptible to modification by acetyltransferases, 
phosphotransferases and nucleotidyltransferases in bacteria as they are large molecules with 
exposed hydroxyl and amide groups.73 Another mechanism to lower intracellular drug 
concentrations is to physically remove the drug via efflux pumps that span the cell envelope. Efflux 
pumps extrude hydrophobic cations and amphipathic compounds across the outer membrane that 
are unneeded by the cell.74 Efflux pump expression can be increased in response to environmental 
signals, such as iron limitation, or acquired through mutations in the regulatory network controls 
efflux pump expression.75 
Finally, bacteria rely on the cell envelope to act as a barrier to prevent the drug from 
entering the cell. However, some species further decrease their susceptibilities to antibiotics by 
modifying the cell surface through biofilm production or by reducing the expression of membrane 
porins, which allow for nutrient transport.76 Point mutations in efflux pumps genes can change 
substrate specificities and similarly preclude drug entry.77 Bacteria can also export molecules that 
sequester antibiotics extracellularly.78  
1.1.3 Current antibacterial targets 
Antibiotics and their targets need to meet strict criteria in order to be successful, thus 
delivering a new drug to market is a significant challenge.80 It is estimated that 80% of drugs fail in 
clinical trials during drug development, and the two main reasons for failure are a lack of efficacy 
and toxicity.81,82 A successful antibacterial drug needs to combine efficacy, specificity and 
bioavailability with suitable chemical and pharmaceutical properties for chemical optimisation and 
effective dosing.83 Meanwhile, a good antibacterial target needs to be essential for infection and 
sufficiently different from human orthologues, ideally absent from the human genome entirely, to 
minimise side effects.84  
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Successful antibacterial agents exploit the fundamental differences between prokaryotic 
and eukaryotic cells. The majority of antibacterial drugs that are used today have nonprotein targets 
and prevent or subvert just five essential cellular processes conserved across bacteria.85 Current 
antibiotic classes (figure 2C) are limited to mechanisms as cell wall inhibitors, which target the 
synthesis and cross-linking of peptidoglycan; folate metabolism inhibitors, which target the 
metabolic pathway needed to synthesise nucleobases and DNA; nucleic acid synthesis inhibitors, 
which target the DNA gyrase, topoisomerase and RNA polymerase enzymes involved in DNA 
replication; protein synthesis inhibitors, which target the ribosome to arrest protein translation; 
and membrane inhibitors, which disrupt the integrity and function of the cell membrane.86 
As shown by decades of clinical successes, these antibacterial drugs and their targets make 
excellent use of the physiological differences between human and bacterial cells. There are multiple 
classes at our disposal for each validated drug target; however, it is an unfortunate reality that 
resistance to one antibiotic soon spreads to the whole class, and the more a class of antibiotics is 
used, it seems that resistance is more likely to develop as a result of selective pressure.87  Awareness 
of resistance can lead to more responsible antibiotic stewardship and medical practices, which can 
help to prolong a drug’s therapeutic value, but resistance will eventually defeat all antibiotics. 
Therefore, as long as they are required, we need to prioritise scientific innovation to find novel 
antibacterial agents as old antibiotics are lost to resistance.  
 
1.2 Antibacterial drug discovery in the resistance era 
  
The need for new antibiotics is evident; however, the shortage of unique targets in clinical 
use and the bare research and development (R&D) pipeline threaten our ability to combat 
antibiotic resistance in the future. The World Economic Forum concluded in an annual report on 
global risks of antibiotic-resistant bacteria that, “We live in a bacterial world where we will never 
be able to stay ahead of the mutation curve. A test of our resilience is how far behind the curve 
we allow ourselves to fall.”88 In the past 20 years, only five novel antibiotic classes were launched: 
oxazolidinone (2000), lipopeptide (2003), pleuromutilin (2007), fidaxomicin (2011), and 
diarylquinoline (2012).89 Most of these classes were discovered decades ago and are only being 
revisited out of need. These classes also do not possess activity against Gram-negative bacteria. 
From this, it is clear that industry is struggling to replace antibiotics as they become obsolete.90–94 
The growing deficit of antibacterial R&D stems from economic, regulatory and scientific 
problems that have been exacerbated by antibiotic resistance. Policy changes to incentivise the 
reformation of antibiotic misuse have been enacted by government agencies including the World 
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Health Organisation (WHO), the European Centre for Disease Prevention and Control (ECDC), 
and the Infectious Diseases Society of America (IDSA).95 Public education campaigns, such as the 
UK’s One Health Initiative,  highlight the need for improved antibiotic stewardship, which 
encourages a more cautious approach towards medical and veterinary antibiotic usage.96 The US 
and EU governments have been collectively investing nearly $1 billion to stimulate new 
antibacterial R&D.97,98 However, most of this funding is for early stages of preclinical development, 
leaving gaps in funding for clinical development and the commercialisation of new antibiotics. 
There is also a lack of international coordination across these active initiatives, which could hinder 
future progress.99,100 
Just as government agencies are issuing calls and providing funding for antibiotic 
development to evade a looming public health crisis, significant players in the pharmaceutical 
industry are pulling out of the antibacterial discovery space. As of 2019, there are only four 
multinational pharmaceutical companies with active antibiotic programmes: Merck & Co., Roche, 
GlaxoSmithKline, and Pfizer.101 For industry, the economic incentives are too weak, and returns 
on investment are too low as drug reimbursement is based on the volume of drugs sold, which is 
lower for antibiotics because they are prescribed for short-term use.102 
Additionally, the rigid regulatory hurdles currently in place have stifled antibacterial drug 
discovery. Recruiting the required amount of patients for antibacterial clinical trials is difficult 
sometimes if the antibacterial agent is addressing specific pathogens or emerging resistance.103 
Also, under the current FDA application process, demonstrating a clinical benefit in a reasonable 
timeframe is challenging due to the sporadic nature of antibiotic resistance and the difficulty in 
demonstrating the superiority of a novel agent over an existing, curative antibiotic.104 
1.2.1 Scientific approaches to antibacterial drug discovery  
While economic and regulatory issues are complex factors impinging on the shrunken 
R&D pipeline, they can ultimately be influenced in the long term by the trajectory of quality 
science. The infectious disease community can continue to contribute to antibacterial drug 
discovery by identifying new targets and new drug candidates in innovative ways. Scientists have 
made several advances in understanding microbial physiology in the past few decades, such as 
acquiring knowledge that bacteria form biofilms,105 that pathogens inject effectors into host cells,106 
and the mechanisms underlying horizontal gene transfer.107 However, there are several 
shortcomings in historical approaches towards antibacterial R&D that have resulted in a dearth of 
new antibiotics reaching the market.  
Briefly, the first shortfall is a lack of chemical novelty. Natural product drug discovery, rich 
in chemical diversity, was abandoned as the rate of rediscovery became too high after the golden 
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era of antibacterial drug discovery in the 1960s.108 Fortunately, advancements in synthetic 
chemistry made it possible to study semi-synthetic derivatives of antibiotics, which caused the field 
to focus on a few good antibiotic scaffolds and their targets.109 As established previously, a 
resistance that emerges towards a particular mechanism of action or target will usually extend to 
all the derivatives in the class, and scientists have been focused on improving or modifying the 
same few chemical scaffolds for decades.  
Another more complex shortfall is the use of target-based screening for the past several 
decades to identify new antibacterial hit compounds. Pharmaceutical companies have historically 
responded to the rise in antibiotic resistance by focusing on high-tech discovery approaches 
(genomics and high-throughput screening) on novel genetically-essential, isolated targets to find 
new antibacterial agents.87 Two notable examples of this in industry are analyses on R&D efforts 
by GlaxoSmithKline and AstraZeneca, which both had immense genome platforms in the late 
1990s that ultimately yielded no new tractable leads. The reasons for these failures were credited 
to too many self-imposed restrictions placed on screening, such as rejecting targets with unknown 
function and seeking compounds with broad-spectrum activity. Another reason for these target-
based screening failures was that the hits were biased towards more lipophilic physicochemical 
properties than the hits from whole-cell screens.110,111 
A final shortfall is improper target validation, which results in poor in vivo efficacy of 
antibacterial drug candidates.112 Target validation techniques range from measuring the target’s 
expression levels in disease states to modulating target genes and observing phenotypic endpoints. 
Biological targets that are found to be intractable at later stages in drug development is expensive; 
therefore, a thoroughly performed, multi-validation approach is necessary during early stages of 
drug development to reduce attrition rates.113  
Although some believe that novel and diverse chemistry is the best way forward to tackle 
the discovery void,114 others believe that a parallel strategy is required as well that adjusts traditional 
screening methods to better reflect in vivo infection conditions.113 An example is a study from Pfizer 
that found inhibitors of Gram-negative bacteria by targeting Lipid A biosynthesis. Not only was 
this a novel target, but it was also an opportunity to probe with inhibitors to gain a better 
biochemical understanding of the pathway and unravel its importance in vivo. This included testing 
for the spontaneous generation of resistance to the inhibitors.115  
Other logical strategies include focussing on finding narrow-spectrum antibiotics that act 
against a specific bacterial strain. This has been explored in Mycobacterium tuberculosis, where the 
ability to kill the pathogen (not just inhibit replication) is crucial for treating M. tuberculosis 
infections.116 An encouraging example is a study in which the target, aminotransferase BioA, 
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involved in the biosynthesis of biotin, was identified in M. tuberculosis. Then, three different 
screening approaches were employed; first, BioA was demonstrated as genetically essential and 
vulnerable in vivo and in vitro, and chemical libraries were screened against the enzyme. Second, the 
same libraries were screened in a whole-cell assay with biotin added to the medium to identify 
which hits contained whole-cell activity that was biotin-dependent. Third, an assay was done on a 
BioA-depleted bacterial strain, which allowed for the identification of weaker hits that would have 
been otherwise missed in the wild-type strain.117   
However, it is essential that strain-specific antibiotics are coupled with rapid diagnostics in 
order for this strategy to be successful in hospitals. The current regulatory framework would also 
have to change to allow strain-based clinical trials and approvals. There have been minimal 
improvements in the diagnostics of bacterial infections over the years, which contrasts the progress 
made in other diseases, such as diabetes or cardiovascular disease.118 
There is also a strong case for moving the search for antibiotics to compounds that have 
more than one cellular target.119,120 Some of the most successful antibiotics are broad spectrum and 
hit multiple cellular targets, diminishing the probability of developing resistance. An example is 
ciprofloxacin, a fluoroquinolone that targets DNA gyrase and DNA topoisomerase.94 Another 
example is augmentin, a combination antibiotic of amoxicillin and clavulanic acid, which are β-
lactam and β-lactamase inhibitors, respectively. A more recent example is the S. aureus inhibitor 
kibdelomycin, which targets both gyrase B and topoisomerases IV proteins.121 The justification for 
this approach is that many single gene knockouts in model organisms show no (or small) 
phenotypic effects by themselves. Compounds that hit multiple targets simultaneously can explore 
“synthetic lethal” interactions that further expand the number of available targets in an organism.122 
These are just a few examples of how the scientific paradigm for developing antibiotics is shifting 
in response to unmet needs. One of the multidrug-resistant pathogens where there is a tremendous 
unmet need for new antibacterial agents is Pseudomonas aeruginosa. 
 
1.3 Pseudomonas aeruginosa 
 
Pseudomonas aeruginosa is a Gram-negative, mono-flagellated bacillus of the 
Pseudomonadaceae family and the γ-proteobacteria class. Pseudomonas is derived from a 
combination of the Greek word, ψευδής (pseudes), meaning false, and the Greek word, μονάς (monas), 
meaning a single unit. The word, aeruginosa, is derived from the Latin, verdigris, meaning copper 
rust.123 P. aeruginosa is an obligate aerobe and has been isolated from a wide range of ecological 
niches, including soil and fresh water, and is also an opportunistic pathogen with a variety of plants, 
animals and humans among its target hosts.124  
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P. aeruginosa is unique because it contains one of the largest genomes among bacteria, with 
between 5.5 and 7 million base-pairs and a G-C content of around 65%.125 The vast genome is 
divided between the core genome and the accessory genome. The core genome is conserved 
among P. aeruginosa strains, even among samples obtained from patients,126 while the accessory 
genome varies greatly between clones of the same species and contributes to the overall genetic 
plasticity, which is central to P. aeruginosa evolution. Genes for lipopolysaccharide O antigen, iron-
scavenging pyoverdine, resistance to various antibiotics, and virulence factors have been traced to 
the accessory genome, which provides profound advantages for the survival of this species.127–129 
Generally, P. aeruginosa does not affect healthy individuals but is a notorious opportunistic 
pathogen that colonises and displays pathogenic behaviour in immunocompromised hospital 
patients, accounting for 10% of HAIs in the European Union.130 It is renowned for its metabolic 
versatility and subsequent widespread distribution, which results in potent and persistent infections 
that escalate the need for surgical intervention, increase the overall length and costs of 
hospitalisation stays and can carry an average mortality rate in hospitals of 40-60%.131 P. aeruginosa 
is exceptionally difficult to overcome by chemotherapy due to its ability to develop resistance 
mechanisms to multiple drug classes, often during the course of treatment, and most notably 
during combination antibiotic treatment.131,132 Its aggressive nature and broad adaptability can be 
attributed to its nutritional adaptability and both endogenous and acquired antibiotic resistance 
mechanisms.  
1.3.1 Infection scenarios 
Of the Gram-negative bacteria responsible for HAIs, P. aeruginosa ranks as the second most 
problematic.133 One of the largest patient groups affected by P. aeruginosa’s opportunism is burn 
victims. The skin is the body’s first line of immune defence, and when this barrier is breached 
whilst in hospital, P. aeruginosa can very easily colonise the wounds. Once an infection is detected, 
medical staff must move quickly to prevent the infection from spreading. These acute infections 
are associated with haemorrhaging and lung tissue necrosis as a result of P. aeruginosa producing 
several exotoxins and proteases.134 Despite the high risk of infection in burn victims, lung 
infections are associated with the highest mortality rates, particularly hospital-acquired and 
ventilator-associated pneumonia.135 
Probably the most prominent example of P. aeruginosa opportunism is seen in its ability to 
infect the pulmonary airways of cystic fibrosis (CF) patients. CF is a hereditary disease caused by 
mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator. This 
results in defects in the membrane-associated chloride channels, which are expressed primarily in 
epithelial tissues and serve multiple roles, including the coordination of fluid secretion. In the 
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pulmonary airways, enhanced sodium absorption and impaired chloride transport lead to mucosal 
thickening and inefficient mucociliary clearance.136,137 This situation provides an environment 
depleted in salt, iron and proteins, whilst rich in lipids that is highly conducive to bacterial 
proliferation.138,139 Once bacteria colonise the lungs, several species can thrive, and this leads to a 
diverse microflora in CF patients at what is the start of a chronic infection. Despite this diversity, 
P. aeruginosa eventually dominates due to its superior adaptability and establishes chronic infections 
correlated with declining lung function from scarred tissues and eventual mortality.140  
Although the prognosis of CF patients has greatly improved over the years, life expectancy 
still ranges from 12-40 years old in Europe while the patients are plagued with chronic P. aeruginosa 
infections.141 One way that P. aeruginosa is suited to the unique physiological environment in CF 
airways is through anaerobiosis. As the lungs are colonised with bacteria, free oxygen is consumed, 
and oxygen gradients form within the mucus. Under these microaerobic or aerobic conditions, P. 
aeruginosa employs nitrate and nitrite as alternative electron acceptors to oxygen.142 In cases where 
iron availability is limited, P. aeruginosa secretes a greater number of virulence factors such as 
proteases and elastases and increases its production of alginate, which provides further protection 
from the host immune system and may also confer an advantage in terms of iron utilisation.143,144 
When typical nutrient sources are scarce in the lungs, the conservation of metabolites is essential 
for cell proliferation. P. aeruginosa isolated from CF lungs are often auxotrophic for various amino 
acids and display chemotaxis towards phosphatidylcholine (PC), which is the main component 
(80%) of lung surfactant.145 PC is cleaved by P. aeruginosa lipases and phospholipase C into fatty 
acids, glycerol and phosphorylcholine, which are then transported into the cell by the fatty acids 
transporter (FAT), where they undergo β-oxidation.146  
1.3.2 Intrinsic resistance   
 Unfortunately, P. aeruginosa infections are especially difficult to resolve because of the high 
intrinsic antibiotic resistance of P. aeruginosa. As already discussed, the outer membrane is a feature 
of all Gram-negative bacteria and is highly impermeable to antibiotics. What is unique about P. 
aeruginosa is that its outer membrane has been estimated to have 1-3% of the diffusion rates for 
carbapenems and zwitterionic compounds as the Escherichia coli outer membrane.147 In P. aeruginosa 
laboratory strain PAO1, the completed genome sequence revealed that there are nearly 300 outer 
membrane transport systems known as porins.148 Porins are water-filled channels that are selective 
for hydrophilic, charged compounds and have size limitations (<600 Da) on which molecules can 
pass. These porin proteins form cylindrical openings in the outer membrane with polar amino acid 
side chains lining the inside of the opening. The water molecules interacting with the channel-
lining amino acids have to be removed and replaced temporarily by the drug molecule in order to 
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gain entry.149 There are three major families of porins in P. aeruginosa. The OprF family accounts 
for the majority of nonspecific permeation through the outer membrane. The OprB family allows 
for the diffusion of glucose and other antibiotic-like molecules. The OprD family is part of a larger 
family and is responsible for the uptake of nutrients like cationic amino acids.148 These latter porins 
are narrower and less efficient than the OprF family.150 Loss of OprD through a point mutation 
confers resistance to the β-lactam imipenem.151 
Other intrinsic antibiotic resistance mechanisms in P. aeruginosa include the multidrug 
efflux pumps, belonging to the resistance-nodulation-cell division (RND) superfamily. These 
pumps are composed of an energy-dependent pump in the cytoplasmic membrane (Mex 
component), an outer membrane porin (Opr component), and another Mex component joining 
the three together.152 Four RND systems have been studied in P. aeruginosa: MexAB-OprM, 
MexXY-OprM, MexCD-OprJ and MexEF-OprN.153 Small and hydrophobic or large and 
zwitterionic compounds are often recognised as multidrug efflux pump substrates. Examples 
include MexAB-OprM, which recognises and extrudes β-lactam and quinolone antibiotics, while 
MexXY-OprM extrudes aminoglycosides.154  
 1.3.3 Acquired resistance   
P. aeruginosa has acquired resistance to many antibiotics in the β-lactam and aminoglycoside 
classes through the horizontal transfer of plasmids.155 Other than acquiring resistance mechanisms, 
bacteria can spontaneously mutate. If a random mutation is beneficial for survival, then it will 
remain in that organism’s genome and be passed down to its progeny. The normal mutation rate 
is 10-6 to 10-9 per nucleotide per generation in response to antibiotic selective pressure. P. aeruginosa 
has been observed to develop mutations 100x faster than this normal mutation rate towards 
ciprofloxacin in certain infections, such as in the CF airways.156 Certainly, these extreme 
endogenous and acquired resistance mechanisms combined with the lack of new anti-
Pseudomonal drugs available to the clinical community has driven the WHO to classify P. aeruginosa 
recently as a critical priority pathogen for the development of new antibiotics.9 
1.3.4 Central metabolism 
 The tricarboxylic acid (TCA) cycle, first discovered in bacteria in the 1950s by Krebs, 
Kornberg and Monod, is positioned in the centre of cellular metabolic pathways where the 
biosynthesis of key intermediates are produced.157,158 The main function of the TCA cycle is to 
generate electron carriers that can be used in the final stage of cellular respiration, oxidative 
phosphorylation. Cellular respiration is a metabolic process that occurs in three stages; (1) organic 
fuel molecules, e.g. glucose, fatty acids, and amino acids, are oxidised to yield two-carbon (C2) 
fragments in the form of the acetyl group of acetyl coenzyme A. (2) These C2 groups are fed into 
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the TCA cycle, which enzymatically oxidises them to carbon dioxide (CO2). The energy released 
by this oxidation is conserved in the reduced electron carriers, NADH and FADH2. (3) NADH 
and FADH2 are then oxidised themselves, releasing protons and electrons. The electrons are 
transferred along a chain of electron-carrying molecules to O2, where they are reduced to form 
H2O. During electron transfer, large amounts of energy are released and conserved in the form of 
ATP.159  
The TCA cycle was first discovered in Pseudomonas aeruginosa in 1951.160 The presence of 
oxygen and glucose in the environment allows for the complete oxidation of glucose via cellular 
respiration. In P. aeruginosa, sugars are catabolised mostly by the Entner-Doudoroff pathway (EDP) 
pathway, which cleaves glucose into two molecules of pyruvate in stage 1 of cellular respiration. 
There are two other glucose-catabolising pathways in bacteria: the oxidative pentose phosphate 
pathway and the Embden-Meyerhof Parnas (EMP) pathway. The EMP pathway also yields two 
molecules of pyruvate from one molecule of glucose.161–163 Before entering the TCA cycle, pyruvate 
is converted to acetyl coenzyme A by pyruvate dehydrogenase.  
Once metabolites are fed into the TCA cycle, eight catalytic reactions occur; (1) acetyl 
coenzyme A reacts with oxaloacetate to form citrate and coenzyme A; (2) citrate is restructured 
to form isocitrate; (3) isocitrate is oxidised to form α-ketoglutarate, losing a molecule of CO2 
in the process; (4) α-ketoglutarate is oxidised to form succinyl coenzyme A, losing another 
molecule of CO2 in the process; (5) succinyl coenzyme A is enzymatically converted to 
succinate; (6) succinate is oxidised to form fumarate; (7) fumarate is hydrated to yield malate; 
and finally, (8) malate is oxidised to oxaloacetate. Each completion of the cycle results in the 
regeneration of oxaloacetate and the formation of two CO2 molecules, two ATP molecules, and 
reducing equivalents for electron transport, or stage 3, in cellular respiration.164 
Acetyl coenzyme A plays a pivotal role in central metabolism as the end product of 
glycolysis, fatty acid β-oxidation and amino acid degradation; however, the synthesis of 
gluconeogenic precursors from acetyl coenzyme A alone is not possible. This means that when 
the surrounding environment is depleted of metabolic inputs complementary to acetyl coenzyme 
A like sugars, bacteria are unable to generate biomass. Nonetheless, we have seen from the range 
of environments in which P. aeruginosa can thrive and cause infections, that glucose is not always 
present, yet P. aeruginosa can rewire its central metabolism depending on nutrient availability.165 
The solution to this bacterial problem is a modified TCA cycle. This modification is known 
as the glyoxylate shunt, which is an anaplerotic, or replenishing pathway, which allows for the net 
conversion of acetyl coenzyme A into malate without glucose, see figure 3.166 The glyoxylate shunt 
was first discovered in Pseudomonas KB1 in 1957 by Kornberg and Krebs.167 When P. aeruginosa’s 
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only access to nutrients is limited to carbon-poor sources, such as fatty acids, the bacterium 
employs lipases and transporters in the outer membrane to liberate and transport the fatty acids 
into the cell.168 Once inside the cell, the fatty acids undergo β-oxidation, where they are oxidised 
into molecules of acetyl coenzyme A by acetyl coenzyme A synthetase. Acetyl coenzyme A then 
feeds into the TCA cycle where the first two reactions occur, as described previously. However, 
instead of undergoing oxidative decarboxylation to yield α-ketoglutarate, isocitrate is diverted away 
from the TCA cycle reactions and provided a direct route to malate, thereby circumventing the 





Figure 3. Glyoxylate shunt schematic. The two metabolic reactions catalysed by the glyoxylate 
shunt are shown within the eight catalytic steps of the TCA cycle. The glyoxylate shunt allows the 
bypassing of the CO2-producing reactions of the TCA cycle. This gives a substantial advantage 
when the bacteria grow on limited carbon sources such as acetate.   
 
The glyoxylate shunt is composed of two enzymes: isocitrate lyase (ICL) and malate 
synthase (MS), see figure 3. ICL enzymatically cleaves isocitrate to yield glyoxylate and succinate 
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in a reversible reaction. This reaction is then followed by an irreversible condensation of glyoxylate 
and acetyl coenzyme A yielding the formation of malate and CoA by MS.170–172 The glyoxylate 
shunt is present in a wide range of prokaryotic and lower eukaryotic organisms, and it enables 
these microorganisms to grow on carbon sources with a C2 backbone, such as short-chained fatty 
acids, like acetate or ethanol.169,173  
Isocitrate is the substrate for ICL but is also the substrate for two isocitrate dehydrogenases 
(ICD/IDH) present in P. aeruginosa, which together, mandate carbon flux either through the 
glyoxylate shunt or around the TCA cycle.174 Thus, there is a competition between these enzymes 
for isocitrate. Despite its initial discovery in P. aeruginosa, much of what is understood about the 
regulation of the glyoxylate shunt has been studied in E. coli.175 Carbon flux in E. coli is controlled 
based on isocitrate dehydrogenase kinase/phosphatase (AceK) phosphorylating or 
dephosphorylating ICD in the presence of acetate or glucose, respectively. Phosphorylation 
deactivates ICD, directing isocitrate through the shunt to ICL.176 Because the P. aeruginosa genome 
also encodes a second isocitrate dehydrogenase isoform (IDH), which is not a substrate for AceK-
dependent inhibition, the E. coli model of metabolic regulation of the glyoxylate shunt is probably 
an over-simplification of what is happening in P. aeruginosa.174  
1.3.4.1 Isocitrate lyase  
 Isocitrate lyase (ICL) is responsible for cleaving isocitrate into succinate and glyoxylate as 
the first enzyme of the glyoxylate shunt in what is inferred as a Claisen-type condensation from an 
enolic intermediate.177 ICL has been structurally characterised in one eukaryotic species: Aspergillus 
nidulans (PDB entry 1DQU), and three prokaryotic species: M. tuberculosis (PDB entry 1F61), E. coli 
(PDB entry 1IGW), and more recently in the Welch laboratory, P. aeruginosa (PDB entry 6G1O). 
These studies all concurred that the oligomeric status of ICL is a tetramer.174,178–180 However, the 
amino acid sequences of the enzymes differ. M. tuberculosis ICL (ICLMt) and E. coli ICL (ICLEc) have 
a predicted molecular mass of 48 kDa, while A. nidulans ICL (ICLAn) has a predicted mass of 67 
kDa and P. aeruginosa ICL (ICLPa) has a predicted mass of 59 kDa. These differences in secondary 
sequence manifest in the tertiary and quaternary structures. For example, ICLPa has more than 100 
extra amino acids in its sequence than ICLEc or ICLMt, which results in elongated α-helices and 
extends the contacts between the four protomers in the tetramer.  
The four ICL structures all share a conserved TIM-barrel domain, which contains the active site 
that is also highly conserved between organisms. Acetate has been shown to upregulate ICLPa 
transcription, and carbon flux between the TCA cycle (ICDPa/IDHPa) and the glyoxylate shunt 
(ICLPa) is rheostatically regulated, depending on the concentration of various metabolic 
intermediates present in the cell. This is because ICLPa and ICDPa/IDHPa have similar affinities 
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towards isocitrate. For example, pyruvate was shown reciprocally to inhibit ICLPa and activate 
IDHPa.
174 
1.3.4.2 Malate synthase G 
Malate synthase is responsible for catalysing the final step in the glyoxylate shunt: the 
condensation of glyoxylate and acetyl coenzyme A to yield malate and coenzyme A. All malate 
synthases described in the literature to date are found either as isoform A or isoform G. The 
monomeric malate synthase isoform G (MSG) has been found only in bacteria, whereas the 
oligomeric malate synthase isoform A (MSA) occurs in plants and fungi, as well as some species 
of bacteria.169 Both are represented in pathogenic organisms. For example, MSG occurs in M. 
tuberculosis, and MSA is present in C. albicans.181,182 E. coli is unique because it contains the genes for 
both isoforms: aceB for MSA, where the expression is regulated by the presence of fatty acids; and 
glcB for MSG, where the expression is regulated by the presence of glycolate.183 Although the G 
isoform is predominantly monomeric, one study has suggested that M. tuberculosis MSG acts as 
both a monomer and dimer under physiological conditions and proposed that the dimeric form is 
more stable.184 
X-ray crystal structures have been solved for E. coli MSA (PDB entries: 3CUZ and 3CV1). 
The structure of MSG from four prokaryotic species has been resolved by X-ray crystallography: 
E. coli (PDB entries 1P7T and 1D8C), M. tuberculosis (PDB entries for apo and substrate-bound 
structures include 1N8W, 1N8I, 2GQ3, 5H8P, and 5H8U), Mycobacterium marinum (PDB entry 
6AXE), and Mycobacterium leprae (PDB entry 4EX4). Also, the E. coli MSG structure has been solved 
by NMR (PDB entries 1Y8B and 2JQX). These structural studies of MSG reveal that there are 
four structural domains: an 8α/8β TIM barrel fold centred by an N-terminal helical clasp and an 
α/β domain insertion. Several α-helices comprise the C-terminal domain, which borders the active 
site along with the TIM barrel.181,182,185–188 The structural difference between MSG and MSA is that 
the α/β insertion is missing in MSA.185,187 Pseudomonas aeruginosa MSG (MSPa) has a predicted mass 
of 78 kDa with overall amino acid sequence identities of 56% and 70% to E. coli and M. tuberculosis, 
respectively.187 Since the 8α/8β TIM barrel and helical C-terminus are shared among the malate 




1.4 The glyoxylate shunt as a target for antibacterial 
intervention 
 
Beyond their role in carbon fixation, ICL and MS have been implicated in virulence, 
persistence, and antibiotic resistance in medically relevant organisms. Expression levels of the 
glyoxylate shunt enzymes are upregulated in chronic P. aeruginosa infections of cystic fibrosis 
patients.189 ICLPa has also been linked with the induction of Type III Secretion System (T3SS) 
expression, an important virulence mechanism during infections. Under oxygen-limited 
conditions, a ΔICLPa mutant significantly reduced the expression of the four main structural 
components of the T3SS machinery, PcrV, PopN, ExoS, and ExsD.190  
Additionally, an MSMt deletion mutant resulted in decreased severity of lung lesions in a 
mouse infection model and MS was shown to be essential for the bacteria to resist fatty acid-
associated toxicity.191 An ICLMt deletion mutant has shown an increased susceptibility to clinical 
tuberculosis drugs than WT strain.192 In another study, an ICLMt deletion mutant displayed an 
increased rate of clearance from the lung and a reduced level of tissue damage in a rat pulmonary 
infection model.193 Likewise, a P. aeruginosa double deletion mutant (ΔICL ΔMS) was found to be 
completely avirulent in a mouse pulmonary infection model, and the glyoxylate shunt was 
discovered to be conditionally essential for survival in mammalian systems as there were no 
recoverable colonies from the lung tissue after 48 hours.194 Thus, both ICL and MS are attractive 




1.4.1 Project aims 
In this dissertation, I propose to investigate the glyoxylate shunt as a target for antibacterial 
intervention in Pseudomonas aeruginosa. This proposition is supported by the critical need for new 
antibacterial agents against P. aeruginosa and the looming threat of antibiotic resistance to current 
treatments. Targeting the glyoxylate shunt in P. aeruginosa could potentially be efficacious as the 
shunt is a part of central metabolism and therefore, conditionally important. Also, the glyoxylate 
shunt is essential in many hospital-acquired infection situations that impact large patient 
populations. The glyoxylate shunt as an antibacterial target would also be selective because there 
are no mammalian orthologues of either enzyme known. It could further be potentially broad 
spectrum as the glyoxylate shunt is present in many pathogenic bacteria. Finally, simultaneously 
targeting both enzymes could provide a successful antibacterial agent that theoretically delays the 
development of resistance due to the multi-targeted approach. To investigate this further, I 
pursued the following objectives:  
 
 To biochemically characterise MS from P. aeruginosa by resolving the X-ray crystal 
structure, studying the kinetic properties, and analysing the target enzyme to assess 
its suitability as a drug target. 
 To test small molecules against both purified enzymes of the glyoxylate from P. 
aeruginosa as well as against P. aeruginosa cultures to assess and validate their potential 
as dual inhibitors. 
 To determine the suitability of any hit compounds as lead candidates by evaluating 








2.1 Microbiological procedures 
 
2.1.1 Bacterial strains 
Bacterial strains used in this work (see table 1) were stored at -80°C in growth medium 
containing 25% (v/v) glycerol. Viable bacteria were stored on agar media plates at room 
temperature for up to five days.  
 
Table 1. List of bacterial strains and plasmids used in this study.  









Clinical isolate, isolated from blood 
B. Iglewski 






FDA strain Seattle 1946 
BL21 derivative of E. coli B 
Derivative of E. coli BL21  
Clinical isolate, reference strain for 
antimicrobial susceptibility testing 
Miroux et al.195 
Novagen 
ATCC 25922 
Klebsiella pneumoniae K6 Clinical isolate from urine, produces 
beta-lactamase SHV18 
ATTC 700603 
Acinetobacter baumannii 2208  Type strain isolated from urine ATCC 19606 
Staphylococcus aureus Rosenbach Clinical isolate from a wound (Wichita) ATTC 29213 
Enterococcus faecium 
Orla Jensen 
Quality control strain 
ATTC 35667 
Enterobacter aerogenes  
NCDC 819-56 
Type strain isolated from lung sputum 
ATTC 13048 
Plasmid Description Source 
pGEX-6P-1::glcB 
Vector for inducible expression of N-
terminally glutathione S-transferase-
tagged glcB, CbR 
Roucourt et al.196 
pET19m::aceA 
Vector for inducible expression of N-
terminally His6x -tagged aceA, Cb





2.1.2 Bacterial growth media 
Growth media and constituents are listed in table 2. Media and solutions were sterilised 
either by autoclaving at 121°C for 15 minutes in glass bottles or by filtering with 0.22 µm 
membrane stericups (Millipore).  
 
Table 2. Media and solutions used to grow and assay bacteria.  
Media and solutions Components per litre 
Luria Bertani broth 10 g peptone 
5 g yeast extract 
5 g sodium chloride 
2×TY broth 16 g tryptone 
10 g yeast extract 
5 g sodium chloride 
MHB medium 22 g Mueller Hinton II Broth powder (cation-
adjusted) (Becton Dickinson) 
1x M9 minimal medium 200 mL 5x M9 minimal salts solution (Difco)  
0.2% (w/v) magnesium sulphate 
0.01% (w/v) calcium chloride 
0.5% (w/v) carbon source 
1x MOPS minimal medium 100 mL of 10x MOPS minimal salt solution 
20-60 mM carbon source 
32 µM calcium chloride 
0.29 mM potassium sulphate 
1.32 mM dipotassium phosphate 
8 µM iron(II) chloride 
Solid agar plates Growth media containing 1.5% (w/v) agar 
Solutions Components per litre 
M9 minimal salts, 5x (Difco) 33.9 g disodium phosphate 
15 g monopotassium phosphate 
2.5 g sodium chloride 
5 g ammonium chloride 
MOPS minimal salts, 10x 40 mM MOPS, pH 7.5 
4 mM Tricine, pH 7.5 
0.01 mM iron(II) sulphate 
9.52 mM ammonium chloride 
0.5 µM calcium chloride 
0.52 mM magnesium chloride (hexahydrate) 
50 mM sodium chloride 
1x micronutrients 
Micronutrients, 100x 3 mg ammonium molybdate tetrahydrate 
24 mg boric acid 
7 mg cobalt chloride 
3 mg cupric sulphate 
16 mg manganese chloride 




2.1.3 Bacterial growth on solid media 
Colonies were grown in 10 cm diameter Petri-dishes containing 25 mL of suitable growth 
media (see table 2) and incubated at 37°C overnight. When growing cells from frozen stocks, cells 
were defrosted on the surface of the agar at room temperature. A sterile inoculation loop was used 
to spread the cells across the agar using the streaking method to produce single colonies.  
2.1.4 Bacterial overnight cultures  
A single bacterial colony was inoculated in 10 mL of required growth medium in a 25 mL 
plastic universal tube. The culture was grown at 37°C for approximately 18 hours on a rotating 
wheel. If appropriate, the antibiotic selection was maintained throughout the incubation. Unless 
otherwise stated, experiments were conducted in triplicate using three biological replicates from 
three independent bacterial colonies.  
2.1.5 Antibiotics 
The antibiotics used in this work are listed in table 3. Antibiotics were either solubilised in 
water and stored at 4°C, or were solubilised in a 50% (v/v) ethanol solution and stored at -20°C 
for up to one month. All antibiotics were filter-sterilised before use with 0.22 µm membrane filters 
(Millipore).  
 
Table 3. Antibiotics used in this work. 
Working antibiotic concentrations (µg mL-1) 
Bacteria Carbenicillina Ciprofloxacinb Gentamicinb Linezolidb 
P. aeruginosa 250 1 50 - 
E. coli  50 0.015 10 - 
S. aureus - 0.5 - - 
K. pneumoniae - 0.5 - - 
A. baumannii - 1.2 - - 
E. faecium - 0.5 - 4 
E. aerogenes - 0.04 - - 
Antibiotics were either dissolved in a 50% (v/v) ethanol or b deionised water.  
 
2.1.6 Minimal inhibitory concentrations and growth curves 
Bacterial overnight cultures were inoculated to a starting optical density at 600 nm (OD600 
nm) of 0.05 in the relevant medium. Diluted bacterial suspensions (198 µL) were added in triplicate 
to 96-well, sterile, clear U-bottom plates (Thermo Fisher Scientific). Stock concentrations (100x) 
of test compounds (2 µL) were added to the plates in two-fold dilutions, and the plates were 
covered with gas-permeable adhesive seals (Scientific Laboratory Supplies). Assay controls 
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included 1% DMSO, a positive antibiotic control, and media-only wells as a control for 
background absorbance.  
For minimum inhibitory concentration (MIC) assays and growth curves, plates were 
incubated in a FLUOstar® Omega microplate reader (BMG Labtech) for 18 hours at 37°C with 
200 rpm agitation, and automatic OD600 nm well scans were recorded of individual wells every 60 
minutes. For MIC assays on the ESKAPE pathogens, plates were incubated at 37°C with 500 rpm 
agitation between measurements at OD620 nm at 0, 4, 8 and 24-hour intervals using a Multiskan Go 
plate reader, according to CLSI and EUCAST guidelines.197,198 MICs were determined as the lowest 
concentration in which more than 75% of bacterial growth (calculated from ΔOD600 nm using 
untreated and media wells) was inhibited. MICs were also determined and confirmed by visual 
inspection of wells. 
2.1.7 Minimal bactericidal concentrations and viable cell counts 
After MIC determination in 96-well plates, 100 µL from each well was serially diluted with 
sterile deionised water. The diluted samples (10-1-10-9) were added in 2 µL spots to agar plates of 
corresponding media.199 The lowest concentration that resulted in no viable colonies after 48 hours 
of incubation at 37°C was determined as the minimum bactericidal concentration (MBC).  
 
2.2 Purification of target enzymes 
 
The glyoxylate shunt enzymes from Pseudomonas aeruginosa were overexpressed and purified 
in order to yield sufficient amounts of purified protein for biochemical characterisation and to 
study protein-ligand interactions. Table 4 consists of the protein purification buffers and solutions 
used in this study.  
2.2.1 Overexpression of malate synthase G 
The gene encoding malate synthase G (glcB, PA0482) from P. aeruginosa strain PAO1 was 
overexpressed with a PreScission protease-cleavable, N-terminal Glutathione S-Transferase tag. A 
2 L culture of E. coli strain BL21 containing the plasmid [pGEX-6P-1 (glcB)] in 2×TY medium was 
inoculated with 3 mL of an overnight culture grown in LB medium with carbenicillin (50 µg mL-
1). The culture was grown at 37°C with 250 rpm agitation to an approximate OD600 nm of 0.6. The 
flasks were cooled to 16°C, and isopropyl-β-thiogalactopyranoside (IPTG) was added to a final 
concentration of 0.2 mM to induce overexpression of the cloned glcB open reading frame (ORF). 




Table 4. List of the protein purification buffers used in this study.  
Buffer Components per litre 
10x phosphate buffered saline (PBS) 10 PBS tablets (Dulbecco A) 
Lysis buffer (GST-tagged) 1x PBS 
1 mM DTT 
1 cOmplete Mini EDTA-free protease tablets 
(Roche) 
pH 7.0 
Protein purification buffer (GST-tagged) 50 mM Tris-HCl 
150 mM sodium chloride 
1 mM EDTA 
0.1 mM TCEP 
pH 7.5 
Protein purification buffer (Ni-tagged) 50 mM sodium phosphate 
200 mM sodium chloride  
10% (v/v) glycerol 
10 mM imidazole 
pH 8.0 
Elution buffer (GST-tagged) 50 mM Tris-HCl 
150 mM sodium chloride 
10 mM reduced glutathione 
1 mM DTT 
pH 8.0 
Elution buffer (Ni-tagged) 50 mM sodium phosphate 
200 mM sodium chloride 
10% (v/v) glycerol 
250 mM imidazole 
pH 8.0 
Dialysis buffer 50 mM Tris-HCl 
150 mM sodium chloride 
pH 7.5 
Protein loading dye 50 mM Tris-HCl 
2% (w/v) SDS 
0.1% (w/v) bromophenol blue 
10% (v/v) glycerol 
10 mM DTT 
SDS-PAGE stacking buffer, 5x 60 g Tris-HCl 
0.5% (w/v) SDS 
pH 6.8 
SDS-PAGE resolving buffer, 5x 151 g Tris-HCl 
0.5% (w/v) SDS 
pH 8.8 
SDS-PAGE running buffer, 10x 30 g Tris-HCl 
150 g glycine 






2.2.2 Malate synthase G protein purification 
The E. coli BL21 cells were harvested by centrifugation (3430×g for 30 minutes at 4°C). 
The cell pellets were resuspended in 30-40 mL of ice-cold lysis buffer, see table 4. The bacterial 
suspension was lysed to completion by sonication with continuous cooling on ice (10 pulses of 30 
seconds, 13 A, with 1 minute pauses between pulses). The cellular debris was removed by 
ultracentrifugation (9900×g for 30 minutes at 4 °C), and the clarified supernatant was filtered 
through 0.45 μm membrane filters (Sartorius). Subsequent purification was performed using an 
ÄKTA FPLC system where the filtered sample was loaded immediately onto a 5 mL Glutathione 
Sepharose column (GSTrapFF) pre-equilibrated with lysis buffer, see table 4. The column was 
washed with 10 column volumes of protein purification buffer, and the bound protein was eluted 
with 2 column volumes of elution buffer. 
Meanwhile, 5 mL of slurried Glutathione Sepharose 4B resin (GE Healthcare) was 
equilibrated with protein purification buffer in a 50 mL polypropylene tube. The GST-tagged MS 
fusion protein was added to the Glutathione Sepharose 4B resin along with 100 units of 
PreScission Protease (GE Healthcare). The mixture was then incubated for 48 hours at 4°C with 
gentle mixing to allow the cleavage of the fusion protein from the immobilised GST tag at the 
recognition sequence (LeuGluValLeuPheGln↓GlyPro).  
The Glutathione Sepharose 4B resin was sedimented by centrifugation, and the 
supernatant was loaded directly onto a 16-600 Superdex 200 preparatory grade column (GE 
Healthcare) equilibrated at room temperature with de-gassed purification buffer. The flow rate was 
0.8 mL min−1. The elution profile was monitored with a multi-wavelength UV-vis display (UPC-
900) at 230, 260, and 280 nm, and UV-active fractions were collected in 2 mL vials.  
Fractions containing purified MS (confirmed by SDS-PAGE) were pooled and 
concentrated to 18 mg mL-1 using a Vivaspin with a molecular weight cut-off of 30 kDa (Sartorius). 
This mixture was divided into 100 µL aliquots, snap-frozen in liquid nitrogen, and stored at −80°C. 
Before freezing, I determined the protein concentration by measuring the absorbance at 280 nm 
and calculating the concentration, based on a modified Beer-Lambert law,200 with the molar 
extinction coefficient for MSPa (εcalc = 75,985 M
−1 cm−1) predicted from the amino acid sequence 




) × 𝑴𝑾 × 𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏 𝒇𝒂𝒄𝒕𝒐𝒓   
(1) 
 
 Where c is the molar concentration of the protein; A is the absorbance at 280 nm; ε is the 
molar extinction coefficient of the protein (M-1 cm-1); L is the path length of the cuvette (cm); MW 
is molecular weight of the protein (g mol-1). 
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2.2.3 Preparation of Mg2+-depleted malate synthase G 
After purification, 50 mM EDTA (pH 8.0) was added to a portion of purified MS to 
remove bound metals for fluorescence studies, see section 2.9. MS was then dialysed extensively 
(4 × 1 L) at 4°C in 50 mM Tris-HCl, pH 7.5 containing 100 mM NaCl and 10 mM EDTA. The 
EDTA was then removed from the sample by dialysing at 4°C against  
3 × 1 L of 50 mM Tris-HCl, pH 7.5 containing 100 mM NaCl. The final protein concentration 
was adjusted to 175 μM using equation 1. 
2.2.4 Overexpression of isocitrate lyase 
Isocitrate lyase (ICL, aceA, PA2634) from P. aeruginosa strain PAO1 was overexpressed with 
a TEV protease-cleavable, N-terminal Histidine6x tag kindly provided by Dr Stephen Dolan from 
the Welch laboratory. A 2 L culture of E. coli Rosetta strain containing plasmid [pET19m (aceA)] 
was grown at 37°C in LB medium with 250 rpm agitation to an OD600  nm of 0.5-0.6. The 
temperature was then decreased to 20°C, and IPTG was added to a final concentration of 1 mM 
to induce overexpression of the cloned aceA ORF, and protein expression was continued for a 
further 16 hours at 20°C.  
2.2.5 Isocitrate lyase protein purification 
The E. coli Rosetta cells were harvested by centrifugation (3430×g for 30 minutes at 4°C), 
and the cell pellets were resuspended in 30 mL of ice-cold lysis buffer without DTT. The bacterial 
suspension was lysed to completion by sonication with continuous cooling on ice (10 pulses of 30 
seconds, 13 A, with 1 minute pauses between pulses). The cellular debris was removed by 
ultracentrifugation (9900×g for 30 minutes at 4 °C), and the clarified supernatant was filtered 
through 0.45 μm membrane filters (Sartorius). Subsequent purification was performed using an 
ÄKTA FPLC system. The filtered sample was loaded immediately onto a 5 mL Ni-NTA superflow 
cartridge (Qiagen) pre-equilibrated with protein purification buffer, see table 4. The column was 
washed with 10 column volumes of the purification buffer, and the bound protein was eluted with 
2 column volumes of elution buffer. The eluted protein sample was added with 1 mg of TEV 
protease in dialysis tubing with a 10-12 kDa MWCO (Thermo Fisher), and was dialysed extensively 
(3 × 2 L) at 4°C with gentle stirring for 24 hours to allow for the complete cleavage of the His6 
tag and removal of residual imidazole from the protein sample.  
Meanwhile, 5 mL of slurried Ni-NTA resin (BioRad) was equilibrated with dialysis buffer 
in a 50 mL polypropylene tube. The cleaved protein sample was added to the resin and was 
incubated for 2 hours at 4°C while being gently mixed to allow for the removal of the TEV 
protease and any remaining fusion protein from the sample. UV-active (estimated by A280 nm) 
fractions containing purified ICL (confirmed by SDS-PAGE) were pooled and concentrated to 20 
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mg mL-1 using a Vivaspin with an MWCO of 10 kDa (Sartorius). This mixture was divided into 
100 µL aliquots, snap-frozen in liquid nitrogen, and stored at −80°C. The protein concentration 
was determined by spectrophotometry using the calculated molar extinction coefficient for ICLPa 
(εcalc = 54,820 M
−1 cm−1), predicted by the ExPASy ProtParam tool,201 see equation 1.  
 
2.2.6 SDS-PAGE preparations and staining  
Protein samples (10 µL) were diluted with deionised water and 4x concentrated loading 
dye and denatured by heating at 95°C for 10 minutes. Samples were separated on 12% 
poly(acrylamide) separating gel, prepared as described in table 5. SDS-PAGE gels were run at 10 
V cm-1 for three hours. Gels were incubated overnight in Coomassie stain [1 g/L Coomassie 
Brilliant Blue G (Sigma), 50% (v/v) methanol, 10% (v/v) methanol, 10% (v/v) acetic acid] and 
destained for three hours with Destain I [50% (v/v) methanol, 7% (v/v) acetic acid] and for 
destained a second time for three hours with Destain II [10% (v/v) methanol, 7% (v/v)  acetic 
acid]. Protein samples sizes were determined by comparing migration against a Precision Plus 
Protein Standard (BioRad). 
 
Table 5. Preparations for a 12% SDS-PAGE gel. 
Gel Phase Components per 10 mL 
6% Stacking gel 2 mL 30% Bis-Acrylamide solution (Severn Biotech) 
1 mL 5x stacking buffer 
7 mL dH2O 
50 µL 20% (v/v) SDS 
100 µL 8% (v/v) APS 
5 µL TEMED 
12% Resolving gel 4 mL 30% Bis-Acrylamide solution (Severn Biotech) 
5 mL 5x stacking buffer 
50 µL 20% (v/v) SDS 
100 µL 8% (v/v) APS 
5 µL TEMED 
 
2.3 Data fitting and processing 
 
All data fitting was performed with GraphPad Prism version 7.04 (GraphPad 7 Software, 
Inc., USA). The solid lines are the result of fitting the data to the equations denoted in relevant 
experimental sections. In all graphs, unless otherwise stated, the data points are the mean of 
experimental triplicates, and all error bars correspond to ±1 standard deviation. For all bar graphs, 





2.4 Kinetic measurements of malate synthase G 
 
The enzymatic activity of purified MS was measured using a modified coupled assay in 
which the amount of free thiol (present in the reaction product, coenzyme A) was titrated using 
5,5′-dithio(2-nitrobenzoic acid) (DTNB).203 Reaction mixtures contained 50 mM potassium 
phosphate and 10 mM MgCl2 buffer, pH 7.5 supplemented with 0.2 mM DTNB, acetyl coenzyme 
A, and glyoxylate (as indicated in results). The mixture was equilibrated at 37°C for 1 minute before 
the reaction was initiated by the addition of 1 µL of MS (final concentration, 25 nM). The initial 
linear change in absorbance (ΔAbs.) was recorded at 412 nm using a Biospectrometer (Eppendorf). 
Reaction rates were calculated using the molar extinction coefficient of the assay product  2-nitro-
5-thiobenzoic acid (TNB) (14,150 M−1 cm−1).204 Initial velocity studies were conducted at fixed, 
saturating concentrations of glyoxylate and varying concentrations of acetyl coenzyme A and vice 
versa. The kinetic parameters were calculated from the best-fit nonlinear regression based on the 
Michaelis-Menten equation.205  
𝒗 =  
𝑽𝒎𝒂𝒙 ×  [𝑺]
(𝑲𝑴 + [𝑺])
 
  (2) 
 
Where v is enzymatic reaction velocity, Vmax is the maximum reaction velocity; KM is the 
Michaelis-Menten constant, or the substrate concentration needed to achieve half-maximal 
enzyme velocity; [S] is the substrate concentration. kcat, the turnover that each enzyme site converts 
substrate to product per unit of time, was calculated using the following equation.206 
𝒗 =  
𝑬𝒕  ×  𝒌𝒄𝒂𝒕  × [𝑺]
(𝑲𝑴 + [𝑺])
 
                             (3) 
 
Where v is enzyme velocity; [S] is the substrate concentration; Et is the concentration of 
catalytic sites in the enzyme in the same units as [S] and KM. If the enzyme has multiple subunits, 
the value of Et will be higher than the concentration of the enzyme. 
   
In the case of non-Michaelis-Menten kinetics, or when an allosteric sigmoidal data 












Where v is enzyme velocity; Vmax is the maximum reaction velocity; [S] is the substrate 
concentration; Khalf is the concentration of substrate needed to achieve a half-maximal enzyme 
velocity; h is the Hill slope. When h=1, this equation is identical to the Michaelis-Menten equation. 
When h>1, the curve is sigmoidal due to positive cooperativity.208  
 
2.5 Kinetic measurements of isocitrate lyase 
 
The enzymatic activity of isocitrate lyase (ICL) was measured using a modified coupled 
assay in which the number of exposed ketones (present in the reaction product, glyoxylate) was 
titrated using phenylhydrazine HCl.209 Reaction mixtures contained 30 mM imidazole buffer, pH 
6.8 and 5 mM MgCl2 supplemented with D-L-isocitric acid (as indicated in results), 1 mM EDTA, 
and 4 mM phenylhydrazine. The mixture was equilibrated at 37°C for 1 minute before the reaction 
was initiated by addition of 1 µL of ICL (final concentration, 170 nM). The initial linear rate was 
recorded at A324 nm using a Biospectrometer (Eppendorf). Rates were calculated using the molar 
extinction coefficient of the assay product, glyoxylate-phenylhydrazone (16,800 M−1 cm−1). Kinetic 
parameters were calculated for ICL from the best-fit nonlinear regression using equations 2 and 
3.  
 
2.6 IC50 determinations of enzyme inhibition 
 
Test compounds were assessed for their ability to reduce or impede the enzymatic activities 
of ICL and MS. Test compounds were solvated in DMSO, added to the respective reaction 
mixtures (concentrations indicated in results chapter 4) with a total DMSO concentration of 1%, 
and were allowed to incubate with the enzymes for 5 minutes at 37°C. Reactions were initiated by 
adding the enzyme’s substrate (as indicated in results chapter 4), and the initial linear change in 
absorbance at appropriate wavelengths were measured (detailed previously in the kinetics sections). 
Dose-response curves were generated as normalised percentages of the initial linear reaction rates, 
and the concentrations which yielded 50% inhibition (IC50 values) were calculated from the best-










Where Response, in this context, is the per cent enzyme activity in the presence of inhibitors; 
the denominator of the fraction is the per cent response at the bottom plateau of the sigmoidal 
curve; the numerator of the fraction is the per cent response at the top plateau of the sigmoidal 
curve, or 100; [I] is the concentration of inhibitor added; LogIC50 is the dose when the inhibition is 
halfway between the top and bottom plateaus. Hill slope describes the steepness of the curve and 
has no units.  
 
2.7 Determining the mode of inhibition kinetically 
 
Kinetic assays were conducted on MS and ICL by titrating their respective substrates in 
the presence of fixed concentrations of inhibitors to see how they influenced the rate of enzymatic 
reactions. Concentrations of the inhibitors near to calculated IC50 values were added to reaction 
mixtures with the enzyme present and allowed to incubate for 5 minutes at 37°C. Reactions were 
initiated with pH-adjusted substrate solutions (concentrations specified in results chapter 4). The 
initial linear change in absorbance was measured, and kinetic parameters were calculated using the 
best-fit nonlinear regression. The enzyme activity versus substrate concentration plots were 
















Where v is enzymatic reaction velocity; Vmax is the maximal reaction velocity; KM is the 
Michaelis-Menten constant; [S] is the substrate concentration.  The parameters of the linear 
regressions (x- and y-intercepts and slopes) of the double reciprocal plots were analysed along with 
apparent changes observed in KM, Vmax and kcat values (equations 2 and 3) in the presence and 
absence of inhibitors to determine whether the mode of inhibition was competitive, 
uncompetitive, or displayed any of the three types of mixed inhibition. The inhibition constants 
were calculated differently, depending on the type of inhibition observed. The following equation 
for the best fit nonlinear regression is a modification of equation 2 and was used as a mathematical 













app are defined as apparent values calculated in the presence of 
inhibitors. 
2.7.1 Mixed inhibition  
Mixed inhibition is when the inhibitor can bind to both the enzyme and the enzyme-
substrate complex, but usually has a binding preference for one state over the other.211 There were 
three types of mixed inhibition visually observed from the Lineweaver-Burk plots. 
 In type 1 mixed inhibition, [-I] and [+I] lines intersected between the x- and y-axes 
in the second quadrant of the graph. This type indicates that [I] binds to [E] with 
greater affinity than to [ES]; Thus, Ki < Ki’, KM
app > KM and Vmax
app = Vmax. This 
type mimics competitive inhibition. 
 In type 2 mixed inhibition, [-I] and [+I] lines intersect at the x-axis between the 
second and third quadrants of the graph. This type indicates that [I] binds with 
equal affinity to [E] and [ES]; Thus, Ki= Ki’, KM
app = KM, and Vmax
app < Vmax. This 
type is traditional non-competitive inhibition. 
 In type 3 mixed inhibition, [-I] and [+I] lines intersect below the x-axis in the third 
quadrant of the graph. This type indicates that [I] binds to [ES] with greater affinity 
than to [E]; Thus, Ki > Ki’, KM
app < KM,
 and Vmax
app < Vmax. This type mimics 
uncompetitive inhibition.  
 
Where [-I] and [+I] are the linear regressions without and with inhibitor added, 
respectively; [E] is the free enzyme; [ES] is the enzyme-substrate complex; KM
app and Vmax
app are 
apparent KM and Vmax values calculated in the presence of inhibitors; Ki is the inhibition constant 
with respect to binding to the free enzyme; and Ki’ is the inhibition constant for binding to the 
enzyme-substrate complex. In types 1 and 3 mixed inhibition, both Vmax and KM are altered in the 
presence of an inhibitor.212  Vmax
app is altered by the value of Ki’, which depending on the value, can 
decrease Vmax















 is influenced by the ratio of Ki and Ki’ inhibition constants. If the inhibition constant 
for [E] is larger than the inhibition constant for [ES], then (Ki’ > Ki), KM
app < KM, and [I] has a 
stronger affinity for [E]. If Ki’ < Ki, then KM
app > KM and [I] has a stronger affinity for [ES]. This 
phenomenon is illustrated in the following equation:  
   
𝑲𝑴
𝒂𝒑𝒑 =










Combining the changes to Vmax
app and KM
app in the presence of an inhibitor from equations 
8 and 9 into equation 7 algebraically, a final equation representing all types of mixed inhibition is 
attained: 
 
𝒗 =  
𝑽𝒎𝒂𝒙 × [𝑺]
((𝑲𝑴 × (𝟏 +
[𝑰]
𝑲𝒊






2.7.2 Uncompetitive inhibition 
In some cases, the nonlinear regression best fit an uncompetitive mode of inhibition (see 
results chapter 4), despite being visually declared as mixed inhibition by linear regression analysis. 
Equation 7 can be used to analyse an uncompetitive inhibitor. In typical uncompetitive inhibition, 
the inhibitor exclusively binds to [ES]. As a result, Vmax
app and KM
app are both influenced by Ki’, 























The modifications to Vmax
app and KM
app in the presence of an inhibitor from equations 11 
and 12 can be substituted into equation 7 for a final equation representing uncompetitive 
inhibition: 
𝒗 =  
𝑽𝒎𝒂𝒙 × [𝑺]






2.7.3 Competitive inhibition  
In some cases, the nonlinear regression best fit a competitive mode of inhibition, despite 
being visually declared as mixed inhibition by linear regression analysis. As equation 7 is a 
modified Michaelis-Menten equation (derived from equation 2), it can be used to analyse a 
competitive inhibitor. In competitive inhibition, the inhibitor exclusively binds to [E], and 
inhibition can be overcome when high concentrations of the substrate are added. As a result, 
Vmax
app= Vmax and only KM
app is influenced by Ki, see the following equation: 
𝑲𝑴






In this type of inhibition, KM
app > KM, which reduces the enzyme’s catalytic efficiency. 
Equation 14 can be substituted into equation 7 for a final equation representing competitive 
inhibition: 









From equations 6, 10, 13 and 15, Vmax
app, KM
app, Ki, and Ki’, were all calculated for 
individual concentrations of inhibitor added for both MS and ICL. Ki and Ki’ values common to 
all the concentrations were calculated using GraphPad Prism version 7.04. These calculated 
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constants, along with visual analysis of Lineweaver-Burk plots, were taken into consideration when 
identifying the mode of inhibition of hit compounds.  
 
2.8 Isothermal titration calorimetry 
 
 Isothermal titration calorimetry (ITC) was performed on both MS and ICL to validate the 
hit compounds and to establish the thermodynamics of binding. Protein samples were dialysed (2 
× 1 L) in a D-tube dialyzer (Merck) for three hours in dialysis buffer (25 mM Tris-HCl, 100 mM 
NaCl, and 0.1 mM TCEP). Adjustments to the concentrations were made using the same dialysis 
buffer before sample loading. Samples were degassed and loaded under a vacuum pump. MS (110 
µM) or ICL (202 µM) were titrated into the calorimeter cell containing 11 µM of the hit compound 
using a VP-ITC (Malvern Panalytical) at 25°C with 200 rpm stirring. The syringe and the cell both 
contained a final concentration of 0.1% DMSO.  
The injection parameters for MS were set with a reference power of 15 µcal sec-1, an initial 
injection of 3 µL over 3.6 seconds, and subsequent injections of 10 µL throughout 12 seconds. 
Injections were spaced by 150 seconds with a filter period of two seconds. The injection 
parameters for ICL were set with a reference power of 15 µcal sec-1, an initial injection of 3 µL 
over 3.6 seconds, followed by subsequent injections of 8 µL over 10 seconds. Injections were 
spaced by 170 seconds with a filter period of two seconds. Data were analysed first in NITPIC213 
for baseline calculations and then fit for thermodynamic parameters using the OneSite model in 
Origin 7.0 software. The parameters were analysed using the following equations.214 
 
𝜟𝑮 = 𝜟𝑯 − 𝑻𝜟𝑺 
(16) 
Where ΔG is the total free binding energy. ΔH is the measure of the energy of bonds 
broken and created, known as enthalpy. T is the temperature in Kelvin, and ΔS is the entropic 
term of binding, which is driven by hydrophobic interactions. Favourable or spontaneous 
interactions include a ΔH < 0 and a ΔS > 0. Because of the way the free energy of the system is 
defined, if both the enthalpic and entropic terms favour a reaction, then ΔG < 0. Free binding 
energy can also be defined by: 
 
∆𝑮 = −𝑹𝑻 𝐥𝐧 𝑲𝒂 
(17) 
 In which R is the gas constant; T is the absolute temperature; Ka is the equilibrium 
association constant. Other parameters derived from the ITC binding isotherm include the 
equilibrium dissociation constant, Kd, and the stoichiometry between protein and ligand, n, which 
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indicates how many binding sites are in the protein. In order to confirm the accuracy of n, I used 
the following equation: 
 





 Where n is the value of stoichiometry of the interacting species; st is the stoichiometry and 
indicates the number of binding sites on the protein; AFcell is the active fraction of contents in the 
main cell, denoted as [active cell content]/ [total cell content]; AFsyringe is the active fraction of 
content in the syringe, denoted as [active syringe content]/ [total syringe content]. When 
concentrations of the cell and syringe are 100% accurate and contain 100% active species, n and st 




Fluorescence spectra were recorded on a PerkinElmer LS55 luminescence spectrometer 
using an optical cuvette with a 1 cm path length. Mg2+-depleted MS was added to a buffer 
composed of 50 mM Tris-HCl, pH 7.5 and 100 mM NaCl, giving a final MS concentration of 0.88 
μM. MgCl2, glyoxylate, and acetyl coenzyme A were added to give the final concentrations 
(indicated in results chapter 3). The mixtures were equilibrated at 25°C using a water bath for two 
minutes before measurements were taken. An excitation wavelength of 295 nm was used for 
measuring intrinsic tryptophan fluorescence, and the emission spectra were recorded between 300 
and 400 nm. The excitation and emission slit widths were 2.5 nm each.  
Quenching experiments were performed as described above with the addition of increasing 
the concentrations of neutral quencher, acrylamide. The data presented are the mean of three 




=  (𝟏 + 𝑲𝒔𝒗[𝑸])(𝟏 + 𝑲𝒂[𝑸]) 
(19) 
Where I0 is the intensity or rate of fluorescence without a quencher; I is the intensity or 
rate of fluorescence with a quencher; [Q] is the concentration of quencher added; Ka is the 
association constant; Ksv is the Stern Volmer constant, derived from the slope of the plot of [Q] 
versus I/I0. Mg
2+ titrations were performed as described above, and data were fit to hyperbolic 
binding curves using GraphPad Prism version 7.04. The data presented are the mean of three 





= 𝒏𝑲𝒂 − 𝒓𝑲𝒂 
 (20) 
Where r is the concentration of bound ligand to total available binding sites; [L]free is the 
concentration of unbound ligand; n is the number of binding sites in the protein. Ka is the 
association constant derived from the concentrations of the ligand-protein binding complex per 
the individual concentrations of ligand and protein. 
 
2.10 Protein crystallisation 
 
Crystallisation conditions for purified proteins were screened in high-throughput industry 
screening plates using sitting drop vapour diffusion. A sparse matrix approach was used on both 
MS and ICL in initial crystallisation trials, see table 6. First, 2-drop 96-well industry screening 
plates were thawed, and 200 nL of purified protein and either 200 nL or 100 nL of reservoir 
solution were deposited per drop using a Mosquito crystal liquid handling robot (TTP Labtech).  
 
Table 6. Sparse matrix industry screens used in protein crystallisation. 
Supplier Screening plate Protein screened 
Qiagen AmSO4 Suite MS 
Qiagen Classics Suite MS 
Molecular Dimensions JCSG+  MS & ICL 
Molecular Dimensions MIDAS MS 
Molecular Dimensions PACT premier Suite MS & ICL 
Qiagen PEGS Suite I MS & ICL 
Qiagen PEGS Suite II MS & ICL 
Qiagen PH Clear I MS 
Molecular Dimensions Wizard I & II MS 
Molecular Dimensions Wizard III & IV MS 
Abbreviations: AmSO4, ammonium sulphate; JCSG, Joint Centre for Structural Genomics; ICL, 
isocitrate lyase; MS, malate synthase G; PACT, pH-, anion- and cation-testing; PEGS, polyethylene 
glycol. 
 
Crystallisation optimisations were performed using fine-grid matrices, which were created 
by designing concentration gradients of the precipitating agents in the original crystallisation 
condition. Stock solutions of precipitants and salts were prepared using high-purity chemicals 
(Sigma) and water produced by a Milli-Q system (Millipore) and were then syringe-filtered through 
0.22 µm filters (BioRad). These solutions were deposited into the wells (80 µL) of Polystyrene 
MRC 2-drop 96-well plates (Molecular Dimensions) using a Dragonfly crystal liquid handler (TTP 
Labtech). Then, the protein samples were deposited by Mosquito, as mentioned above. All plates 
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were carefully sealed using clear packing tape and a roller and were placed into a Rock Imager 1000 
automated imaging and hotel system (Formulatrix) to equilibrate at 19°C. Images were checked 
daily using the protein crystallisation software Rock Maker Web (Formulatrix). Plates were 
discarded after three weeks if no crystals were observed.  
For drops which contained good quality single crystals with the largest dimension of >100 
µm in length, the sealed tape over the drop of interest was opened using a scalpel and removed 
using tweezers. The crystals in the drop were quickly treated with 0.5 µL of a cryoprotectant 
solution [24% (v/v) ethylene glycol and 76% (v/v) mother liquor], gingerly mounted in nylon 
loops of the corresponding crystal size to minimise the formation of ice crystals and thermal 
damage to the crystals, and flash-frozen in liquid nitrogen prior to data collection.  
2.10.1 Crystallisation of native malate synthase G 
A sparse matrix screening approach was used on native MS, and the best crystals were 
obtained after 3-6 days with a 1:1 mixture of ≥11 mg mL-1 purified protein and reservoir solution. 
The optimised condition (JCSG+ screen, well D9) contained concentration gradients of 0−25 mM 
ammonium sulphate, 13−17% (v/v) glycerol, and 20−27% (w/ v) PEG 4000 that resulted in 
several single crystals suitable for harvesting.  
2.10.2 Soaking malate synthase G 
Soaking experiments were undertaken on MS crystallised as detailed in the previous 
section. A stock concentration of hit compounds in DMSO was diluted in the cryoprotectant 
solution, and 0.5 µL of this mixture was added directly to the drop, giving a final concentration of 
1 mM SB002 in 6.25% DMSO. Depending on the soaking times, drops were quickly sealed to 
prevent crystal dehydration, or crystals were mounted directly into nylon loops.  
2.10.3 Co-crystallisation of malate synthase G and SB002 
Co-crystallisation was first attempted with the optimised native MS condition detailed 
previously. Additional sparse matrix screens were attempted with industry plates using sitting drop 
vapour diffusion with 75 µM or 146 µM purified protein. MS was pre-incubated for ≥60 minutes 
on ice with different concentrations of SB002 and other additives like MgCl2 or glyoxylate. The 
mixture was then centrifuged at 11,363×g for 5 minutes at 4°C to sediment possible protein 
aggregates or ligand precipitation before setting up the crystallisation plates. Images of drops were 
monitored daily for signs of precipitation, crystalline nucleation or crystal growth.  
2.10.4 Co-crystallisation of isocitrate lyase and SB002  
A sparse matrix screening approach was attempted using sitting drop vapour diffusion 
with 340 µM or 170 µM of purified ICL. The protein was incubated with different concentrations 
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of SB002 as well as product glyoxylate for ≥60 minutes on ice and then centrifuged at 11,363×g 
for 5 minutes at 4°C to sediment possible protein aggregates or ligand precipitation. The 
crystallisation mixture from the reservoir (200 nL) was added to the 200 nL of protein in the drop 
in the crystallisation plates. Images of drops were monitored daily for signs of nucleation, 
precipitant, crystals and crystalline growth.  
 
2.11 X-ray diffraction, structure determination, and 
refinement 
 
All diffraction data were collected remotely on the MX-I03, I04, and I04-1, beamlines at 
the Diamond Light Source Synchrotron (DLS, Didcot, UK) equipped with multi-axis goniometers 
and P3-6M, Eiger2 × 16M, and P6M-F detectors, respectively. Diffraction data were processed 
using Xia3 DIALS,217 and data statistics were examined for quality. Structures were determined by 
molecular replacement using CCP4’s Phaser.218 I used an apo MS structure from Mycobacterium 
tuberculosis (PDB entry 1N8I) as a model for phasing native Pseudomonas aeruginosa MS, and then 
later I used my model (PDB entry 5AOS) of native MS as a template for molecular replacement 
with MS-ligand complexes. I used the apo ICL structure from Pseudomonas aeruginosa (PDB entry 
6G1O) as a template for co-crystallised ICL.174 Automated refinement was performed using 
PHENIX.refine or CCP4’s Refmac.219 Iterative runs of manual modelling and refinement were 
performed in COOT.220  
 
2.12 Computational analysis of malate synthase G 
 
All computational analyses of the native MS crystal structure were completed by Prashanthi 
Medarametla, an early stage researcher in the Marie Skłodowska Curie Actions project consortium, 
from the University of Eastern Finland in Kuopio, Finland. The Schrödinger suite (Schrödinger 
LLC, New York, NY) was used for all computations. Protein Preparation Wizard with default 
parameters was used to prepare the MS structure for downstream in silico analyses.221 
2.12.1 Analysis of potential drug binding sites 
SiteMap was used to predict putative binding pockets in MS. SiteMap’s algorithm predicts 
binding pockets in proteins based on the geometry, size, volume, and the 
hydrophilicity/hydrophobicity character of amino acid residues.222 SiteMap predicts druggable 
pockets and ranks them using two parameters: the SiteScore and the druggability, or “Dscore.” 
SiteScores reveal the highly promising binding sites in the protein that can potentially be targeted 
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with drug-like molecules, and the Dscores indicate the druggability of the predicted site. SiteMap 
was run using a fine grid option with a more restrictive definition of hydrophobicity to exclude 
solvent-exposed regions during binding site prediction. 
2.12.2 Analysis of hydration sites 
The solvation network available to a protein plays an essential role in the protein to ligand 
binding affinity. It is useful to understand the effects of the solvation network when designing or 
conducting virtual screens of potential inhibitors. Theoretical hydration sites and associated 
thermodynamic properties were predicted using the WaterMap module.223 WaterMap predicts 
probable hydration sites and their properties in user-defined regions based on molecular dynamics. 
WaterMap was run using default parameters to understand the druggability of MS through its 
solvation network. 
 
2.13 Mammalian cell lines 
 
Mammalian cell lines used in this work were obtained from the American Type Culture 
Collection (ATTC) and are displayed in table 7. Cell lines were stored in liquid nitrogen in cryovials 
containing growth medium and 5% (v/v) DMSO. Cell lines were subcultured from frozen stocks 
and passaged for 2-3 weeks prior to performing cytotoxicity assays. All media was stored at 4°C 
for no longer than three weeks.  
 
Table 7. List of mammalian cell lines used in this work. 
Cell line Description  Source 
A-375 
Homo sapiens skin epithelia; malignant 
melanoma cells 
ATTC CRL-1619 
A549 Homo sapiens lung epithelia; carcinoma cells ATCC CCL-185 
BALB/c 3T3 
Clone A31 
Mus musculus, embryo fibroblast; normal cells ATTC CCL-163 
Hs27 Homo sapiens foreskin fibroblast; normal cells ATTC CRL-1634 
U937 




Five mammalian cell lines were used to assess cytotoxicity. A-375 was selected because it 
is robust.224 Hs27 was selected as a representative for normal human cells. BALB/c 3T3 Clone 
A31 (BALB/c) mouse cells were selected as a representation of the potential viability of future in 
vivo work. A549 was selected as a representative of the prospective clinical applications of this work 




2.14 Mammalian cell culture maintenance  
 
All mammalian cells were grown from frozen stocks by quickly thawing in a 37°C water 
bath, and then transferring into a 15 mL centrifugation tube (Falcon) containing 10 mL of pre-
warmed growth medium. The cells were centrifuged at 125×g for 7 minutes. The supernatant was 
discarded, cells were resuspended with 1 mL of pre-warmed medium and then were transferred 
into 25 cm2 culture flasks (Greiner) containing 5 mL of pre-warmed media. The flasks were kept 
in an incubator (Thermo Fisher Scientific) at 37°C, 5% CO2, 95% humidity. 
 
Table 8. Media used in mammalian cell culturing and cytotoxicity assays. 
Media Components per litre 
Growth medium for A-375, A549, and 
Hs27 cells 
900 mL Glutamax DMEM, high glucose 
(Gibco) 
100 mL FBS (Gibco) 
Growth medium for BALB/c 3T3 Clone 
A31 cells 
900 mL Glutamax DMEM, high glucose 
(Gibco) 
50 mL NBCS (Gibco) 
50 mL FBS (Gibco) 
Growth medium for U937 cells 980 mL RPMI1640 (2 mM Glutamine) (Sigma) 
20 mL FBS, heat inactivated (Sigma) 
10 mL of 10,000 units penicillin and 10 mg 
streptomycin mL-1 
Assay medium for A-375 and Hs27 cells 950 mL Glutamax DMEM, high glucose 
(Gibco) 
50 mL FBS (Gibco) 
Assay medium for A549 cells 900 mL DMEM, phenol red-free (Thermo 
Fisher) 
100 mL FBS, heat-inactivated (Sigma) 
Assay medium for BALB/c 3T3 Clone A31 
cells 
950 mL Glutamax DMEM, high glucose 
(Gibco) 
25 mL NBCS (Gibco) 
25 mL FBS (Gibco) 
Assay medium for U937 cells 980 mL RPMI-1640, phenol red-free (Sigma) 
20 mL FBS, heat inactivated (Sigma) 
 
2.14.1 Subculturing adherent cell lines 
Before subculturing, the flasks were viewed under a light microscope (100x magnification) 
to assess the degree of confluence and to confirm the absence of microbial or other cell line 
contaminants. When the cells were 70-90% confluent, the old medium was discarded by suction 
with a vacuum pump, and the cell monolayer was washed with 10 mL of sterile 1x PBS. 1x TrypLE 
trypsin with no phenol red (Gibco) (1 mL) was added to the washed monolayer, and the flask was 
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manually tilted to ensure the monolayer was covered with trypsin. The flask was incubated for 5 
minutes at 25°C until the cells were visibly detached under the microscope from the bottom of 
the flask.  
Growth medium pre-warmed at 37°C in a water bath was added (10 mL), and any clumps 
of cells were dispersed by gently pipetting. The cells were transferred to a 15 mL centrifugation 
tube (Falcon) and centrifuged at 125×g for 7 minutes. The supernatant was discarded, and the cells 
were rewashed with pre-warmed media before being transferred into a 75 cm2 cell culture flask 
(Greiner) containing 20 mL of pre-warmed medium. The culture to fresh media ratios were 1:8, 
1:4, 1:10, and 1:8 for A-375, Hs27, A549, and BALB/c 3T3 Clone 31A, respectively. The cell lines 
were subcultured every 2-4 days, depending on the degree of confluency, or the number of 
adherent cells in the flask.  
2.14.2 Subculturing suspension cell lines 
Before subculturing U937 culture, the flasks were viewed under a light microscope (100x 
magnification) to visualise the number of live cells and confirm the absence of microbial or other 
cell line contaminants. A 1:1 mixture of 10 µL of the cell suspension and 10 µL of Trypan blue 
solution (Sigma) was placed into the chamber of a single use haemocytometer. Cells were counted 
in each of the counting grids (0.10 µL) in the four corners of the haemocytometer under a 
microscope at 100x magnification. Cells were considered dead if they were dyed blue by the Trypan 
solution.224 The number of cells per µL was calculated as:  
 
𝒄𝒆𝒍𝒍𝒔 µ𝑳−𝟏 =
𝑺𝒖𝒎 𝒐𝒇 𝟒 𝒔𝒒𝒖𝒂𝒓𝒆𝒔
𝟒
 × 𝟐 × 𝟏𝟎 
(21) 
Where the average of cells counted is obtained and then multiplied by two because of the 
dilution with Trypan blue and then multiplied by a factor of 10 to obtain units in µL. The 
suspension culture was diluted by 20 mL of fresh, pre-warmed growth medium. Typically, a 1:40 
dilution was suitable for a weekly subculture, and a 1:4 dilution was suitable for use in an assay 
later in the week.  
 
2.15 Determining cytotoxicity using luminescence 
 
The CellTiter-Glo® Luminescent Cell Viability Assay (Promega; Lot# 0000200446) was 
performed as a homogeneous method of determining the number of viable cells in a culture based 
on quantifying the amount of ATP present, which signals the presence of metabolically active cells. 
The A-375, Hs27, and BALB/c 3T3 Clone A31 cells lines were used to assess the cytotoxicity of 
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hit compounds using a luminescence-based assay. The measurement of ATP present is based on 
the luciferase reaction.  
 
 
Figure 4. The luciferase reaction. The oxygenation of Beetle luciferin is catalysed by luciferase 
in the presence of magnesium, ATP, and molecular oxygen to form oxyluciferin, carbon dioxide, 
AMP, and light.  
 
2.15.1 Seeding into microtitre plates 
Cells were harvested from 75 cm2 culture flasks according to the adherent cell subculturing 
protocol detailed in section 2.14.1 and were counted before they were seeded into sterile, white-
framed 96-well plates with clear bottomed wells (PerkinElmer). Briefly, a mixture of 50 µL of 
sample cells and 50 µL of Trypan blue was prepared in an Eppendorf tube. 10 µL of the sample 
was placed into each of the two chambers of a single-use haemocytometer, and the number of live 
cells was determined with Countless II automated cell counter (Thermo Fisher Scientific).  
After counting, the cells were diluted with fresh growth medium to the appropriate density 
for each cell line. A-375 cells were seeded at a density of 10,000 cells well-1, and Hs27 and BALB/c 
3T3 Clone A31 were added at a density of 7,500 cells well-1 in 100 µL of growth media per well. 
The last column in the microplate was filled with growth medium instead of cells as a control. Cell 
culture plates were incubated for 20-24 hours at 37°C, 5% CO2, 95% humidity. Plates were 
checked before performing the assay for a consistent, confluent monolayer in the wells.  
2.15.2 Luminescence-based cell viability assay 
The growth medium was removed from the assay plates by turning the plate upside down 
and firmly tapping the plate into a waste reservoir. Cells were washed with assay medium twice 
before 200x stock solutions of test compounds and controls (diluted in assay medium) were added 
in triplicate to the assay plate. Controls included 0.5% DMSO and positive controls; e.g. 
Camptothecin for A-375 and Hs27, and Polymyxin B for BALB/c 3T3 Clone A31. Camptothecin 
induces apoptosis by inhibiting DNA topoisomerase I and preventing DNA re-ligation.208 
Polymyxin B is a polycationic antibiotic which interacts with lipopolysaccharide, an anionic 
molecule, in cell membranes, which results in membrane permeability and cell leakage.225 Plates 
were incubated at 37°C, 5% CO2, 95% humidity for 48 hours.  
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The CellTiter-Glo® substrate (Promega) was thawed and added to the CellTiter-Glo® 
reagent (Promega). Cells were washed with 100 µL of 1x PBS twice. Both 50 µL of assay media 
and 50 µL of the CellTiter-Glo® mixture were added into each well. The contents were mixed for 
two minutes on a plate shaker at 25°C, and then the plate was incubated for 10 minutes at 25°C 
to stabilise the luminescent signal. Air bubbles in the wells were popped using a sterile needle to 
prevent interference with the absorbance signal. The luminescence was measured using a 
VarioSkan LUX multimode microplate reader (Thermo Fisher Scientific), and the percentage of 
cytotoxicity of each sample was calculated relative to controls.  
 
2.16 Determining cytotoxicity using colourimetry 
 
The CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega) is a colourimetric-
based cytotoxicity assay that was used to determine the total number of cells affected by necrosis 
after exposure to test compounds. Cell lines A549 and U937 were assessed for cytotoxicity using 
the colourimetric assay. Lactate dehydrogenase (LDH) is a stable cytosolic enzyme that is released 
upon cell lysis. Released LDH in culture supernatants was measured with a coupled enzymatic 
assay, which results in the conversion of a tetrazolium salt into a red formazan product that can 
be detected at 492 nm, see figure 5. 
 
 
Figure 5. The LDH reaction. The release of lactate dehydrogenase (LDH) from damaged cells 
is proportional to the quantity of red formazan measured at absorbance 412 nm. Formazan is 
created by supplying lactate, NAD+ and INT dye as substrates in the presence of lactate 
dehydrogenase and diaphorase. 
 
2.16.1 Preparation of an A549 cell monolayer 
A549 cells were detached from a culture flask according to the adherent cell subculturing 
protocol, as outlined in section 2.14.1. A sample of the cell suspension was mixed with 4% Trypan 
blue solution (1:1 ratio) and counted via a haemocytometer under the microscope at 100x 
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magnification. The cell suspension was diluted to 5 × 105 cells mL-1 with fresh, pre-warmed growth 
medium, and 100 µL of the cell suspension was dispensed into each well of a clear, 96-well flat-
bottomed sterile plate (Thermo Fisher) to yield 50,000 cells well-1. The plates were incubated at 
37°C, 5% CO2 overnight.  
2.16.2 Preparation of a U937 cell suspension 
A sample of U937 cells was counted via a haemocytometer as described above, and the 
entire contents of the flask were collected by centrifugation at 425×g for two minutes. The 
supernatant was discarded, and cells were resuspended with 5 mL of assay medium and washed 
twice more. The cells were then resuspended in assay medium to produce a cell suspension with a 
density of 5 × 105 cells mL-1.  
2.16.3 Lactate dehydrogenase measurement 
For A549 cells, the growth medium was removed from the assay plate before adding test 
compounds by turning the plate upside down and firmly tapping it over a waste reservoir. The 
cells in the assay plate were washed twice with assay medium, and a final volume of 99.5 µL of 
assay medium was added to each well of the assay plate. For U937 cells, 99.5 µL of the prepared 
cell suspension was added to the wells of a clear, 96-well sterile U-bottomed plate (Greiner). Then, 
0.5 µL of 200x stock solutions of test compounds and controls were added in triplicate to both of 
the assay plates. Controls included 0.5% DMSO, cells reserved for total lysis, and a media-only 
background. The plates were shaken for 1 minute at 100 rpm on a plate shaker and were then 
incubated for 4 hours at 37°C and 5% CO2.  
After 3.5 hours of incubation, CytoTox 96® 10x lysis solution was added to the wells 
reserved as lysis controls, which represented maximum LDH release, and the plates were left to 
incubate at 37°C for another 30 minutes. After, 50 µL of supernatant from each assay plate was 
transferred to a clear, 96-well sterile flat-bottomed plate (Thermo Fisher). Pre-thawed 
CytoTox 96® buffer (Promega) was added to the CytoTox 96® substrate (Promega), and 50 µL 
of this CytoTox 96® mixture was added into each well. The plates were incubated for 10 minutes 
in darkness at 25°C to allow the enzyme reaction to occur. CytoTox 96® stop buffer (50 µL) was 
added to stop the enzymatic reaction, and the plates were left to incubate for another 15 minutes 
at 25°C. Any air bubbles were popped using a sterile needle. The absorbance was measured at 492 
nm using a CLARIOstar® multimode microplate reader (BMG Labtech), and the percentage of 
cytotoxicity of each sample was calculated from the fully lysed cells as:  
 
% 𝑪𝒚𝒕𝒐𝒕𝒐𝒙𝒊𝒄𝒊𝒕𝒚 = 𝟏𝟎𝟎 × 
𝑬𝒙𝒑𝒆𝒓𝒊𝒎𝒆𝒏𝒕𝒂𝒍 𝑳𝑫𝑯 𝒓𝒆𝒍𝒆𝒂𝒔𝒆 (𝑶𝑫𝟒𝟗𝟐 𝐧𝐦)





2.17 Determining CYP450 activity in liver microsomes 
 
The metabolic stability of hit compounds was performed at Aptuit (Verona, Italy) using 
liver microsomes from humans and preclinical species, and evaluation of intrinsic clearance was 
completed using liquid chromatography-tandem mass spectrometry. Verapamil (metabolised by 
cytochrome P450 3A4) and dextromethorphan (metabolised by cytochrome P450 2D6) were used 
as positive controls and guaranteed the appropriate test system performance during the 
experiments. Acceptance clearance criteria for verapamil and dextromethorphan, based on 
Aptuit’s historical data, was ≥100 and ≥10 µL minute-1 mg-1 of microsomal proteins, respectively. 
All compounds were dissolved in methanol to obtain 10 mM stocks. 
 
Table 9. Commercially available liver microsomes used in this study. 
Organism Description Source 
Human Mixed gender, 50-donor, 20 mg mL-1 BioreclamationIVT (Lot# IHG) 
Rat Male Sprague-Dawley, 20 mg mL-1 BD Gentest (Lot# 60614) 
Mouse Male CD-1, 20 mg mL-1 Xenotech (Lot# 1610148) 
 
2.17.1 Preparing microsomal incubations 
An automated incubation procedure was performed using the RSP Freedom Evo liquid 
dispensing and incubation system (TECAN). Five microlitres of 50 µM test compounds or positive 
controls were added to 445 µL of microsomal solution (comprised of pooled and homogenised 
liver microsomes at 0.56 mg mL-1 in 50 mM potassium phosphate, pH 7.4)  in 96 deep well 1 mL 
plates and incubated at 37°C for 5 minutes.  
The enzymatic reactions were initiated by adding 50 µL of pre-warmed NADPH 
regenerating buffer (prepared by adding 1.7 mg of NADP, 7.8 mg of Glucose-6-phosphate, and 6 
units of Glucose-6-phosphate dehydrogenase per mL of 2% sodium bicarbonate solution) per 
well. Reaction plates were incubated at 37°C, and 50 µL aliquots were taken from the plates and 
dispensed into quenching plates at 0, 3, 10, 15, 30 and 45-minute intervals to precipitate protein 
and quench the reactions.  
Quenching plates were prepared in advance by dispensing 150 µL of acetonitrile into each 
well of 96-deep well 1 mL plates. Quenching plates were centrifuged at 825×g for 10 minutes, and 
100 µL of the supernatant was added to a plate with 200 µL of internal standard (100 ng mL-1 
Rolipram in water), which was optimal for LC-MS/MS analysis. All the incubations were carried 
out in duplicate. 
 
2.17.2 LC-MS/MS analysis  
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 Dr Mahmud Kajbaf from Aptuit performed the tandem mass spectrometry tuning method 
to create methods for the hit compounds’ analyses. Tuning included establishing selected ion 
monitoring transitions that were specific to the compounds, as well as optimising the collision 
energy to induce fragmentation of the selected ions in the gas phase, the declustering potential, 
and the collision exit potential.  
 Measurements were performed using an API4000 Qtrap mass spectrometer (Applied 
Biosystems/MDS SCIEX) coupled with an HP1100 series HPLC system (Agilent Technologies) 
and a CTC-PAL auto-injector (CTC Analytics AG). The analytical column was a Synergi “Max-
RP” reverse phase C12 with TMS endcapping (30 mm × 2 mm, 4 µm particle size) (Phenomenex, 
Inc.), selected for the best separation of hydrophobic compounds in neutral pH values. The 
column temperature was maintained at 60°C. The injected sample volume was 10 µL, and analytes 
were eluted at a flow rate of 800 µL min-1 by a linear gradient with a mobile phase, which consisted 
of a mixture of mobile phase A (water with 0.1% formic acid) and mobile phase B (acetonitrile 
with 0.1% formic acid). The gradient conditions for elution were 5% B (0.00–0.20 minutes); 5–
95% B (0.20–1.00 minutes); 95% B (1.00–1.30 minutes); 95–5% B (1.30–1.31 minutes); 5% B 
(1.31–1.50 minutes). The mass spectrometer was operated in positive electrospray mode with an 
ion source temperature of 650°C. The analytes were quantified in multiple reaction-monitoring 
mode. The mass transitions used for positive controls and test compounds are listed in table 10. 
 







SB002 371.0 259.0 Positive 
SB023 362.2 145.1 Positive 
4-chloro-2-aminopyridine 129.0 85.0 Positive 
Rolipram (internal standard) 276.1 208.2 Positive 
Verapamil (positive control) 455.1 165.1 Positive 
Dextromethorphan (positive control) 272.1 171.1 Positive 
 
Metabolic stability was calculated from the peak area ratio of the test and control items 
with the internal standard versus time. Peak areas were integrated using Integrator Software from 
Agilent. The integrated peak areas of the test and control items at selected time points were divided 
by the respective peak areas of the internal standard (IS), and the percentage of parent compound 
remaining was calculated by normalising the peak area ratio of the parent compound to that of the 
IS at time 0. The half-life of the compounds’ metabolism was derived from the initial linear portion 
of the slope of the natural log of per cent parent compound remaining over time. Intrinsic 









Where k in mL min-1 is the rate of depletion of the parent compound; V is the volume of 
the incubation in mL; M is the number of microsomal proteins in the incubation in mg mL-1. The 
amount of protein in the incubations was also scaled relative to average liver and body masses of 
each species to obtain intrinsic hepatic clearance in an in vitro to in vivo correlation. 
 
Table 11. Species-specific body and liver masses, hepatic blood flows, and scaling factors 
used to calculate intrinsic clearance. 
 Liver microsomes species 
 Human Rat Mouse 
Scaling factor 1a (g) 52.5 52.5 52.5 
Average liver weight (g) 1800 11.0 1.75 
Average body weight (kg) 70 0.25 0.025 
Scaling factor 2b (g kg-1) 25.7 44.0 70.0 
Blood flow (mL min-1) 20.7 85.0 95.0 
a Aptuit’s generic scaling factor for liver microsomal protein (mg) to liver (g). 
b Scaling factor for liver mass (g) to body mass (kg) that is used to predict in vivo drug clearance.  
 
Hepatic intrinsic clearance of the compounds was estimated from the following equation. 
𝑪𝒍𝒉,𝒊𝒏𝒕 = (((𝒌 ×  
𝑽
𝑴
) × 𝟏𝒔𝒕 𝑺𝒄𝒂𝒍𝒊𝒏𝒈 𝒇𝒂𝒄𝒕𝒐𝒓) × 𝟐𝒏𝒅𝑺𝒄𝒂𝒍𝒊𝒏𝒈 𝒇𝒂𝒄𝒕𝒐𝒓)  
(24) 
Where Clh, int is intrinsic hepatic clearance in mg min
-1 kg-1.  k (in mL min-1) is the rate of 
depletion of the parent compound; V is the volume of the incubation in mL; M is the number of 
microsomal proteins in the incubation in mg mL-1. The microsomes to liver and liver to body 
weight scaling factors are depicted in table 11. These scaling factors were used along with the 








Where Clh is in vivo hepatic clearance in mL min
-1 kg-1.  Clh, int is intrinsic hepatic clearance 
(in mg min1 kg-1) calculated from the previous two equations 23 and 24. Q is the median hepatic 




2.18 Evaluation of hit compounds as CYP450 inhibitors in 
human liver microsomes 
 
2.18.1 Preparing microsomal incubation 
The cytochrome P450 (CYP450) inhibition was determined by measuring the reaction 
products of known CYP450 substrates called probes. Probe substrate solutions were prepared by 
diluting probe stock solutions to final indicated concentrations, see table 12, with buffer (100 mM 
Tris-HCl, pH 7.5 and 0.5 mM EDTA) and 180 µL of pooled human liver microsomes at 20 mg 
mL-1 (BioreclamationIVT).  
 
Table 12. CYP450s, their respective substrate probes, and positive controls used in this 
work.  
CYP450 Substrate probe Solvent Positive controlsa 
CYP1A2 Phenacetin acetonitrile Fluvoxamine 
CYP2C8 Rosiglitazone methanol Quercetin 
CYP2C9 Diclofenac water Sulfaphenazole 
CYP2C19 S-Mephenytoin methanol Ticlopidine 
CYP2D6 Bufuralol water Quinidine 
CYP3A4 
Atorvastatin methanol 
Ketoconazole Midazolam methanol 
Nifedipine acetonitrile 
a Positive controls were all dissolved in methanol.  
 
First, the probe substrate solutions (195 µL) were dispensed into 96-well plates with low 
evaporation lids (Falcon) and were pre-warmed to 37°C in a thermomixer (Hamilton). Next, 5 µL 
of the test compounds and positive controls were added to the plates and incubated for a further 
5 minutes at 37°C. Then, 50 µL of NADPH regenerating solution (prepared by adding 1.7 mg of 
NADP, 7.8 mg D-Glucose-6-phosphate, and six units of Glucose-6-phosphate dehydrogenase in 
1 mL of a 2% sodium bicarbonate solution) was dispensed into the incubation plates using a 
Microlab STAR liquid handling system (Hamilton).  
CYP450 mixtures with phenacetin, rosiglitazone, mephenytoin, atorvastatin and nifedipine 
as probes were incubated for 10 minutes at 37°C, while those with midazolam and diclofenac were 
incubated for only 5 minutes at 37°C, see table 13. Aliquots (100 µL) from each incubation mixture 
and acetonitrile (200 µL) were added using the liquid handling system to a 96-deep well plate to 
quench the reactions. The plates were centrifuged at 3000×g for 10 minutes at 4°C and 
supernatants were automatically transferred to a new plate and further diluted in water containing 
5 ng mL-1 Rolipram as an internal standard for LC-MS/MS analysis.  All incubations were carried 




Table 13. Final effective concentrations of test compounds, substrate probes, and positive 
controls incubated with CYP450s. 
CYP450 Substrate probes  Positive controls (µM) Test compounds (µM) 
CYP1A2 35 µM Phenacetin 
Fluvoxamine 
(0, 0.01, 0.03, 0.1, 0.33, 






(0, 0.1, 0.33, 1, 3.3, 10, 
33, 100) 
CYP2C8 3 µM Rosiglitazone 
Quercetin 
(0, 0.01, 0.03, 0.1, 0.33, 
1, 3.3, 10) 
CYP2C9 8 µM Diclofenac 
Sulfaphenazole  
(0, 0.1, 0.33, 1, 3.3, 10, 
33, 100) 
CYP2C19 50 µM S-Mephenytoin 
Ticlopidine 
(0, 0.01, 0.03, 0.1, 0.33, 
1, 3.3, 10) 
CYP2D6 5 µM Bufuralol 
Quinidine 
(0, 0.01, 0.03, 0.1, 0.33, 
1, 3.3, 10) 
CYP3A4 
50 µM Atorvastatin Ketoconazole 
(0, 0.01, 0.03, 0.1, 0.33, 
1, 3.3, 10) 
2.5 µM Midazolam 
10 µM Nifedipine 
 
2.18.2 Substrate probe depletion by LC-MS/MS analysis 
During metabolism by CYP450s, the probe substrates received a hydroxyl functional 
group as a first step to increase the aqueous solubility for further hepatic metabolism.228 Therefore, 
the analytes detected by liquid chromatography-tandem mass spectrometry (LC-MS/MS) were the 
products of the CYP450 enzymatic reactions. 
 
Table 14. List of the probe products measured in this study. 
CYP450 Substrate probes Probe product 
CYP1A2 35 µM Phenacetin paracetamol 
CYP2C8 3 µM Rosiglitazone Par-hydroxyrosiglitazone 
CYP2C9 8 µM Diclofenac 4’-hydroxydiclofenac 
CYP2C19 50 µM S-Mephenytoin 4-hydroxymephenytoin 
CYP2D6 5 µM Bufuralol 1-hydroxybufuralol 
CYP3A4 
50 µM Atorvastatin o-Hydroxyatorvastatin 
1’-hydroxymidazolm 
oxidised nifedipine 
2.5 µM Midazolam 
10 µM Nifedipine 
 
The probe products were separated by different Ultra Performance Liquid 
Chromatography (UPLC) methods validated by Aptuit, which depended on the probe’s chemistry. 
Table 15 shows the UPLC instrumentation, analytical column, and conditions for analysing probe 
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products from CYP2C8 and CYP3A4 reactions. Table 16 shows the UPLC separation method 
and gradient profiles for CYP2C8 and CYP3A4 probe products.  
 
Table 15. UPLC conditions for o-Hydroxyatorvastatin, 1’-hydroxymidazolm, oxidised 
nifedipine, and Par-hydroxyrosiglitazone. 
Instrument Waters Acquity UPLC system 
Strong wash solvent Acetonitrile/methanol/isopropanol (50:30:20) 
Weak wash solvent Water/acetonitrile (50:50) 
Typical injection volume 10 µL 
Flow rate 800 µL min-1 
Analytical column Acquity BEH C18 (50 × 2.1 mm, 1.7 µm particle size) 
Column temperature 60°C 
Mobile phase A Water with 0.1% formic acid 
Mobile phase B Acetonitrile with 0.1% formic acid 
 
Table 16. UPLC gradient profile for o-Hydroxyatorvastatin, 1’-hydroxymidazolm, oxidised 
nifedipine, and Par-hydroxyrosiglitazone.  
Time (min) Flow (mL min-1) Mobile phase A (%) Mobile phase B (%) 
0.00 0.8 95 5 
0.20 0.8 95 5 
1.50 0.8 5 95 
1.75 0.8 5 95 
1.80 0.8 95 5 
2.00 0.8 95 5 
 
Table 17 shows the UPLC instrumentation, analytical column, and conditions for 
analysing probe products for CYP1A2, CYP2C9, CYP2C19 and CYP2D6 reactions. Table 18 
shows the UPLC separation method and gradient profiles for CYP1A2, CYP2C9, CYP2C19 and 
CYP2D6 probe products. 
 
Table 17. UPLC conditions for paracetamol, 4’-hydroxydiclofenac, 4-hydroxymephenytoin 
and 1-hydroxybufuralol. 
Instrument Waters Acquity UPLC system  
Strong wash solvent Acetonitrile/methanol/isopropanol (50:30:20) 
Weak wash solvent Water/acetonitrile (50:50) 
Typical injection volume 10 µL 
Flow rate 700 µL min-1 
Analytical column Acquity BEH phenyl (50 × 2.1 mm, 1.7 µm particle size) 
Column temperature 45°C 
Mobile phase A Water with 0.1% formic acid 




Table 18. UPLC gradient profile for paracetamol, 4’-hydroxydiclofenac, 4-
hydroxymephenytoin and 1-hydroxybufuralol. 
Time (min) Flow (mL min-1) Mobile phase A (%) Mobile phase B (%) 
0.00 0.7 0 100 
0.10 0.7 0 100 
2.30 0.7 80 20 
2.40 0.8 80 20 
2.90 0.8 80 20 
3.00 0.7 0 100 
3.80 0.7 0 100 
 
The tandem mass spectrometry conditions for probe analysis were the same for all CYP450 
enzymes and are displayed in the following table 19. The mass transitions used to analyse the 
probe products are depicted in table 20. 
 
Table 19. Mass spectrometry conditions for probe products.  
Mass spectrometer Applied Biosystems 4000QTrap 
Ionisation/interface TurboIonSpray at 650°C 
Pause time 5 ms 
Curtain gas setting 15 
Collision gas setting 4 
Ion source Gas 1 60 
Ion source Gas 2 40 
 
Rolipram was used as an internal standard (IS) to gauge the performance of the LC-
MS/MS analysis. Data were processed to give triplicate mean values, and the IC50 values were 
determined using nonlinear regression analysis of the plot of percentage control activity versus 
concentration of the test compounds (equation 5). The percentage control activity was calculated 
based on a comparison between the peak area ratio of the sample and the peak area ratio of the 
control sample. 
 
Table 20. Mass spectrometry ionisation of probe products.   
Analyte Precursor ion (m/z) Product ion (m/z) Polarity 
o-Hydroxyatorvastatin 575.10 440.40 Positive 
Oxidised nifedipine 345.00 284.00 Positive 
1’-Hydroxymidazolam 342.10 203.00 Positive 
Paracetamol  152.00 110.20 Positive 
Para-
hydroxyrosiglitazone 
374.00 151.00 Positive 
4’-Hydroxydiclofenac 312.00 150.00 Positive 
4-Hydroxymephenytoin 235.01 150.20 Positive 
1-Hydroxybufuralol 278.40 186.00 Positive 
Rolipram (internal 
standard) 




3. Results and discussion 
Biochemical characterisation of malate synthase G 
 
3.1 Background 
Malate synthase isoform G (MS) is the second enzyme of the glyoxylate shunt and is 
encoded by glcB in Pseudomonas aeruginosa. MS catalyses the irreversible condensation of glyoxylate 
and acetyl coenzyme A into malate and coenzyme A. Glyoxylate is generated for MS by the 
cleavage of isocitrate in a reversible reaction catalysed by isocitrate lyase (ICL). Isocitrate is diverted 
into the glyoxylate shunt from the TCA cycle during bacterial growth on fatty acids, which allows 
for the production of gluconeogenic precursors from metabolic inputs with only a C2 backbone.
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The glyoxylate shunt replenishes biosynthetic intermediates, generates biomass and appears to be 
vital for P. aeruginosa to survive in infection scenarios. For example, expression levels of the 
enzymes are upregulated in chronic P. aeruginosa infections of cystic fibrosis patients.189 ICL and 
MS are also vital for P. aeruginosa fitness in mammalian infection models. For instance, a double 
deletion mutant of the shunt enzymes (ΔICL ΔMS) was found to be completely avirulent in a 
mouse pulmonary infection model.194 Thus, MS is an attractive target for drug discovery efforts 
but has never been fully characterised before in P. aeruginosa.  
In this chapter, I investigate the structure and biochemical function of MS from 
Pseudomonas aeruginosa (MSPa). The SDS-PAGE and size exclusion chromatography (SEC) analysis 
of MS assesses the quality of the enzyme after purification. I will present the enzyme kinetics, the 
first published crystal structure of MSPa, and results from intrinsic fluorescent experiments that 
detail magnesium co-factor binding. Then, I will present the binding pockets in the MSPa crystal 
structure that are most suitable for drug development based on the druggability of the pockets, 
which were determined computationally from the result of a collaboration. These results will be 
discussed in the context of other medically relevant pathogens. Lastly, I will present results from 
a molecular dynamics simulation that predicts the likely physiological hydration network of the 




3.2 Protein purification 
 
The investigation of MSPa began with the purification of the enzyme. First, the glcB gene 
was PCR-amplified from the PAO1 genome and cloned into a pGEX-6P-1 plasmid. The vector 
carrying glcB was introduced into E. coli BL21 to overexpress the protein. A previous laboratory 
member in 2015 performed this cloning. I then purified MSPa using the following workflow: the 
first step involved affinity chromatography, which used a glutathione sepharose column to purify 
the construct according to the affinity between the fusion protein’s GST tag and the resin. The 
second step involved PreScission Protease digestion to cleave the GST tag from the N-terminus 
of purified MSPa. The final step was SEC, see figure 6, which required a 16-600 Superdex 200 
preparatory grade column to separate the native protein, any uncleaved fusion protein, the cleaved 




Figure 6. Size exclusion chromatogram of MSPa elution. The single large peak corresponds to 
purified untagged MSPa, and the smaller shoulder peak could be indicative of a dimer or larger 
aggregates from purification due to high loading concentration. The first small peak is most likely 
contaminants or degradation products. 
 
SEC revealed a tall and narrow single elution peak measured by UV (at 280 nm), which is 
indicative of pure protein. The small, rounded peak that eluted first could be resulting from 
impurities like keratin contamination, degraded protein fragments, or DNA.229 The second elution 
was a shoulder peak to the purified MSPa and could designate a dimer or larger order aggregates 
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from the purification due to high loading concentrations. The purity of a protein batch is important 
for applications like protein crystallisation,230 so an SDS-PAGE analysis was performed to 
determine the protein size and purity. The SDS-PAGE gel (figure 7) was prepared with a protein 
sample after SEC. The image of the gel shows a band of purified MSPa that migrated with an 
apparent molecular mass between 75 and 100 kDa. This corresponds to a monomeric molecular 
mass of 78.66 kDa predicted from the MSPa amino acid sequence by the ExPASy ProtParam tool.
201 
MSPa was successfully expressed and purified to homogeneity with adequate yields (~25 mg L
-1), 






Figure 7. Coomassie blue-stained SDS-PAGE analysis after 
MSPa purification. This gel shows the final untagged protein after 
protein purification. A clear single band is visible just above 75 kDa, 
compared with the molecular mass ladder displayed on the left. This 







3.3 Amino acid sequence alignments 
 
Amino acid sequence alignments of other pathogenic bacteria revealed that MS is 
remarkably well conserved among species, see figure 8. MS amino acid sequences sourced from 
the UniProt database (Pseudomonas aeruginosa, Q9I636; Escherichia coli, P37330; Mycobacterium 
tuberculosis, P9WK17; Mycobacterium leprae, O32913) were aligned using ClustalOmega231,232 and were 
displayed with Jalview.233 
There is a 60% amino acid sequence identity between MSPa and E. coli  MS (MSEc), and a 
70% amino acid sequence identity between MSPa and M. tuberculosis MS (MSMt). The amino acids 
identical among all four species are highlighted in purple in figure 8, and the known catalytic 




Figure 8. Amino acid sequence alignment of MSPa with MS homologues. Amino acid 
sequences from pathogens whose structures have been determined by X-ray crystallography were 
aligned with MSPa: E. coli, P37330 (PDB entry 1P7T); M. tuberculosis, P9WK17 (PDB entry 1N8I); 
and M. leprae, O32913 (PDB entry 4EX4). Amino acids are coloured by sequence identity, where 
regions of 100% identity are highlighted in purple. Amino acids known to be involved in catalysis 
in MSEc and MSMt are highlighted in orange, and these amino acids are conserved among all four 
organisms shown. 
 
3.4 Kinetic analysis 
 
Purified MSPa exhibited Michaelis−Menten kinetics, see figure 9. The kinetic analysis at 
variable concentrations of substrates revealed that the KM values were 34 µM and 48 µM for 
glyoxylate and acetyl coenzyme A (AcCoA), respectively. Vmax was determined as 2.36 µM s
-1 for 
glyoxylate and 1.64 µM s-1 for AcCoA. Glyoxylate is the conjugate base of glycolic acid and chiefly 
exists as a gem-diol, which is highly reactive.191 This means that glyoxylate will readily react with 
Tris buffer, forms of reactive oxygen species, and cellular metabolites at physiological pH.191,234,235 
This type of chemical reactivity, while excess glyoxylate (200 µM) was present, could account for 
the lower Vmax when AcCoA was titrated.  
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The first order rate catalytic turnover (kcat) for glyoxylate, calculated for monomeric MSPa, 
was 94 second-1. MS is a central metabolism enzyme, and it has been suggested that these enzymes 
operate with increased catalytic turnover and are under strong selective pressures to perform 
efficiently.236 Kinetic analysis of purified MSPa has been performed in just one study prior to this 
investigation, which reported a lower substrate affinity for glyoxylate (70 µM) and a higher 
substrate affinity for acetyl coenzyme A (12 µM) than is reported here.196  
 
Figure 9. Kinetic analysis of MSPa. Michaelis-Menten plots of enzyme velocity measured by (A) 
fixing the concentration of acetyl coenzyme A at 0.2 mM while varying the concentration of 
glyoxylate as indicated; or by (B) fixing the concentration of glyoxylate at 0.2 mM while varying 
the concentration of acetyl coenzyme A as indicated.  
 
Kinetic studies of MS from other pathogenic bacteria have been performed as well, 
including M. tuberculosis, E. coli, and Corynebacterium glutamicum. Results from these analyses were 
comparable to that of MSPa and are displayed in table 21. Additionally, the MSPa enzymatic reaction 
has been determined to proceed through a sequential, bi-bi mechanism in a ternary complex with 
both substrates binding before the reaction is catalysed, as opposed to a substituted enzyme 
mechanism.196,237 This is common for enzymes with two substrates catalysing a group transfer.238  
 







-1 s-1) kcat (s
-1) Reference 
P. aeruginosa 34 48 1200 94 This work 
P. aeruginosa 70 12 990 - 196 
M. tuberculosis 30 10 - 23
 239 
M. tuberculosis 57 30 360 - 187 
E. coli 21 9 2160 48 186 
C. glutamicum 30 12 - - 240 




3.5 Crystal structure of MS 
 
The three-dimensional structure of MSPa was determined by molecular replacement using 
MSMt (PDB entry 1N8I) as a template. The MSPa crystal diffracted to 1.6 Å resolution, and it 
crystallised with one molecule in the asymmetric unit composed of 725 amino acids. The final 
model is presented in figure 10 in the apo form.  The full statistics for data collection and 
refinement are listed in appendix 1. The atomic coordinates and structure factors obtained in this 
work are available in the PDB under the accession code 5OAS, and appendix 1 contains a few of 
the validation elements from PDB submission, including the Ramachandran plot and Polygon 
analysis. The model was optimised with an Rwork of 16.7% and an Rfree of 19.6%. The 
Ramachandran distribution of all amino acid dihedral angles in the protein structure indicates that 
98% of the amino acids are in favoured or allowed regions.  
 
Figure 10. Cartoon representation of the MSPa crystal structure. (A) The structural domains 
in MSPa include a TIM barrel fold (blue), α-helical domain (green), and a β-sheet-rich domain (red). 
The N-terminal helices (amino acids 2−115) are coloured light cyan. (B) A closer look at the active 
site shows the proposed substrate-binding residues, Glu432 and Asp460 (magenta sticks), and the 
proposed catalytic residues, Asp631 and Arg340 (orange sticks). The residues involved in catalysis 
are oriented around the Mg2+ ion, which is depicted as a chartreuse sphere.  
 
The first MS structure to be elucidated by X-ray crystallography in 2000 was from E. coli 
and contained magnesium and glyoxylate bound (PDB entry 1D8C).185 Now, there are several 
structures in the PDB of MS in apo, substrate-bound, and product-bound forms from four 
prokaryotic species: E. coli (PDB entries 1P7T and 1D8C); M. leprae (PDB entry 4EX4), deposited 
in 2012;  M. marinum (PDB entry 6AXE), deposited in 2017; and M. tuberculosis (PDB entries 1N8I, 
1N8W, 2GQ3, 5H8P, and 5H8U), first deposited in 2003. Also, while the manuscript on which 
this chapter is based was in preparation, I became aware that a structure of MSPa with glyoxylate 
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bound had been deposited in the PDB in April 2017 (entry 5VFB). However, to the best of my 
knowledge, this structure has not been described in the literature.  
In common with these previously reported MS structures, MSPa is composed of three 
domains: a TIM barrel domain with eight α-helices and eight β-strands (amino acids 116−135 and 
266−589), a second α-helical domain (amino acids 590−725), and a third β-sheet-rich domain 
(amino acids 136−265) inserted between the first α-helix and second β-sheet of the TIM barrel 
domain. Near the N-terminus of the protein is a strikingly long α-helix (amino acids 32−71) that 
partially wraps around the TIM barrel domain (figure 10A). Comparison of the structure presented 
here with known MS structures from other organisms revealed that the protein is highly conserved 
across species. For example, the backbone rmsd of the superposition between the MSMt (used as 
the molecular replacement template; PDB entry 1N8I) and MSPa is 0.94 Å over 682 Cα atoms.  
In particular, comparison of the MSPa structure with other MS structures revealed that the 
active site residues and the Mg2+ ion are highly conserved across species. The active site pocket in 
MSMt and MSEc sits between the TIM barrel and a loop (amino acids 615−631 in MSPa) from domain 
II.185,187 Known active site residues in MSMt and MSEc are also present in the MSPa crystal structure, 
and they occupy the same positions (not shown). The MSPa active site, when aligned with the MSMt 
active site, has an rmsd of 0.20 Å. The active sites compared between the apo (PDB entry 5H8P) 
and a substrate-bound (PDB entry 1N8W) MSMt crystal structures are also practically identical, 
except for the tightening of the aforementioned loop from domain II when glyoxylate is bound. 
This means that MS generally does not undergo major conformational changes during catalysis. 
Additionally, comparison of the apo MSPa structure presented here with the glyoxylate-bound 
structure of MSPa recently deposited in the PDB (entry 5VFB) revealed no conformational 
differences except for a small shift in a solvent-exposed loop (amino acids 305−312) far from the 
active site. 
 
3.6 Influence of Mg2+ on substrate binding 
 
The F0 – Fc difference map for the MSPa crystal structure uncovered electron density in the 
active site for an Mg2+ ion and a molecule of ethylene glycol (referred as EDO), which was the 
cryoprotectant used during crystal harvesting. Mg2+ is reportedly essential for the enzymatic 
function of MS and is present in every MS crystal structure published thus far.181,185,187,241,242 In these 
other structures, the Mg2+ is coordinated by four water molecules and conserved Glu and Asp 
residues in an octahedral conformation. However, in my structure, the Mg2+ appears to be 
coordinated by the EDO molecule, one water molecule, and the carboxylate side chains of Glu432, 
Asp460, Glu274, and Asp275, as shown in figure 11. These side chains are all located within 3.5 
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Å of the metal ion and could be interacting to decrease the overall energy. A conserved tryptophan 
residue, Trp539, was noticed nearby (~6 Å), which could be useful as a fluorescent reporter to 
monitor binding events in the active site. 
 
 
Figure 11. Mg2+ coordination in the MSPa crystal structure. The magnesium ion is coordinated 
by Glu274, Asp275, Glu432, Asp460, ethylene glycol, and a single water molecule in the active 
site. Trp539 is located 6.0 Å from the magnesium ion. The electron density map is contoured at 
1.5σ. 
 
I measured the intrinsic tryptophan fluorescence of MSPa to examine the effect of Mg
2+ on 
substrate(s) binding and to quantify Mg2+ binding affinity. In order to investigate the Mg2+ binding 
properties of MSPa, any prebound Mg
2+ from the purified protein was first removed by dialysis 
with 50 mM EDTA, followed by 10 mM EDTA. There was a change in relative tryptophan 
fluorescence intensity and λmax upon the addition of Mg
2+ and substrates to demetallised MSPa, see 
figures 12A-D. λmax for demetallised MS was determined as 340 nm, which red-shifted slightly to 
342 nm upon the addition of 10 mM MgCl2. This red-shift indicates that the environment around 
the tryptophan residue(s) became hydrophilic and exposed to more solvent in the presence of 
Mg2+. Conversely, λmax blue-shifted to 337 nm after the addition of 1 mM glyoxylate (after MgCl2 
was added), indicating that the environment around Trp539 and other tryptophan residues became 
more hydrophobic and less exposed to the bulk solvent (figure 12A).243 When 1 mM glyoxylate 
was added to demetallised MS in the absence of Mg2+, there was no deviation in λmax or 
fluorescence intensity compared with the spectrum of the demetallised protein alone, implying 
that Mg2+ is needed in the active site for glyoxylate to bind (figure 12B). When a saturating 
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concentration of AcCoA was added to demetallised MS in the absence of Mg2+ or glyoxylate 
(figure 12C), no change in fluorescent intensity or λmax was observed; however, once MgCl2 was 
added alongside AcCoA, λmax red-shifted again similar to when MgCl2 was added to demetallised 
MS in figure 12A. This means that AcCoA does not bind to MSPa before Mg
2+ or glyoxylate.  
 
 
Figure 12. Intrinsic tryptophan fluorescence of demetallised MSPa. The λmax for all spectra is 
indicated by a vertical dotted line of the corresponding colour. (A) Spectra of demetallised MSPa 
(black), demetallised MSPa with 10 mM MgCl2 (red), and demetallised MSPa with 10 mM MgCl2 and 
1 mM glyoxylate (blue). (B) Spectra of demetallised MSPa (black), demetallised MSPa with 1 mM 
glyoxylate (orange), and demetallised MSPa with 10 mM MgCl2 and 1 mM glyoxylate (blue). (C) 
Spectra of demetallised MSPa (black), demetallised MSPa with 110 µM AcCoA (orange), and 
demetallised MSPa with 10 mM MgCl2 and 110 µM AcCoA (red). (D) Spectra of demetallised MSPa 
(black), demetallised MSPa with 10 mM MgCl2 (red), demetallised MSPa with 10 mM MgCl2 and 100 
µM glyoxylate (blue), and demetallised MSPa with 10 mM MgCl2, 100 µM glyoxylate, and 110 µM 
AcCoA added (violet). Abbreviations: AcCoA, acetyl coenzyme A; RFU, relative fluorescent 
units.  
 
The order of substrate binding is further supported by figure 12D, which again shows λmax 
red-shifted after the addition of Mg2+ and blue-shifted after the addition of Mg2+ and glyoxylate 
compared with the demetallised protein spectrum. However, when a saturating concentration of 
AcCoA was added after Mg2+ and glyoxylate, the spectrum recovered to that of the Mg2+-bound 
spectrum. This is consistent with a sequential reaction mechanism proposed by Quartararo et al.,239 
in which glyoxylate binding is a prerequisite for AcCoA binding, and that Mg2+ remains bound in 




Figure 13. Stern−Volmer analysis of MSPa. No global conformational changes occur due to 
Mg2+ or glyoxylate binding to MSPa as indicated by measuring fluorescence while increasing the 
concentration of neutral intrinsic quenching agent, acrylamide. 
 
Comparing the structure described here with that of the glyoxylate-bound MSPa structure 
(PDB entry 5VFB) reveals no apparent conformational differences between the active sites. 
Together with the results outlined here, this is consistent with the physical occlusion of the bulk 
solvent in the active site by the substrate glyoxylate. To establish whether binding of Mg2+ or 
glyoxylate to MSPa is accompanied by global conformational changes, I measured the accessibility 
of the tryptophan residues to an extrinsic neutral quencher, acrylamide. The presence of increasing 
concentrations of acrylamide caused progressively stronger quenching of tryptophan fluorescence, 
but the apparent dynamic quenching constant (KSV = 10.5 ± 0.2 M
−1) was similar for Mg2+-bound 
or glyoxylate-bound enzyme as the demetallised enzyme (figure 13). This indicates that the 
changes in tryptophan fluorescence from Mg2+ or glyoxylate binding arise as a consequence of 
changes in the local microenvironment of one or more tryptophan residues, most likely Trp539, 
in the active site, rather than global changes in protein conformation. 
Because the tryptophan fluorescence in MSPa following the addition of Mg
2+ was enhanced, 
it suggested that this spectroscopic signal might be used quantitatively to measure binding of Mg2+ 
to the enzyme. MSPa tryptophan fluorescence increased hyperbolically as the Mg
2+ concentration 
increased, as is typical of a saturable binding system. In the presence of glyoxylate, the same Mg2+ 
titration also yielded a binding isotherm, except that increasing Mg2+ concentrations led to saturable 
quenching of fluorescence (figure 14A). Scatchard analysis of the fluorescence data from Mg2+ 
yielded apparent Kd values for the Mg
2+−MSPa complex of 525 and 653 μM in the absence and 
presence of 1 mM glyoxylate, respectively (figure 14B). This is comparable with the binding 





Figure 14. Magnesium binding to MSPa. (A) Mg
2+ binding curves in the presence (blue) and 
absence (black) of 1 mM glyoxylate. Note that glyoxylate quenches the tryptophan fluorescence of 
MSPa when Mg
2+ is added. (B) Scatchard analysis of Mg2+ binding data in the presence (blue) and 
absence (black) of 1 mM glyoxylate. 
 
3.7 Identification of potential binding sites 
 
Because P. aeruginosa is such a high-priority pathogen for new antibiotic discovery efforts, 
I collaborated with Prashanthi Medarametla and Professor Antti Poso from the University of 
Eastern Finland to understand the enzyme’s potential as a druggable target through a 
computational lens. There is an important difference between the druggability of a protein and its 
suitability as a drug target.245 Druggability refers to any structural features that favour interactions 
with drug-like small molecules, whereas useful drug targets are those that possess structural and 
functional features that are relevant to disease states.246 MSPa is relevant to particular disease states, 
making it a suitable drug target, but I also wanted to identify any potential binding sites in MSPa 
that might facilitate structure-based drug design efforts. Therefore, we analysed the MSPa crystal 
structure using Schrödinger’s SiteMap. I denoted the five top-ranking binding sites identified by 
SiteMap as A−E, and their SiteMap parameters are listed in table 22.  
 
Table 22. Binding sites A-E in the MSPa crystal structure predicted by SiteMap. 
Site SiteScore Size (# of site points) Dscore Volume (Å3) Hydrophobic Hydrophilic 
A 1.10 123 1.16 475.01 1.60 0.72 
B 0.99 188 1.02 569.03 0.58 0.95 
C 0.97 163 1.02 461.24 0.59 0.89 
D 0.96 110 0.97 269.12 0.50 1.06 
E 0.87 80 0.87 156.53 0.79 1.04 
 
The purpose of the SiteScore is to define and rank binding sites based on an equation that 
calculates druggable parameters, such as the number of site points, the enclosure score, and a 
hydrophilic score based on the polarity of the amino acids within the site. In a large-scale study of 
538 proteins taken from the PDBbind database, SiteMap was able to correctly identify the known 
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binding site as the top-ranked site in 86% of cases. The SiteScore equation caps the hydrophilic 
variable at 1.0 to limit the impact of hydrophilicity in charged and highly polar sites when ranking 
the sites. The main difference between the SiteScore and the Dscore, or druggability score, is that 
in the Dscore equation, the hydrophilic score variable is not capped, which allows hydrophobicity 
to play a larger role in assessing druggability of binding sites. The Dscore should be ≥1.0 for the 




Figure 15. Predicted binding sites in MSPa. (A) Coloured mesh represents the possible binding 
pockets predicted by SiteMap in the MSPa structure (grey): site A, yellow; site B, orange; site C, 
magenta; site D, blue; site E, cyan. Site A is located between a β-hairpin (amino acids 622−628) 
in domain II and α-helices in the TIM barrel. Site B is composed of loops in the TIM barrel and 
domains II and III. Site C is located on the edge of the protein between helix α1 in the N-terminal 
region and the final α-helix of the protein at the C-terminus, along with a β-hairpin (amino acids 
345− 350) from the TIM barrel. Site D is composed of a loop in the N-terminal region and α-
helices in the TIM barrel. Site E sits near the loops of the N-terminus and C-terminus, and a 
flexible loop in the TIM barrel. (B) Site A and its hydrophobic binding site residues are shown as 
green sticks. (C) The polar and hydrophobic residues of site B are shown as green sticks. These 
include the Arg340 and Asp631 amino acid side chains involved in catalysis and the active site 
fluorophore, Trp539. 
 
The location of each site on the MSPa crystal structure is shown in figure 15A as a coloured 
mesh (site A, yellow; site B, orange; site C, magenta; site D, blue; site E, cyan). Sites A−E all 
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possess a SiteScore ≥0.80, which is the minimum recommended value to distinguish between a 
drug binding and non-drug binding site.222 Site A is the top-ranked potential binding site with a 
SiteScore of 1.10 and a Dscore of 1.16. Site B is the second-ranked site with a SiteScore of 0.99 
and a Dscore of 1.02. These scores are consistent with those from earlier studies of proteins in 
which drugs that bind with submicromolar affinity have been identified.247 This indicates that sites 
A and B are promising binding sites that could be used for structure-driven drug design.  
Site A (figure 15B) is narrow and highly hydrophobic, with a hydrophobic-to-hydrophilic 
character ratio of 2.22. For reference, the mean hydrophobic-to-hydrophilic ratio for tight binding 
sites in proteins is 1.60.222 This ratio, along with the suitable SiteScore and Dscores calculated by 
SiteMap, implies that this pocket is suitable for exploration using drug-like molecules. Also, 
because the pocket is located deep within the protein, small molecules could be accommodated by 
the site, rather than larger ones, whose entry may be hindered. Site B has the largest predicted 
volume (569 Å3) and spreads over the entrance of the active site. Site B has a hydrophobic interior 
region and a hydrophilic exterior, with a hydrophobic- to-hydrophilic character ratio of 0.61. The 
residues in site B are displayed in figure 15C.  
Having identified potential ligand binding sites in MSPa, I judged the likely impact of ligand 
binding in these sites on enzyme function. I also assessed the degree of conservation of the amino 
acid residues in the predicted binding sites by aligning crystal structures across species, including 
M. tuberculosis (PDB entry 5CC5), E. coli (PDB entry 1P7T) and M. leprae (PDB entry 4EX4). The 
protein structural alignment revealed that there were no differences in the tertiary structures of MS 
from the four species, except for slight orientations of a flexible loop of approximately seven 
amino acids in length (amino acids 305-312 in P. aeruginosa; not shown). Aligning the four structures 
of MS also revealed that predicted ligand binding site B incorporates the known substrate binding 
sites of MS (figure 16) and contains two of the amino acids predicted to be involved in catalysis 
in P. aeruginosa, Arg340 and Aps631, as well as the active site fluorophore, Trp539 (see figure 15C 
for amino acids). Site A also partially overlaps with the substrate binding pocket, surrounding the 






Figure 16. Alignment of MS crystal structures. The MS crystal structures of P. aeruginosa (grey), 
E. coli (green), M. tuberculosis (cyan), and M. leprae (orange) were aligned to locate any differences in 
tertiary structures. Predicted binding site B is shown as an orange mesh with substrates glyoxylate 
and acetyl coenzyme A present to show location (shown as sticks). 
 
Because of the structural conservation and functional significance of sites A and B, I 
looked for published inhibitors of MS in other organisms that might bind in these sites. To date, 
however, the few known inhibitors of MS solely target the active site and are either glyoxylate 
analogues, Mg2+ chelators, or endogenous metabolic intermediates.173,182,187,240–242 An example of a 
Mg2+ chelator is a class of compounds, phenyldiketoacids (PDKA), that was discovered to inhibit 
MSMt. MSMt complexed with the PDKA inhibitors did not show significant conformational 
changes; however, as seen for ethylene glycol in this work, the 1,2-diol moiety in these inhibitors 
acted as a bidentate ligand of Mg2+ in the MSMt active site. Another example is a study in which a 
high-throughput screen against P. aeruginosa grown on acetate identified small molecule inhibitors 
of MS. In silico binding of these hits following an induced-fit docking procedure to homology 
models of an MSMt crystal structure alluded to a possible interaction with the active site Mg
2+.194 In 
a different study of MSMt complexed with chemical fragments, 18 fragments were identified that 
formed a hydrogen bond with the backbone carbonyl of Met631 in the active site.241 Met631 
(Met629 in MSPa) is conserved in the MS superfamily and is present in site A. Finally, a recent study 
has employed computer-aided drug design to predict the binding positions accurately and poses 
of 16 substituted PDKAs to MSMt.
248 The scarcity of MSPa inhibitors highlights the potential of 




3.8 Computational analysis of structural waters 
 
The solvation network in a crystal structure plays an important role in determining protein-
ligand binding affinities computationally. The MSPa crystal structure incorporates 691 water 
molecules per molecule, as opposed to just 450 water molecules per molecule in MSMt (PDB entry 
1N8I). However, hydration networks in proteins are dynamic, so Prashanthi Medarametla from 
the University of Eastern Finland used the molecular dynamics simulator, WaterMap by 
Schrödinger, to better understand the possible impact of water molecules on ligand binding. The 
location of the predicted stable hydration sites was consistent with the observed crystallographic 
waters, and the predicted hydration sites and crystal water molecules in the active site are shown 




Figure 17. Comparison of predicted hydration sites with crystallographic waters. Hydration 
sites (brown spheres, representing unstable water molecules and green spheres, representing stable 
water molecules) predicted by WaterMap were superimposed with MSPa crystallographic waters 
(cyan spheres) and checked for spacial positions. Catalytic amino acid residues (Arg340, Glu432, 
and Asp631) are shown as sticks to illustrate the location. 
 
The hydration sites predicted by WaterMap gave additional insights into the 
thermodynamics of the solvation network (figure 18). The water molecules in the hydration sites 
coloured green are high-energy water molecules. Typically, these water molecules are favourable 
for binding, and ligands that displace these water molecules must compensate for the loss in free 
energy. Thus, it is better to avoid these sites during ligand design. Conversely, hydration sites 
coloured red/brown portray lower-energy or unfavourable sites. Thus, replacing these water 
molecules should favour an increase in free energy. WaterMap also predicts cavity regions that are 
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devoid of water molecules and targeting these regions may also help in the search for high-affinity 
binders. The WaterMap analysis confirmed the top-ranked predicted binding sites, A and B (table 
22), as druggable. WaterMap revealed cavity regions along with unstable hydration sites in site A 




Figure 18. Computational analysis of MSPa hydration sites. (A) MSPa hydration sites predicted 
by WaterMap. The relative free energy of the water molecules in the hydration sites are indicated 
by a green (high energy) to red (low energy) colour gradient. Predicted binding sites A and B are 
also outlined in yellow and brown, respectively. (B) Site A. Yellow surface defines the site. Amino 
acids within the site are displayed as green sticks, and blue labels indicate hydration site numbers. 
(C) Site B. Orange surface outlines the site. A cavity region (blue mesh) partially occupies the site, 
along with the hydrophobic amino acids within the site (green sticks), and number hydration sites 
(labelled in blue). 
 
The full thermodynamic parameters associated with the hydration sites shown in panels B 
and C of figure 18 are provided in appendix 2. Site B has fewer unstable hydration sites than site 
A does, which supports the hydrophilic nature of the pocket analysed by SiteMap. In contrast, site 
A is more hydrophobic. However, the unstable hydration sites in site A are not contiguous, 
suggesting a requirement for a larger molecule with several hydrophobic regions to fit neatly in the 
site. One particularly interesting cavity is located near the AcCoA binding site that is so 
unfavourable for hydration that a void is present (shown as blue mesh in figure 18C and figure 
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19). Huang and colleagues’ fragment screening found 18 fragments that inhibit MS activity in M. 
tuberculosis by binding to the active site.241 Upon scrutinisation of these fragments, one particular 
hydrophobic fragment, indole-3-carboxylic acid (ICO), occupies the space between the glyoxylate 
and AcCoA binding sites, see figure 19, (PDB entry 5CC5), and this corresponds to the exact 




Figure 19. The MSPa cavity region predicted by WaterMap. The MSMt inhibitor, Indole-3-
carboxylic acid (ICO; green sticks), partially occupies the cavity region (blue mesh) predicted in 
MSPa in the MSMt crystal structure (PDB entry 5CC5). Substrates glyoxylate (GLV; dark teal) and 
acetyl coenzyme A (AcCoA; cyan) are also presented from an MSEc crystal structure (PDB entry 
1P7T) to illustrate the binding location.  
 
Cavity regions, or “dry regions”, represent an under-exploited tactic regarding the search 
for protein-ligand binding affinities. Typically, the computational strategy is to find a ligand of 
interest which displaces unfavourable waters and replaces them with groups that are 
complementary to the protein surface. This has been established as a principal driving force for 
protein-ligand binding in many systems, particularly in the pharmaceutical industry. However, if a 
ligand is placed in a cavity region and the ligand’s chemistry is complementary to the protein 





When establishing an infection, Pseudomonas aeruginosa adapts to the physiology of its 
environment. In the pulmonary airways of CF patients, for example, this adaptation occurs by 
69 
 
metabolising fatty acids as a primary source of carbon. These fatty acids are oxidised into acetyl 
coenzyme A and processed by the glyoxylate shunt, which bypasses the decarboxylative steps of 
the tricarboxylic acid cycle and enables P. aeruginosa to survive on short-chain fatty acids alone. 
Growing recognition of the important link between the glyoxylate shunt and infections has made 
it a prime target for the development of new antibacterial therapies. Prior work has shown that P. 
aeruginosa double shunt mutants are avirulent in a mouse pulmonary infection model, which shows 
that no other mechanism can bypass the loss of the glyoxylate shunt, thereby supporting the 
validity and tractability of this biological target.  
Moreover, work from the Welch laboratory has demonstrated the association between 
shunt activity and increased virulence phenotypes, such as the expression of type III secretion-
related virulence factors,190,250 so understanding how to inhibit the glyoxylate shunt’s function 
would also be useful in undermining diverse P. aeruginosa infections. The biochemistry of the 
glyoxylate shunt has been well studied in E. coli and M. tuberculosis. However, very little is known 
about its structure and function in P. aeruginosa. What is known from these model organisms about 
the structure and function of the shunt should not be extrapolated in P. aeruginosa; therefore, in 
this work, I generated structural and functional information to contribute to our biochemical 
understanding of malate synthase G in Pseudomonas aeruginosa.  
In this chapter, I report the first X-ray crystal structure of P. aeruginosa malate synthase G 
in the apo form at 1.62 Å resolution. The first crystal structure of MS was elucidated in 2000 in E. 
coli and then in 2003 in M. tuberculosis. Seven years ago, interest in pursuing MSMt as a drug target 
emerged, and structure-based drug design efforts began. Fragment-based screenings have 
flourished with nearly 50 fragments available in the PDB that show binding to MSMt. The MS 
amino acid sequences between species indicate that they are highly conserved, and this is also 
visible in the crystal structures of MSMt, MSEc and MSPa when they are aligned. MSPa appears to be 
monomer in solution, which was suggested from SEC analysis in protein purification. This is 
consistent with other bacterial species in which MS isoform G has been characterised.181,182  
Based on sequence and structural similarity, I propose that the amino acid residues 
involved in catalysis in MSPa are Arg340, Glu432, Asp460, and Asp631 (refer to figures 10B and 
11 for locations). I propose a mechanism, consistent with the fluorescence data as well as with 
previous studies on MSMt and MSEc,
187,239 in which Mg2+ is coordinated in an octahedral 
conformation by the carboxylate side chains of Glu432 and Asp460, along with four water 
molecules. In this model (see figure 20), glyoxylate enters the active site and displaces two of the 
water molecules in the Mg2+ coordination sphere. Following this, acetyl coenzyme A enters the 
active site. Asp631 then deprotonates acetyl coenzyme A. The resulting enolate attacks glyoxylate 
70 
 
(activated by chelation of Mg2+) to form a malyl-CoA intermediate that, in turn, deprotonates a 
proximal water molecule. This affords a hydroxide anion that can attack and hydrolyse the 
thioester. Arg340 then acts as a catalytic acid, protonating CoA, which causes CoA to leave the 
active site first, followed by malate. 
 
Figure 20. Schematic of the proposed catalytic cycle of MSPa. Coordination of glyoxylate by 
the Mg2+ co-factor renders it susceptible to a conjugate attack by acetyl coenzyme A. The Michael 
adduct is then hydrolysed by a catalytic amino acid to liberate malate and coenzyme A. 
 
The crystal structure was useful in influencing further experimentation, where I also 
showed that events in the enzyme active site could be monitored non-invasively using intrinsic 
tryptophan fluorescence as a probe. Fluorescent studies confirmed the requirement of magnesium 
for substrate binding and catalysis, as well as that there were no global conformational changes 
during catalysis. I have characterised the structure and properties of P. aeruginosa malate synthase 
G with a particular emphasis on identifying potential drug binding sites. Computational data 
derived from a collaboration revealed two sites in the structure as well as the thermodynamic 
properties of hydration sites within the predicted binding sites that are promising starting points 
for drug development. Not all ligand-binding sites have the appropriate physicochemical and 
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topological properties to bind non-covalently to small-molecule drugs with sufficient affinity for 
inhibition. 
These findings contribute to the growing body of evidence that MS is an amenable drug 
target and can provide a means for inhibitor development against P. aeruginosa using structure-
based approaches. The findings reported here, along with the structural similarity and success in 
drugging malate synthase G in other pathogens instils confidence that MS is a chemically and 
biologically tractable target in P. aeruginosa.  
Further work should explore whether there is a contributory network inhibition of 
isocitrate lyase by these small molecules inhibitors of MS. Given the functional relationship of 
these enzymes, it is quite possible that inhibitors of malate synthase G also act upon isocitrate 
lyase, which may contribute to the overall inhibition of shunt activity and minimise the risk of 
resistance from any single-point mutation. Building on this, more work is needed to understand 
the enzymatic regulation of shunt activity in P. aeruginosa. This is particularly important in the case 
of ICL as it mediates bacterial survival in vivo as the first enzyme of the glyoxylate shunt. Malate 
synthase plays a secondary role in this process, enabling glyoxylate detoxification and protecting 
the cell from ketoacidosis.191 Therefore, modulating shunt expression in vivo represents an 
opportunity to disrupt shunt function simultaneously by increased expression of ICL, leading to 
ketoacidosis and inhibition of malate synthase G to arrest gluconeogenesis. Research in this area 




4. Results and discussion 




Pseudomonas aeruginosa overcomes several metabolic challenges in vivo, particularly during 
infection scenarios where nutrients are limited. When the primary source of carbon is derived from 
C2 molecules, the glyoxylate shunt is used for gluconeogenesis instead of the tricarboxylic acid 
cycle. Recent work has shown that carbon flux through the glyoxylate shunt plays a vital role in 
the pathogenicity of medically relevant microorganisms. Mutants of Mycobacterium tuberculosis, for 
example, defective in isocitrate lyase (ICLMt) activity show impaired survival in vivo.
193 Similarly, in 
P. aeruginosa, the glyoxylate shunt is conditionally essential for survival in mammalian systems.194 
Given their importance in pathogenicity and the fact that there are no human orthologues of the 
glyoxylate shunt enzymes, ICL and MS have become attractive targets for drug discovery efforts. 
Studies revealing the glyoxylate shunt as a potential target for antibacterial intervention are 
significant because P. aeruginosa currently occupies the second spot in the WHO’s critical priority 
pathogens list.9 The need for new antipseudomonal agents is dire.  
Nature has already taken the opportunity to target the glyoxylate shunt as an antibacterial 
strategy. The human enzyme, Irg1, synthesises itaconate during macrophage activation and 
supports immune cells during bacterial infections by being a potent ICL inhibitor.251,252 However, 
P. aeruginosa has seized the body’s defence for its own gain to survive inside macrophages by 
acquiring the ability to degrade itaconate into acetyl coenzyme A and pyruvate.253 ICL and MS 
from a variety of pathogens have been structurally elucidated, which have helped facilitate 
structure-based drug design. Examination of the active sites of the crystal structures of ICL and 
MS from M. tuberculosis suggest that the latter would provide a more “druggable” target. This 
implies that MS could better afford small, drug-like molecules perhaps due to its deeper, 
hydrophobic active site that must accommodate the pantothenate tail of acetyl coenzyme A. ICL 
has a smaller and highly polar active site.179,254  
Nonetheless, several ICL inhibitors have already been identified, along with itaconate, such 
as 3-bromopyruvate255 and 3-nitropropionate (3-NP)256 (see figure 21). 3-NP and 3-
bromopyruvate have inhibitory constants (Ki) of 3 µM and 120 µM, respectively, against ICLMt.
257 
Sharma and co-workers showed evidence that Cys191 acts as the catalytic base necessary for the 
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cleavage of isocitrate into glyoxylate and succinate in ICLMt.
179 Another research group discovered 
that Cys191 serves not only in the ionisation of succinate for catalytic turnover but also in the 
mechanism-based inhibition by 3-NP and that Cys191 is conserved across all ICLs and 
methylisocitrate lyases.258 However, these ICL inhibitors are not pharmacologically suitable for use 
in vivo because they display nonspecific hepatotoxicity.259 Also, 3-NP is a succinate analogue and 
also inhibits succinate dehydrogenase, a significant enzyme of the TCA cycle.260 A more recent 
compound, 2-vinyl-D-isocitrate, was developed as a mechanism-based inactivator of ICLMt. The 
retro-aldol cleavage of 2-vinyl-D-isocitrate by ICL reveals a Michael substrate, 2-vinylglyoxylate, 
which forms a covalent adduct with the thiolate form of Cys191 in the active site.261 
 
 
Figure 21. Chemical structures of known isocitrate lyase inhibitors. These inhibitors have 
been shown in M. tuberculosis to interfere with enzymatic cleavage of isocitrate into glyoxylate and 
succinate by interacting with catalytic Cys191 in the active site. 
 
In 2012, Krieger et al. developed potent phenyl-diketoacid (PDKA) inhibitors of malate 
synthase G from M. tuberculosis (MSMt) through structure-based drug design.
242 They initially 
screened 35 substrate analogues, 19 of which exhibited inhibitory activity against MSMt. Analysis 
of the protein structure in complex with five of these inhibitors (PDB entries: 3S9I, 3S9Z, 3SAD, 
3SAZ, and 3SB0) show no significant structural changes upon binding, but do show chelation of 
the magnesium co-factor in the active site by the 1-2-diol. Other common chelating agents, such 
as catechol, were shown to be ineffective MSMt inhibitors, suggesting a degree of specificity in the 
action of the PDKAs.  
Further analysis of the inhibition through structure-activity relationships indicated that 
these PDKA compounds adopt an unusual conformational pose once bound, with the aryl 
substituent twisted out of coplanarity with the benzylic ketone. This allows the compound to 
achieve a close contact between the PDKA’s aromatic ring and the carboxylic acid of a nearby 
aspartate (Asp633, which is one of the amino acids involved in catalysis in MSMt).
187 This pose 
permits the formation of an unusual face-on anion-π interaction, which is a noncovalent binding 
contact between an electron-deficient aromatic moiety and an anion. Intramolecular interactions 
of this sort are uncommon in inhibitors, but are growing in number, and are impacting our 
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understanding of various biological processes such as enzyme inhibition, protein-protein 
interactions, and macromolecular folding.262 The aromatic ring of the PDKAs was confirmed as 
essential for activity as analogues carrying aliphatic chains were inactive as inhibitors of MSMt.
263 
The PDKA hits were then optimised by adding various substitutions to the PKDA scaffold, 
although this resulted in only a modest improvement in activity. However, substitution at the 
ortho-position of the phenyl ring did increase stability 10-fold and improve the IC50 value.
242 The 
potency of the inhibitors improved with increasing electrophilicity of the substituent (2-F > 2-Cl 
> 2-Br > 2-Me > 2-H), which resulted in stronger anion-π interactions.263 
Fahnoe and co-workers were the first to demonstrate the tractability of the glyoxylate 
shunt in Pseudomonas aeruginosa as an antibacterial target using a combined chemical and genetic 
approach.194 They confirmed that the glyoxylate shunt is conditionally essential for survival on 
acetate, and they found that the P. aeruginosa double deletion mutants (ΔICL ΔMS) were completely 
cleared from a pulmonary infection model after 48 hours, indicating that they are also essential to 
establish infections in a mammalian system. The authors identified eight hits capable of preventing 
the growth of P. aeruginosa on acetate as a sole carbon source from an HTS campaign of 150,000 
compounds. They confirmed the same compounds did not affect growth in glucose medium, 
suggesting that they are cell permeable and that they specifically target acetate metabolism. When 
they tested in vitro for their ability to inhibit purified ICL and MS, the eight compounds inhibited 
both enzymes from P. aeruginosa with IC50 values in a low micromolar range. These compounds 
were the first known dual inhibitors of ICL and MS from a HTS campaign. However, the precise 
mechanism of inhibition and specificity of these compounds has yet to be rigorously evaluated. 
 
4.2 The rationale for designing a small molecule library 
 
In collaboration with Dr Sean Bartlett from the Department of Chemistry, we designed 
and synthesised a small collection of structural analogues based upon the chloropyridine derivative 
from Fahnoe et al.’s work.194 We reasoned that combining the structural and electronic features of 
the known inhibitors of the glyoxylate shunt could allow for more potent inhibition of Pseudomonas 
aeruginosa.  
We supposed the chloropyridine derivative was a good starting point because it was an 
effective inhibitor according to the π-acidity of the scaffold, and it was not much larger than the 
PDKAs active against MSMt, see figure 22A. The synthesised compounds all shared the core 2-
aminopyridine structure with tert-butyloxycarbonyl protecting groups and varied only in the 
electronegative substituents at the 4-position of the aromatic ring (figure 22B). Dr Bartlett 
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synthesised an isomeric 2-chloropyridine derivative as a negative control to test if inhibition was 
dependent on constitutional isomerism. We anticipated the new compounds would have a similar 
inhibitory mechanism as the PDKAs on MSMt, so we hypothesised that the IC50 values would 
decrease as the electronegativity of the substituents increased because this would favour stronger 
anion-π interactions.263 We also reasoned that the same could be true of ICLPa inhibition if the 
mechanism of action were similar to MSPa inhibition. It is notable that the test compounds are 
structurally dissimilar to the endogenous substrates of the glyoxylate shunt enzymes or any of the 
known inhibitors of ICL.   
Therefore, in this study, I set out with three experimental objectives. First, I sought to test 
if the small library of compounds could prevent bacterial growth of Pseudomonas aeruginosa in 
conditions relevant to the expression of the glyoxylate shunt enzymes. Second, I tested if the 
compounds could inhibit the activity of both of the glyoxylate shunt enzymes purified from P. 
aeruginosa. Third, I hoped to elucidate the binding mechanism and support a definitive mechanism 
of action on the target enzymes through enzyme kinetics, isothermal titration calorimetry and X-






Figure 22. Analogues and controls synthesised for this study. (A) Structures of glyoxylate 
shunt inhibitors reported in the literature with known or proposed anion-π interactions. (B) The 
compounds (SB001-029) all shared a 2-aminopyridine core structure with tert-butyloxycarbonyl 
protecting groups, varying only in the substituent at the 4-position. SB032 and 2-amino-4-





4.3 Antibacterial assessment of 2-aminopyridines against 
Pseudomonas aeruginosa 
 
I analysed the 2-aminopyridine library to assess antipseudomonal activity through an 
endpoint assay. P. aeruginosa PAO1 culture grown overnight in LB medium was incubated with 200 
µM of test compounds at a starting OD600 nm=0.05. After 18 hours of incubation, the wells with 2-
aminopyridines added were visibly as turbid as the control wells (not shown). The optical density 
readings were blanked using the media-only control wells, and then the final optical density 
readings were subtracted from the initial readings to get ΔOD600 nm. The values were normalised to 
that of the no inhibitor and vehicle control wells, which represented maximal growth, and bacterial 
growth percentage was calculated. None of the compounds affected bacterial growth of PAO1 
after 18 hours in rich medium, see figure 23, except for SB026. It is difficult to say at this point 
why SB026 shows a slight inhibition (~25%) of PAO1 in LB medium, but it does point to the 




Figure 23. Screening 2-aminopyridines on P. aeruginosa in rich medium. The percentage of 
bacterial growth was calculated from ΔOD600 nm relative to that of a “no inhibitor” control. The 
negative control was 2-AP (2-amino-4-chloropyridine), synthesised without tert-butyloxycarbonyl 
protecting groups. All compounds were tested at 200 µM. Values marked with * are significantly 





The same experiment was conducted in M9 minimal medium supplemented with 0.5% 
acetate as the sole carbon source. After 18 hours of incubation, wells with 2-aminopyridines added 
were visibly less turbid compared with control wells with no inhibitor added (not shown). SB001, 
SB026 and SB029 were all capable of partially inhibiting PAO1 growth (~50%), see figure 24. 
SB002 and SB023 were the only compounds to display complete inhibition of bacterial growth at 
200 µM. 2-amino-4-chloropyridine was designed as a negative control due to the absence of tert-
butyloxycarbonyl (Boc) protecting groups and displayed no inhibition. The results were in line 
with expectations, particularly because acetate is a C2 carbon source that requires a functional 
glyoxylate shunt for its metabolism. SB022 showed no inhibition of PAO1 growth. The most 
logical explanation could be because it had poor aqueous solubility, which could have influenced 
the absorbance readings. Another explanation is that somehow the CF3 group on the aromatic ring 
precluded the entry into the bacteria or binding to the target enzymes. This experiment confirmed 
two things. First, that SB002 and SB023 selectively target acetate metabolism via the glyoxylate 
shunt. Second, it shows that these compounds are cell-permeable and can pass the outer 




Figure 24. Screening 2-aminopyridines on P. aeruginosa in acetate medium. SB002 and 
SB023 inhibited PAO1 growth completely relative to that of a “no inhibitor” control. 2-AP (2-
amino-4-chloropyridine) was the negative control. All compounds were tested at 200 µM. Values 
marked with *, **, and *** are significantly different (* = p<0.05; ** = p<0.01; *** = p<0.001; 
n=3).  
 
Next, I tested concentrations of SB002 and SB023 to determine if a dose-dependent 
inhibition was possible. Again, a PAO1 overnight culture was diluted and added to 96-well plates 
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with two-fold dilutions of concentrations of inhibitors (0-200 µM; 1% DMSO), and the plate was 
incubated at 37°C with 200 rpm agitation for 18 hours. Final and initial optical density readings 
were blanked using the media-only control wells, and then the final optical density readings were 
subtracted from the initial readings to get ΔOD600 nm. The values were normalised to that of the no 
inhibitor and vehicle control wells, and bacterial growth percentage was calculated. 
 
 
Figure 25. Dose-response inhibition of PAO1 growth by SB002 and SB023. SB002 (blue) and 
SB023 (orange) were added (0-200 µM) and inhibited PAO1 in M9 acetate in a dose-dependent 
manner. 
 
SB002 and SB023 were able to prevent PAO1 growth in a dose-dependent manner with 
Hill slopes of -1.58 and -0.71, respectively. They also show promising inhibition with minimum 
inhibitory concentration (MIC) values of 1.16 µg mL-1 for SB002 and 13.48 µg mL-1 for SB023, 
see table 23. The MIC for SB002 is in agreement with the value found for the chloropyridine 
derivative in the literature.194  
 
Table 23.  MIC values of SB002 and SB023 on PAO1 in acetate. IC50 values and Hill slopes 
were derived from GraphPad Prism version 7.04. 
 SB002 SB023 
MIC (µg mL-1) 1.16 13.48 
IC50 (µM) 1.45 ± 1.12 9.08 ± 1.18 





4.4 Evaluation of 2-aminopyridines as inhibitors of malate 
synthase G  
 
Next, I tested the compounds to see if they could impede or reduce the enzymatic reaction 
of recombinant malate synthase G from P. aeruginosa (MSPa). Compounds solvated in DMSO were 
incubated at a final concentration of 75 µM (1% DMSO) with 25 nM of purified MS. The 
enzymatic reaction was initiated with 200 µM of substrate glyoxylate, pH 7.5 and a modified 
coupled assay in which the quantity of free thiol (present in the reaction product, coenzyme A) 
was titrated. When the enzymatic reaction of MSPa in the presence of the compounds was 
compared with the control reaction, which represented the enzyme reaction at maximal velocity, 
there was a clear and significant inhibition for SB002 and SB023, and partial, but statistically 
significant inhibition (~50%) for SB026 and SB032, as well as a slight, but statistically significant 
inhibition (~20%) for SB001. SB022 and SB029 surprisingly show an increase in MSPa activity, but 
this was most likely due to their poor aqueous solubility interfering with the absorbance readings 




Figure 26. Screening of 2-aminopyridines on recombinant MSPa. SB002 and SB023 inhibited 
enzymatic activity completely relative to that of the “no inhibitor” control. 2-AP (2-amino-4-
chloropyridine) was the negative control. All compounds were tested at 75 µM. Values marked 





For the compounds which showed significant inhibition during the kinetic screening, I 
generated dose-response curves to determine the IC50 values and visualise complete enzyme 
inhibition, if possible. SB002, SB023, SB026, and SB032 all displayed a reduction in MSPa enzyme 




Figure 27. Dose-response inhibition of MSPa. SB002 (blue), SB023 (orange), SB026 (teal) and 
SB032 (violet) were tested at a range of concentrations (0-75 µM) and inhibited MSPa in a dose-
dependent manner.  
 
SB002 and SB023 were able to abolish the enzymatic activity of MSPa at 75 µM altogether 
and show promising inhibition with IC50 values in the lower micromolar range, see table 24. The 
IC50 value for SB002 is in agreement with the value found in the literature.
194 SB026 and SB032 do 
show inhibition in a dose-response manner, even though they only achieved about 50% inhibition 
at the highest concentration tested. 75 µM was the limit of solubility in DMSO for these 
compounds in these experiments, with higher concentrations visibly precipitating. 
 
Table 24.  IC50 and Hill slope values for 2-aminopyridine inhibitors of MSPa. Values were 
calculated from the dose-response inhibition curves using GraphPad Prism v. 7.04. 
 SB002 SB023 SB026 SB032 
IC50 (µM) 4.50 ± 1.12 14.49 ± 1.10 59.27 ± 1.17 70.55 ± 1.10 




4.5 Evaluation of 2-aminopyridines as inhibitors of isocitrate 
lyase  
 
The 2-aminopyridine compounds were tested to see if they could inhibit the enzymatic 
reaction of recombinant isocitrate lyase from P. aeruginosa (ICLPa). Protein purification and enzyme 
activity are presented in appendix 3. The test compounds were dissolved in DMSO at a final 
concentration of 75 µM and incubated with ICLPa (final concentration: 170 nM) for 5 minutes at 
37°C. The enzymatic reaction was initiated with 200 µM of the substrate, D-L-isocitrate, and a 
modified coupled assay in which the number of ketones (present in the product, glyoxylate) was 
titrated using phenylhydrazine. When compared with the control enzyme reaction with no 
compounds added, which represented the reaction at maximal velocity, there was a full and 
significant inhibition observed at 75 µM for SB002, and partial inhibition for SB023, SB032, 
itaconate, and 3-nitropropionate, figure 28. SB026 and SB029 show partial decreases in enzyme 
activity, but the error between replicates was large and did not result in statistically significant 




Figure 28. Screening of 2-aminopyridines on recombinant ICLPa. SB002 inhibited enzymatic 
activity completely relative to that of the “no inhibitor” control. 2-AP (2-amino-4-chloropyridine) 
was the negative control. ITA (itaconate) at 50 µ) and 3-NP (3-nitropropionate) at 100 µM were 
tested for comparison as positive controls. All other compounds were tested at 75 µM. Values 





For the compounds which showed significant inhibition during the kinetic screening, I 
created dose-response curves to determine the IC50 values and visualise complete enzyme 
inhibition. SB002, SB023, SB032, and itaconate all displayed a reduction in ICLPa enzyme activity 
in a dose-dependent manner (figure 29), with Hill slopes of -3.6, -2.37, -1.2, and-1.3, respectively. 
SB002 was the only compound able to eradicate the enzymatic activity of ICLPa at 75 µM 
completely, and SB002 shows promising inhibition with an IC50 value of 13.28 µM, see table 25.  
 
 
Figure 29. Dose-response inhibition of ICLPa. SB002 (blue), SB023 (orange), SB032 (violet) 
and itaconate (maroon) were tested at different concentrations (0-75 µM; itaconate: 0-50 µM) and 
inhibited ICLPa in a dose-dependent manner. 
 
 The IC50 value for SB002 determined in this study (13.28 µM) is nearly 80x higher than the 
value found in the literature (0.17 µM).194 Fahnoe et al. used a final ICL concentration of 12 nM 
for their assessment, while I used 14x that amount (170 nM) in order to obtain a good 
spectroscopic signal to test for inhibition. A higher concentration of protein yielded a higher IC50 
and a dose-response curve with a steep Hill slope (-3.5). This provides an interesting point of 
discussion about the possible mechanism of SB002. On the one hand, a steep Hill slope (>-1) may 
indicate a tight-binding inhibitor, but on the other hand, it might indicate that the inhibition is 
caused by aggregation or nonspecific binding, which is more discernible at higher enzyme 
concentrations.264 An inhibitor can also undergo a phase transition or colloid formation as its 
concentration rises in the aqueous buffer. A steep Hill slope is more obvious at higher enzyme 
concentrations and should be approached with caution as it could give a false indication about the 




Nevertheless, SB002 was a better inhibitor of ICLPa than the positive controls at the 
concentrations tested. This apparent improvement in inhibition could be due, in the case of 3-NP, 
to the fact that the incubation time was only 5 minutes. 3-NP has been shown to display a covalent 
inhibition of ICLMt that requires several hours for inactivation.
258 Also, both 3-NP and itaconate 
possess exposed ketone groups, which could react chemically with phenylhydrazine in the presence 
of hydrogen atoms. Despite being present in excess (0.2 mM), a portion of phenylhydrazine could 
have reacted with the ketones on 3-NP and itaconate instead of any available glyoxylate, which 
could have reduced the spectroscopic signal for phenylhydrazone (324 nm) and distorted the 
results. Still, SB002 was the only compound that could reduce the enzymatic activity of both of 
the target enzymes completely, which means it has the potential to block the glyoxylate shunt 
pathway in conditions which require a functional pathway for survival. 
 
Table 25.  IC50 and Hill slope values for 2-aminopyridine inhibitors of ICLPa. Values were 
calculated from the dose-response inhibition curves using GraphPad Prism v. 7.04. 
 SB002 SB023 SB026 SB032 ITA 3-NP 
IC50  (µM) 13.28 ±1.08 >75 55.36 ±1.14 >75 24.55 ±1.16 >75 
Hill slope -3.6 ±0.71 -2.4 ±1.30 -2.0 ±0.54 -1.2 ±0.21 -1.3 ±0.22 -2.8 ±0.97 
Abbreviations: 3-NP, 3-nitropropionate; ITA, itaconate. 
 
 The 2-aminopyridine compounds differ only in their electron withdrawing group at the 4th 
position, yet there is significantly different inhibition between them. For example, SB023 (4-CN) 
clearly inhibits MSPa but does not exhibit inhibition with nearly as much potency on ICLPa. This 
was surprising, particularly because of SB023’s ability to completely inhibit PAO1 growth in acetate 
medium. Similarly, SB029 (4-CO2Me)  shows a slight inhibition against ICLPa (~50%) but shows 
no inhibition against MSPa and no ability to inhibit PAO1 growth. SB001 (4-Br) and SB022 (4-CF3) 
should theoretically improve inhibition by encouraging a stronger anion-π interaction in the 
binding site, yet they were consistently ineffective in these assessments. SB002 (4-Cl) and SB032 
(2-Cl) are isomers, yet there is a clear difference in their efficacy on both of the glyoxylate shunt 
enzymes, with SB002 exhibiting more potency. More information about the mechanism for the 





4.6 Kinetic modes of malate synthase G inhibition for SB002 
and SB023  
 
The kinetic mechanism of SB002 inhibition was investigated by determining changes to 
the Michaelis Menten constants (KM
app) and maximum velocities (Vmax
app) of MSPa in the presence 
of the inhibitor. Three concentrations of SB002 (3 µM, 6 µM, and 9 µM), which were near to the 
IC50 value (4.5 µM), were selected to test on MSPa. After initiating the enzymatic reactions by 
titrating substrate glyoxylate (5-400 µM) in the presence of fixed, saturating amounts of acetyl 
coenzyme A (200 µM), there was a dramatic reduction in Vmax
app values concerning all three 
concentrations of SB002 (figure 30A). The KM
app
 values for glyoxylate decreased slightly, which 
indicates that MSPa displayed a better affinity for glyoxylate while in the presence of 3 µM and 6 
µM of SB002, table 26. 
 
Figure 30. Mode of inhibition of MSPa by SB002. (A) Kinetic data obtained by titrating 
glyoxylate (5-400 µM) in the presence of no addition (black), or the presence of 3 µM (red), 6 µM 
(blue), or 9 µM (green) SB002. (B) Lineweaver-Burk plot showing that SB002 displayed mixed 
inhibition when glyoxylate was titrated. (C) Kinetic data obtained by titrating acetyl coenzyme A 
(5-400 µM) in the presence of no addition (black), or in the presence of 3 µM (red) or 6 µM (blue) 
SB002. (D) Lineweaver-Burk plot showing that SB002 displayed mixed inhibition when acetyl 




 of glyoxylate slightly increased when MSPa was incubated with 9 µM 
of SB002. The Lineweaver-Burk plot of 1/velocity versus 1/[glyoxylate] (figure 30B) indicates mixed 
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inhibition. Two types of mixed inhibition were observed concerning glyoxylate. The linear 
regression for the lowest concentration of SB002 (3 µM) intersected with the control line at a 
similar place on the x-axis, which is typical for type 2 inhibition (also known as noncompetitive 
inhibition).212 Type 2 mixed inhibition is where the inhibitor, [I], has equal affinity in binding to 
the free enzyme, [E], as the enzyme-substrate complex, [ES]. The linear regressions for higher 
concentrations of SB002 (6 µM and 9 µM) appear to intersect with the control line, [-I], below the 
x-axis, which is characteristic of type 3 mixed inhibition. In type 3 mixed inhibition, [I] binds to 
both [E] and [ES], but displays a greater binding affinity for [ES]. Additionally, KM
app
 values 
decrease in the presence of higher amounts of inhibitor. The inhibition binding constants of SB002 
to [E] (Ki) and [ES] (Ki’) were calculated (using the relevant equations denoted in chapter 2, 
section 2.7) as 4.5 µM and 3.9 µM, respectively (see table 26), indicating a slight preference 
towards [ES], which is more characteristic of uncompetitive inhibition.266  
Varying acetyl coenzyme A concentrations (5-400 µM) in the presence of a fixed, saturating 
glyoxylate concentration (200 µM) resulted in sigmoidal data distribution in the presence of SB002 
(figure 30C). The Khalf
app
 values of acetyl coenzyme A increased as the concentration of SB002 
increased (table 26). There was also a noticeable decrease in Vmax
app
 with the addition of 6 µM 
SB002, but no change in Vmax
app
 with the addition of 3 µM SB002. This means that the enzyme was 
able to reach maximum velocity while in the presence of SB002, which is typical of competitive 
inhibition.212 According to the double reciprocal plots, however, the two lines appeared to intersect 
between the x- and y-axes, which suggested another type of mixed inhibition: type 1 (figure 30D).  
Type 1 mixed inhibition mimics competitive inhibition, which entails that while binding to both 
enzyme states, [I] binds to [E] with much greater affinity than [ES].267 Additionally, the data best 
fit the competitive inhibition equation in chapter 2 (equation 14), resulting in a Ki value of 1.14 
µM. This implies that SB002 is directly competing with acetyl coenzyme A in its binding pocket 
and that the inhibition is concentration-dependent. Computational analyses from chapter 3 
revealed the binding pocket of acetyl coenzyme A as a druggable binding site (Site B) in MSPa. 
SB002 could compete with acetyl coenzyme A to interact with its binding amino acids in Site B, 
such as Pro543, Phe126, Arg312, or Met629 in MSMt
187, but this would need confirmation through 
structural information.  
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Table 26. Calculated kinetic parameters for SB002 and SB023 inhibition of MSPa. KM/Khalf, 
kcat, and Vmax values were derived from Michaelis-Menten or Hill sigmoidal kinetic analyses. Ki and 
Ki’ values were determined from best-fit equations, and mode of inhibition was determined visually 




































] glyoxylate 33.70 2.40 93.90 N/A N/A Substrate Substrate 
3 µM SB002 29.70 1.80 73.40 12.06 12.06 Mixed (2) Mixed (2) 
6 µM SB002 30.20 0.80 32.50 3.65 3.06 Mixed (3) Mixed (3) 
9 µM SB002 40.60 0.50 17.80 1.63 2.03 Mixed (3) Mixed (1) 
All SB002 N/A N/A N/A 4.48 2.87 N/A Mixed (3) 
glyoxylate 33.70 2.40 93.90 N/A N/A Substrate Substrate 
5.5µM SB023 38.60 2.20 88.80 29.60 88.36 Mixed (1) Mixed (1) 
11 µM SB023 42.30 2.10 82.90 28.16 80.48 Mixed (1) Mixed (1) 
22 µM SB023 52.40 1.60 63.40 32.43 32.43 Mixed (2) Mixed (2) 














AcCoA 48.30 1.60 65.70 N/A N/A Substrate Substrate 
3 µM SB002 97.0a 1.60 N/A 1.14 0.00 Mixed (1) Competitive 
6 µM SB002 167.0a 0.90 N/A N/A N/A N/A N/A 
All SB002 N/A N/A N/A 1.14 0.00 N/A Competitive 
AcCoA 62.00 2.40 98.80 N/A N/A Substrate Substrate 
5.5µM SB023 40.60 2.00 78.90 48.76 0.00 Mixed (1) Competitive 
11 µM SB023 56.10 1.80 70.80 42.17 27.98 Mixed (1) Mixed (3) 
22 µM SB023 57.00a 1.30 N/A N/A N/A N/A N/A 
All SB023 N/A N/A N/A 19.56 46.14 N/A Mixed (1) 
a SB002 and SB023 altered the kinetics from hyperbolic to sigmoidal concerning acetyl coenzyme 
A, so these reported values in the table are Khalf, instead of KM.  
b The value of Et was based on the most likely oligomeric status of the native protein. MSPa was 
assumed to be a monomer.  
c Three types of mixed inhibition were observed from the Lineweaver-Burk plots: (1) [-I] and [+I] 
lines intersected between the x- and y-axes, indicating [I] binds to [E] with greater affinity than 
[ES]; Ki<Ki’, KM
app>KM and Vmax=Vmax
app, which mimics competitive inhibition. (2) [-I] and [+I] 
lines intersect at the x-axis, which indicates that [I] binds with equal affinity to [E] and [ES]; Ki= 
Ki’, KM
app=KM and Vmax
app<Vmax, which mimics noncompetitive inhibition. (3) [-I] and [+I] lines 
intersect below the x-axis, indicating that [I] binds to [ES] with greater affinity than [E]; Ki< Ki’, 
KM
app<KM and Vmax
app<Vmax, which mimics uncompetitive inhibition. 
d The calculated mode of inhibition was determined from the best fit Ki and Ki’ equations as 
denoted in chapter 2. Abbreviations: AcCoA, acetyl coenzyme A; MOI, mode of inhibition; 
N/A, not applicable. 
 
The same experiments were completed for SB023 as the compound inhibited the activity 
of MSPa with micromolar potency. Three concentrations of SB023 (5.5 µM, 11 µM, and 22 µM) 
were selected that were near to the IC50 (14.5 µM) to test on MSPa. After initiating the enzymatic 
reactions by titrating substrate glyoxylate (5-400 µM) in the presence of a fixed, saturating acetyl 
coenzyme A  concentration (200 µM), there were clear increases in the KM
app
 values of glyoxylate 
and slight decreases in Vmax
app
 as the concentration of SB023 increased (figure 31A and table 26). 
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In the double reciprocal plots, the lines for the “no inhibitor” control, [-I], and 22 µM SB023 
(>IC50 value) intersected at the same point on the x-axis, while the lines for 5.5 µM and 11 µM 
SB023 intersected with the [-I] line in the second quadrant between the x- and y-axes, suggesting 
that SB023 is a mixed-type inhibitor (1 & 2) for MSPa (figure 31B). Furthermore, the calculated 
inhibition constants Ki and Ki’ for SB023 were 20.9 and 49.2 µM, respectively. This means SB023 





Figure 31. Mode of inhibition of MSPa by SB023. (A) Kinetic data obtained by titrating 
glyoxylate (5-400 µM) in the presence of no addition (black), 5.5 µM (red), 11 µM (blue), or 22 µM 
(green) SB023. (B) Lineweaver-Burk plot showing that SB023 displayed mixed inhibition when 
glyoxylate was titrated. (C) Kinetic data obtained by titrating acetyl coenzyme A (5-400 µM) in the 
presence of no addition (black), 5.5 µM (red), 11 µM (blue), or 22 µM (green) SB023. (D) 
Lineweaver-Burk plot showing that SB023 displays mixed inhibition when titrating acetyl 
coenzyme A.  
 
When varying AcCoA concentrations (5-400 µM) in the presence of a fixed, saturating 
glyoxylate concentration (200 µM) (figure 31C and 31D), the data displayed a sigmoidal 




between the SB023 concentrations compared with the KM of acetyl coenzyme A, see table 26. 
There was also a definite decrease in Vmax
app with the addition of 22 µM SB023; however, Vmax
app
 
decreased more gradually in the presence of the two lower SB023 concentrations. According to 
the double reciprocal plots, the lines for 5.5 µM and 11 µM SB023 appear to intersect with the [-
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I] line between the x- and y-axes, which suggests type 1 mixed inhibition (figure 31D). The 
inhibition constants for SB023, Ki and Ki’, were determined as 19.6 µM and 46.1 µM, respectively. 
Additionally, the slopes and y-intercepts of the lines increased as the concentration of SB023 
increased, while the x-intercepts fluctuated (table 27). This type of mixed inhibition mimics 
competitive inhibition and implies that while having the capability of binding to both [E] and [ES], 
SB023 favours binding to [E] due to a smaller Ki than Ki’.
211 This might suggest that the inhibitor 
is competing with acetyl coenzyme A in its binding pocket and that the inhibition is concentration-
dependent. Much like SB002, then we can infer the potential binding pocket of SB023, but this 
would need confirmation through further structural evidence.  
 





















glyoxylate 15.87 ± 0.47 0.42 ± 0.03 -0.027 0.9889 
3 µM SB002 19.73 ± 0.42 0.50 ± 0.03 -0.024 0.9941 
6 µM SB002 23.34 ± 1.71 1.49 ± 0.11 -0.068 0.9396 
9 µM SB002 51.45 ± 5.51 2.87 ± 0.37 -0.065 0.8882 
glyoxylate 15.87 ± 0.47 0.42 ± 0.03 -0.027 0.9889 
5.5 µM SB023 19.26 ± 0.58 0.45 ± 0.04 -0.023 0.9876 
11 µM SB023 25.38 ± 1.40 0.48 ± 0.09 -0.019 0.9588 












] AcCoA 31.33 ± 1.56 0.64 ± 0.10 -0.021 0.9666 
3 µM SB002 113.2  ± 11.35 1.12  ± 0.73 -0.010 0.8766 
6 µM SB002 N/A N/A N/A N/A 
AcCoA 19.99 ± 0.43 0.34 ± 0.03 -0.017 0.9940 
5.5 µM SB023 22.56 ± 1.29 0.51 ± 0.08 -0.022 0.9561 
11 µM SB023 31.45 ± 1.56 0.65 ± 0.10 -0.021 0.9667 
22 µM SB023 N/A N/A N/A N/A 





4.7 Kinetic mode of isocitrate lyase inhibition for SB002 
 
 To determine the kinetic mode of inhibition for SB002 on ICLPa, I again selected three 
concentrations (9 µM, 18 µM and 27 µM) near to the IC50 value determined by dose-response 
curves to test against ICLPa. After initiating the enzymatic reactions with increasing concentrations 
of substrate isocitrate (5-400 µM), there were reductions in both KM
app
 and Vmax
app values as the 




Figure 32. Mode of inhibition of ICLPa by SB002. (A) Kinetic data obtained by titrating 
isocitrate (5-400 µM) in the presence of no addition (black), 9 µM (red), 18 µM (blue), or 27 µM 
(green) SB002. (B) The Lineweaver-Burk plot showed that SB002 displayed 
mixed/noncompetitive inhibition of ICL.  
 
Generally, this is a sign of uncompetitive inhibition, but the 1/v versus 1/[isocitrate] plot 
(figure 32B) consisted of all four lines converging at similar points on the x-axis.267 Additionally, 
the slopes and y-intercepts of the lines increased as the concentration of SB002 increased (table 
29), which points towards SB002 displaying type 2 mixed inhibition or classical noncompetitive 
inhibition of ICLPa. The linear regression for the highest concentration of SB002 (27 µM) seems 
to converge with the no inhibitor line below the x-axis, which indicates type 3 mixed inhibition. 
Therefore, SB002 has the capability of binding to both [E] and [ES]; however, the substrate versus 
velocity plots for all three concentrations best fit the equation for type 3 mixed inhibition 
(equation 13 in chapter 2) in GraphPad Prism, simulating uncompetitive inhibition. The 
inhibition constant for binding to [ES], Ki’, from this calculation was 21.3 µM, while Ki was equal 
to 0 µM. Thus, SB002 most likely binds to an allosteric site in the enzyme and favours binding to 
the [ES], which explains why KM
app decreases for isocitrate at higher concentrations of SB002. The 
preferred mode of inhibition for SB002 is uncompetitive against ICLPa.  
91 
 
Table 28. Calculated kinetic parameters for SB002 inhibition of ICLPa. KM, kcat, and Vmax 
values were derived from Michaelis-Menten kinetic analyses. Ki and Ki’ values were determined 
from best-fit inhibition equations. Mode of inhibition was determined visually from linear 
















isocitrate 57.40 1.40 2.10 N/A N/A Substrate Substrate 
9 µM SB002 51.60 1.20 1.80 0.00 51.80 Mixed (2) Uncompetitive 
18 µM SB002 46.20 1.00 1.40 0.00 31.00 Mixed (2) Uncompetitive 
27 µM SB002 19.50 0.50 0.80 0.00 15.60 Mixed (3) Uncompetitive 
ALL SB002 N/A N/A N/A 0.00 21.28 N/A Uncompetitive 
a The value of Et was based on the most likely oligomeric status of the native protein. ICL was 
assumed to be a tetramer. 
b The two types of mixed inhibition observed for ICLPa from the Lineweaver-Burk plots: (2) [-I] 
and [+I] lines intersect at the x-axis, which indicates that [I] binds with equal affinity to [E] and 
[ES]; Ki=Ki’, KM
app=KM, and Vmax
app<Vmax, which mimics noncompetitive inhibition. (3) [-I] and 
[+I] lines intersect below the x-axis, indicating that [I] binds to [ES] with greater affinity than [E]; 
Ki< Ki’, KM
app<KM, and Vmax
app<Vmax, which mimics uncompetitive inhibition. 
c The calculated mode of inhibition was determined from the best fit Ki and Ki’ equations.  
Abbreviations: MOI, mode of inhibition; N/A, not applicable. 
 
To date, only one crystal structure of ICLPa exists (PDB entry 61GO), and in the structure, 
the active site is quite shallow and polar in nature.268 An uncompetitive binding mode for SB002, 
a nonpolar molecule, could explain why the compound can still inhibit ICLPa with decent potency. 
It would be wise in the future to computationally interrogate the ICLPa crystal structure for open 
druggable pockets or allosteric sites in the enzyme where a ligand like SB002 could bind. 3-NP and 
3-bromopyruvate, which are analogues of the enzyme product succinate, are uncompetitive 
inhibitors of ICLMt concerning isocitrate and have been shown to bind covalently to a catalytic 
cysteine residue, Cys191, which exists in ICLPa as Cys222.
259,268 
 









isocitrate 49.58 ± 1.48 0.68 ± 0.09 -0.013 0.987 
9 µM SB002 55.83 ± 2.09 0.75 ± 0.13 -0.014 0.980 
18 µM SB002 66.13 ± 2.02 0.82 ± 0.13 -0.012 0.986 





4.8 Hit validation of SB002 and thermodynamics of binding  
 
Isothermal Titration Calorimetry (ITC) is considered the gold standard for accurately 
determining the thermodynamics of interactions between small molecules and enzymes.269 ITC is 
sensitive enough to detect thermal changes of these interactions without any labelling, 
immobilisation or limit on the size of either interacting entities.270 ITC was performed to see if 
direct binding of SB002 to both MSPa and ICLPa was detectable. I chose SB002 as it had the highest 
potency of the 2-aminopyridines tested and was the only compound to inhibit both enzymes 
completely in the enzyme kinetic analyses. Dr Xavier Chee from the Department of Pharmacology 




Figure 33. Isothermal titration calorimetry plots for SB002 binding to MSPa and ICLPa. The 
top panels illustrate the raw isothermal titration calorimetry data from 30 equal injections of either 
(A) MSPa or (B) ICLPa into the cell containing SB002. Both interactions are exergonic. The bottom 
panels illustrate the respective binding isotherms created by plotting the integrated heat peaks 
against the molar ratio of protein to ligand. 
 
Purified MSPa (110 µM) or ICLPa (202 µM) were reverse titrated into the calorimeter cell 
containing SB002 (11 µM) using a VP-ITC at 25°C. Due to its limited working concentrations, 
SB002 was loaded into the cell rather than the syringe, which required lower concentrations. 
Protein samples were dialysed before loading in the syringe, and the dialysis buffer was used to 
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adjust concentrations of the protein and ligand samples to minimise heat fluctuations due to buffer 
exchange. The syringe and the cell contained a final concentration of 0.1% of DMSO.  
The interactions between MSPa-SB002 and ICLPa-SB002 were exothermic due to the 
negative heat values on the y-axes of the graphs in figure 33. SB002 became saturated with both 
proteins after ten injections, after which the baselines returned to their initial heats. The raw data 
for ICLPa shows a sustained heat accompanying the additional injections after saturation, which is 
a sign of enthalpy of dilution.270 The area of each injection peak was then integrated and plotted 
versus the molar ratio of protein to ligand. The resulting isotherms were fitted to a one-site binding 
model, and the thermodynamic parameters were derived from the fit, see table 30. The slope of 
the sigmoidal binding isotherm is equal to the equilibrium association constant (Ka) of the ligand-
protein complex.271 The inverse of Ka is equal to the equilibrium dissociation constant (Kd) of the 
protein-ligand complex, and Ka and Kd together indicate the overall binding affinity.
272 Thus, larger 
slopes indicate larger Ka values and smaller Kd values, meaning better binding affinities.
273 Visually, 
the slope of the binding isotherm for MS is steeper than for ICLPa. Based on this, SB002 has a 
higher binding affinity for MSPa.  
 
Table 30. Thermodynamic parameters of SB002 binding to MSPa and ICLPa. 
Thermodynamics MSPa ICLPa 
ΔG (kcal mol-1) -10.31 ± 1.79×10-3 -7.98 ± 3.44×10-1 
ΔH (kcal mol-1) -0.47 ± 1.79×10-3 -4.22 ± 3.44×10-1 
-TΔS (kcal mol-1) -9.84 -3.76 
Ka  (M-1) 3.56×107 ± 1.86×106 7.18×105 ± 1.49×105 
Kd (nM-1) 28.60 ± 1.6 1,430 ± 0.30 
n (binding sites) 0.35 ± 8.41×10-4 0.53 ± 3.25×10-2 
Abbreviations: Ka, equilibrium association constant; Kd, equilibrium dissociation constant.  
 
A Gibb’s free energy value (ΔG) <0 means the interaction is exergonic and energetically 
favourable. Therefore, smaller ΔG values correspond to higher binding affinities, signifying that 
less work is required to achieve an interaction between the protein and the ligand.274 ΔG was 
calculated as -10.31 kcal mol-1 for MSPa-SB002 and            -7.98 kcal mol
-1 for ICLPa-SB002, see 
table 30. Enthalpic and entropic terms quantify ΔG (depicted in equation 16 of chapter 2). The 
enthalpic term (ΔH) is a direct measure of the heat or energy associated with forming a 
macromolecular complex at a given temperature. ΔH is the number and strength of bonds broken 
and created during the molecular interaction. Hydrogen bonding and Van der Waals forces are the 
primary contributions to ΔH, and hydrogen bonding corresponds to a better binding affinity as 
the binding is more exothermic than those involved in Van der Waals forces.274 ΔH for MSPa-
SB002 was -0.47 kcal mol-1 and was -4.22 kcal mol-1 for ICLPa-SB002. This is generally low for 
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biomolecular interactions of approved drugs, where is it common to see ΔH values around -30 
kcal mol-1.269 
The entropic term (ΔS), conversely, gives an indication of hydrophobic interactions and 
changes in protein conformation upon binding. Favourable entropic binding affinities are derived 
primarily from hydrophobic interactions.275 An example of a hydrophobic interaction is the release 
of tightly bound water upon ligand binding in the binding pocket. Unfavourable entropy usually 
results from an overall decrease in the degrees of freedom of the protein or ligand when interacting. 
This means that the protein has undergone a large conformational change or that the ligand is very 
flexible.276 -TΔS was -9.84 kcal mol-1 for MSPa-SB002, and was -3.76 kcal mol
-1 for ICLPa-SB002. 
The differences in thermodynamic parameters calculated for MSPa-SB002 and ICLPa-SB002 are 
represented visually in figure 34.  
 
Figure 34. Thermodynamic parameters of MSPa-SB002 and ICLPa-SB002. The 
thermodynamic interactions and the proportions by which enthalpy (ΔH) and entropy (-TΔS) 
contribute to Gibb’s free energy (ΔG) of binding are shown for MSPa-SB002 (left) and ICLPa-
SB002 (right) as determined by isothermal titration calorimetry. MSPa-SB002 binding is driven 
largely by entropy, whereas ICLPa-SB002 binding is driven equally by entropy and enthalpy. 
 
The Kd constants for MSPa-SB002 and ICLPa-SB002 were calculated as 28.6 nM and 1.43 
µM, respectively. The number of binding sites (n) in the proteins was also calculated from the 
molar ratio of protein to ligand near to the inflection point of the binding isotherm (figure 33). 
Because I performed a reverse titration, SB002 was in excess early in the experiment. If there is 
more than one binding site in the protein, then both sites will be occupied by the ligand and will 
contribute to ΔH (e.g. Hsite 1 +Hsite 2).
270 Once enough protein has been added to interact with all of 
the ligands in the cell (after the inflection point in the binding isotherm), then some ligand 
molecules in weaker interactions leave the second binding site to occupy the stronger first site.277  
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The inflection points of the isotherms were estimated visually and calculated from the 
binding isotherm at the molar ratios of 0.35 and 0.53 for MSPa-SB002 and ICLPa-SB002, 
respectively. Therefore, the prevailing binding stoichiometry is two molecules of SB002 for one 
molecule of ICLPa in two identical binding sites in the protein. For MSPa, n = 0.35, suggesting a 
ratio of 2.85 molecules of SB002 for every one molecule of MSPa, which cannot be accurate. The 
error present in the calculated value of n is most likely due to errors in the measured concentration 
of MSPa, or if the measured concentration was correct, that a proportion of the protein sample was 
inactive or unfolded. If we assume an n of 0.5 (2:1 ligand: protein ratio) for MSPa, we can calculate 
(using equation 18 in chapter 2) that approximately 70% of the total concentration of MSPa was 
active in the syringe, which altered the actual active MSPa concentration in the syringe to 77 µM. It 
is worth noting that in a standard titration (ligand titrated into protein), it might be possible to 
observe a 1:1 stoichiometry (n = 1) as the protein is in excess at the start of the experiment, but 
due to experimental design constraints, namely solubility, this was not possible with SB002. 
Overall, SB002 displays a higher binding affinity for MSPa than ICLPa, which correlates with 
the previous kinetic data. The interaction between MSPa and SB002 is largely driven by entropy, 
whereas the interaction between ICLPa and SB002 is driven more equally by enthalpy and entropy. 
This has interesting implications for the molecular binding mechanism of SB002 to the two 
proteins. For MSPa, with a favourable entropic term (-9.84 kcal mol
-1), upon binding, there could 
be some displacement of water molecules tightly-bound to the protein in a hydrophobic binding 
pocket. For ICLPa, there are similar events of hydrogen bonding or Van der Waals interaction 
events (ΔH) as potential conformational changes or water displacement events (-TΔS) upon ligand 
binding.  
ITC may not tell us the exact binding pocket of the ligand in the protein, but the calculated 
thermodynamic parameters do have important consequences in drug discovery. When moving 
from hit to lead validation for a drug candidate, chemically modifying compounds to optimise the 
enthalpic term, while much more challenging than chemically optimising the entropic term 
(through the addition of hydrophobic groups), can result in much better binding affinity.274 More 
favourable ΔH values signify better non-covalent bonding between the protein and the ligand as 
well. In fact, over the course of hit to lead optimisation, the entropic term of a compound usually 
improves as the drug discovery programme proceeds.274 However, there is a limit to the 
improvement that can be gained from increasing the hydrophobic nature of a compound, as 
aqueous solubility is eventually compromised. Ultimately, high-resolution structural data is 




4.9 Crystallisation of protein-ligand complexes 
 
Obtaining an X-ray crystal structure of a protein-ligand complex is a conclusive validation 
of a binding event because it allows for the direct visualisation of protein and ligand interactions 
at atomic resolution.269 Both of the protein purification methods for the target enzymes satisfied 
the requirements for protein crystallisation; namely, they yielded highly pure protein (>95%) and 
highly soluble protein in at high concentrations.230 Gels from SDS-PAGE analyses are shown in 
results chapter 3 and appendix 3 for MSPa and ICLPa, respectively. Both glyoxylate shunt enzymes 
from P. aeruginosa have been successfully crystallised in their native forms in the Welch laboratory; 
malate synthase G by myself (PDB entry 5OAS) and isocitrate lyase by Audrey Crousilles (PDB 
entry 61GO). SB002’s mechanisms of action on the target enzymes were also unclear. I 
endeavoured to obtain crystal structures with the ligand bound for these reasons. 
4.9.1 MSPa-SB002 soaking 
I reasoned from kinetic data that it was possible that SB002 competes with acetyl coenzyme 
A for binding in MSPa. In an MSMt crystal structure (PDB entry 2GQ3), acetyl coenzyme A interacts 
with several amino acids near the entrance of the active site.181 In our computational analysis of 
putative drug binding sites in MSPa in results chapter 3, the acetyl coenzyme A binding site was 
among the highest-scoring druggable sites.  
Ligand soaking experiments with MSPa were undertaken because I had already established 
a crystallisation system. I presumed I had a crystal form suitable for ligand soaking, i.e. that my 
proposed binding site (the acetyl coenzyme A binding pocket) was exposed to solvent channels 
and would be accessible to the ligand. Another requirement for ligand soaking is that the protein 
does not undergo a large conformational change upon ligand binding, which would cause the 
crystal to crack.278 These two requirements allow for the ligand to diffuse into the crystal while 
preserving the crystal’s integrity, which ensures higher quality data collection.  
Purified MSPa (146 µM) was brought to a state of supersaturation, which allowed for small 
aggregates (nuclei) to form spontaneously to spur crystal growth. The degree of supersaturation 
was controlled by the precipitating agents in the crystallisation mixture (PEG 4000 and glycerol), 
which served to immobilise water and increase the effective protein concentration, as well as the 
salt in the mixture (AmSO4), which improved protein solubility. Controlled supersaturation levels 
allowed the protein in solution to support crystalline growth rather than produce additional crystal 
nuclei by shifting into the metastable zone of saturation.279 Crystalline growth in this zone was 
slow enough to form medium-sized crystals of 100-200 µm in length in three-five days. As a 
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crystal’s total scattering power depends on its volume, the crystal needed to be large enough to 
harvest into loops and collect diffraction data manually.280 
I diluted a stock of SB002 in DMSO into a solution of cryoprotectant and added 0.5 µL 
of this ligand-cryoprotectant mixture directly to the crystallisation drops to minimise crystal 
manipulation. SB002 had a final concentration of 1 mM and 6.25% DMSO per drop. All time 
points after 1 hour resulted in visual deterioration of the crystals, a sign that they were sensitive to 
the solvent (not shown). Therefore, I harvested and collected data for a “control” apo crystal (not 
shown), “instant soak” crystals, and crystals soaked for ten minutes and 30 minutes to determine 
diffraction and ligand occupancy, see table 31. 
The best “instant soak” crystal diffracted to a resolution of 2.05 Å, the best of the crystals 
soaked for 10 minutes diffracted to 1.87 Å, and the crystals soaked for 30 minutes did not diffract, 
see table 31. The structures were solved using molecular replacement with the apo structure (PDB 
entry 5OAS). The data processing, model quality, and electron densities were all scrutinised by Dr 
Paul Brear from the Crystallographic X-ray facility before proceeding. When we compared the 
models and electron densities after initial refinement to that of the apo model, we did not see clear 
differences between the calculated electron densities. Any unmodelled electron density in the 
soaked crystal structures was solely indicative of water molecules. Also, aligning the soaked MSPa 
models with the apo model did not reveal any differences between the tertiary structures (not 
shown).  
One reason for the absence of ligand electron density in the soaked crystals could be that 
the binding site was inaccessible to the ligand in that particular crystal form because there was a 
flexible portion of the protein that interfered with the site, or that crystal packing contacts within 
the crystal obstructed the site. I expected the ligand binding site to be the acetyl coenzyme A 
binding site, which was accessible to solvent channels in the apo structure; however, it is 
conceivable that the true binding site could be elsewhere in the protein and not actually accessible 
to the ligand.  
Another conceivable reason for the absence of electron density for SB002 was due to low 
ligand occupancy in the crystals. In order to visualise a ligand in the calculated electron density 
map, at least 50% of all the binding sites in the crystal should be occupied by the ligand. Ideally, 
this occupancy should be closer to 90% for certainty in placing the correct pose of the ligand.278 
Low SB002 occupancy was either caused by insufficient ligand diffusion in the cryoprotectant 
mixture or by inadequate soaking times relative to the crystals’ sizes. 10-20 µm crystals can reach 
80% occupancy in fewer than 30 seconds, and these shorter soak times evidently minimise damage 
to the crystals.278 Soaking smaller crystals was not practical in my situation because they were more  
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146 µM protein 
25 mM ammonium sulphate 
13−17% (v/v) glycerol 
20−27% (w/v) polyethylene glycol 4000 
Soaking 
conditions 
1 mM SB002, 6.25% DMSO + 93.75% cryoprotectant  
(24% ethylene glycol + 76% mother liquor) per drop 
Soaking times  
0 minutes 
(instant harvest) 
10 minutes 30 minutes 
Pre-soaked 
crystals 
   
Harvested 
crystals 
   
Approximate 
crystal length  
~200 µm ~125 µm ~175 µm 
Crystal system orthorhombic orthorhombic orthorhombic 
X-ray source DLS MX-I03 DLS MX-I03 DLS MX-I03 
Wavelength (Å) 0.9763 0.9763 0.9763 












Total reflections 343,006 (16,099) 423,824 (19,335) 
Unique 
reflections 
53,812 (2,459) 66,761 (3,195) 
Multiplicity  6.4 (6.5) 6.3 (6.1) 
Completeness 99.7% (92.1%) 99.9% (96.6%) 
Mean I/σ(I) 8.9 (2.3) 8.2 (1.8) 
CC1/2 1.0 (0.6) 1.0 (0.5) 























No clear ligand 
electron density 
No clear ligand electron 
density 
- 




difficult to harvest manually, and I did not have access to crystal harvesting robotics or in situ data 
collection. These crystals (100-200 µm) could not tolerate high DMSO concentrations as indicated 
by damage accrued during soaking. This naturally dictated changes in any future soaking. 
Ultimately, though, I knew SB002 had poor aqueous solubility, and that I had a limited quantity of 
crystallisable MSPa, so I could not explore options like longer soaks with higher ligand 
concentrations and lower solvent concentrations. Consequently, I attempted co-crystallisation. 
4.9.2 MSPa-SB002 co-crystallisation 
SB002 dissolved in DMSO was added to 146 µM of purified MSPa to achieve a final ligand 
concentration of 300 µM and a protein to ligand ratio of 1:2. In general, it is advised to have the 
ligand concentration 10x higher than the Kd.
230 I thought this ligand concentration would be 
enough to fulfil the binding stoichiometry predicted by ITC, and I also reasoned that 1% DMSO 
was low enough not to affect the crystallisation dynamics. The protein and ligand mixture was left 
to incubate for ≥60 minutes on ice.  The mixture was added to an optimisation plate, and the 
protein was again brought to supersaturation by mixing 200 nL of the reservoir solution with the 
protein in the drop.  
The three best co-crystals diffracted to 1.29 Å, 1.33 Å, and 1.74 Å, which reflects crystal 
lattices with tight packing, see table 32. The structures were again solved using molecular 
replacement with my apo MSPa structure as the template (PDB entry 5OAS). Two crystals 
developed in a monoclinic crystal system (space group P1 21 1) with unit cell dimensions of a=65.27 
Å, b=111.08 Å, c=98.25 Å and a=64.91 Å, b=111.0 Å, c=98.22 Å. Both crystals had two protomers 
in the asymmetric unit (ASU), related by an approximate non-crystallographic two-fold axis. The 
third crystal developed in an orthorhombic crystal system (space group P21 21 21) with unit cell 
dimensions of a=70.80 Å, b=81.50 Å, and c=137.22 Å and one protomer in the ASU. Again, the 
data processing, model quality, and electron densities were all confirmed by Dr Paul Brear before 
proceeding. When we compared all of the initial models and calculated electron densities after 
initial refinement to that of the apo model, we saw an improvement in the electron density quality 
for the monoclinic crystals, but we did not see any obvious electron density for the ligand. 
Unmodelled electron density in the co-crystal structures after refinement was solely indicative of 
water molecules. Also, aligning each structure with the apo structure again did not reveal any 
significant differences between the tertiary structures (not shown).  
Co-crystallisation is known to result in varying ligand occupancies between crystals, as well 
as reduced ligand occupancy in general when compared with soaking.278 I considered the possibility 
that the crystallisation conditions were not compatible with the optimal ligand binding conditions. 
Dr Xavier Chee from the Department of Pharmacology performed a thermal shift assay to find  
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146 µM protein 
300 µM SB002 (2:1 ligand: protein) 
1% DMSO 
25 mM ammonium sulphate 
13−17% (v/v) glycerol 
















~225 µm ~ 225 µm ~200 µm 
Crystal system monoclinic monoclinic orthorhombic 
X-ray source DLS MX-I03 DLS MX-I03 DLS MX-I03 
Wavelength (Å) 0.9763 0.9763 0.9763 
Resolution (Å) 55.54-1.29 111.00-1.33 70.80-1.74 
Total reflections 1,084,450 (32,526) 950,173 (26,852) 519,623 (22,436) 
Unique 
reflections 
337,198 (13,966) 303,930 (12,332) 82,221 (3,982) 
Multiplicity  3.2 (2.3) 3.2 (2.2) 6.3 (5.0) 
Completeness 98.4% (81.8%) 97.6% (79.4%) 100% (98.2%) 
Mean I/σ(I) 11.6 (1.0) 10.4 (1.0) 13.1 (1.1) 
CC1/2 1.0 (0.5) 1.0 (0.7) 1.0 (0.5) 































No clear ligand electron 
density 
No clear ligand electron 
density 
No clear ligand electron 
density 
a Values in parenthesis are statistics for the highest resolution shell. Abbreviations: DMSO, 




the binding conditions most stable against thermal denaturation. We tested MSPa and 1 mM SB002 
in various buffers, pH values, and with or without 10 mM MgCl2 and NaSO4. The analysis showed 
the greatest thermal stability for MSPa-SB002 was at a pH of 7.5 in KH2PO4 buffer with 10 mM 
MgCl2 added, followed by Tris buffer, pH 7.5, with 10 mM MgCl2 added (data not shown). 
Therefore, I set out to find different co-crystallisation conditions that would encourage ligand 
binding. 
 Concentrations of SB002 were added to 75 and 146 µM of MSPa in 50 mM KH2PO4 buffer 
with 10 mM MgCl2 and incubated for ≥60 minutes on ice before samples were added to industry 
screening matrices. The screens were repeated with 1 mM glyoxylate added to the protein-ligand 
mixture in the event it would also stabilise ligand binding. In the second co-crystallisation attempt 
of MSPa and SB002, there was no crystal formation in any condition after eight days; however, the 
best outcomes are displayed in table 33. 
In the first condition listed in table 33 is what appears to be microcrystalline material 
(crystals smaller than 20 µm), which are difficult to differentiate from precipitate unless polarising 
optics are used to detect birefringence.281 Either way, because the contents of the drop are light in 
colour, it signalled that the protein was not denatured. Other conditions contained small (<50 µm), 
poor quality crystals, or spherulites, which are spherical masses of semi-crystalline material and a 
sign that the crystallisation kinetics are too rapid to form crystals.282  
Furthermore, when the substrate glyoxylate was added to the mixture, no apparent 
improvement was observed, with the best of drops containing either spherulites or phase 
separation, which is indicative of a protein-rich phase that separated from the original drop 
solution.279 Some of the chemicals appeared in common between these conditions from the 
secondary screen. One of them was PEG, although at different molecular weights, while another 
was calcium salt that had either acetate or chloride as the anion moiety. The pH of the solutions 
ranged from pH 6.0 to pH 8.5. The theoretical pI of MSPa is 5.47, which could explain why the 
largest crystals formed in the drop with a pH of 6.0.201 
Despite the promising formation of microcrystalline material in some of the screens, the 
conditions were recalcitrant to optimisation attempts. SB002 was hindering the formation of the 
crystal lattice somehow, perhaps because the binding site was near to a critical point for crystal 
packing in the protein. Cases have been reported where additive molecules have made crucial 
interactions between protein molecules in the crystal that helps the secure the formation of the 
lattice.283–285 Such small molecules sometimes have a physiological basis for their presence, but 
others simply provide essential or at least helpful crosslinks within the crystal. Perhaps in the 




Table 33. Images of MSPa-SB002 co-crystallisation drops after eight days. Images and UV-





75 µM protein 
300 µM SB002 
1% DMSO  
 
0.1 M Tris pH 8.5 






146 µM protein 
5 mM SB002 
0.5% DMSO  
 
0.1 M MES pH 6.0 
0.2 M calcium chloride 
20% (w/v) PEG 6000 
 
Small crystals (50 
µm), not suitable 
for diffraction 
146 µM protein 
5 mM SB002 
0.5% DMSO  
 
0.1 M Tris pH 7.0 
0.2 M calcium acetate 
20% (w/v) PEG 3000 
 
Spherulites 
146 µM protein 
5 mM SB002 
1 mM glyoxylate 
0.5% DMSO  
 
0.1 M Imidazole pH 8.0 
0.2 M calcium acetate 
10% (w/v) PEG 8000  
Phase separation 
146 µM protein 
5 mM SB002 
1 mM glyoxylate 
0.5% DMSO  
 
0.1 M HEPES pH 7.5 
0.2 M calcium chloride 
28% (w/v) PEG 400  
Spherulites 




4.9.3 ICLPa-SB002 co-crystallisation 
 ICLPa has been shown to function as a biological tetramer.
174 Its oligomeric status, along 
with an uncompetitive SB002’s binding mode, led me to believe that co-crystallisation would yield 
better results than soaking because the protein might require a conformational change during 
ligand binding. SB002 was added to purified ICLPa (340 µM or 170 µM) to achieve a final ligand 
concentration of 800 µM in 3% DMSO and approximate protein to ligand ratios of 1:2 and 1:4. I 
anticipated this ligand concentration would fulfil the binding stoichiometry predicted by ITC in a 
previous section. 
Multiple chemically-distinct conditions produced crystals after two-five days. Various co-
crystal morphologies formed in several of the conditions, but I prioritised the co-crystals 
containing a bipyramid morphology and a length between 100-200 µm to harvest for data 
collection. I thought these crystals would have tighter crystal packing as a result of more internal 
order, and that they tend to diffract to a higher resolution than other crystal morphologies like 
plates or needles. Table 34 displays the two best diffracting co-crystals from this experiment. 
These crystals diffracted to 1.93 Å and 2.63 Å with unit cell dimensions of a=78.69 Å, b=111.55 Å, 
c=897.34 Å and a=80.93 Å, b=114.99 Å, c=895.10 Å, respectively. Both co-crystals had a c-axis of 
nearly 900 Å in length. Single macromolecules are not usually >200 Å in any single dimension.286 
ICLPa was crystallising in this morphology with several protomers in the ASU. 
Large unit cells often fail to diffract to high resolutions and are sensitive to radiation 
damage due to unusually high solvent content.287 Diffraction patterns of large unit cells also show 
spots that lie very close to each other on the detector, which defines high mosaicity, or the angular 
measure of the degree of long-range order of the unit cells within a crystal.288 Lower mosaicity 
indicates better-ordered crystals that tend to result in better diffraction.289  Because of the high 
mosaicity in the diffraction patterns, see table 35, and the large calculated unit cell, Dr Paul Brear 
again assisted me in processing the data and solving the structure of the 1.93 Å crystal through 
molecular replacement with the native ICLPa solved by the Welch laboratory (PDB entry 6G1O). 
The model resulted in an ordered core but was very disordered in the C and N termini regions 
(not shown). Despite this, we could not discern any electron density for SB002 in the modelled 
protein core after several attempts at refinement.  
I repeated the co-crystallisation screens with larger amounts of ligand (achieved by 
increasing SB002 stock concentrations using sonication at 30°C and 60°C) so that the final SB002 
concentration added to the drop was 6 mM with 0.5% DMSO. Many crystals formed in the same 
conditions as when 800 µM SB002 was added, which was surprising because of the large increase 
in ligand concentration. The best of these crystals is shown in table 34 (3rd column) and diffracted  
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340 µM protein 
800 µM SB002 
3% DMSO 
25% w/v PEG 1500 
0.1 M MIB buffer, 
pH 5.0 
340 µM protein 
800 µM SB002 
3% DMSO 
0.1 M Na3 Citrate 
20% w/v PEG 4000 
5% v/v isopropanol 
340 µM protein 
6 mM SB002 
1% DMSO 
25% w/v PEG 1500 















Crystal length ~200 µm ~150 µm ~225 µm 
Crystal system orthorhombic orthorhombic orthorhombic 
X-ray source DLS MX-I04 DLS MX-I04 DLS MX-I03 
Wavelength (Å) 0.9795 0.9795 0.9762 
Resolution (Å) 66.25-1.93 114.05-2.63 64.36-1.81 
Total reflections 1,343,265 (11,506) 812,923 (37,736) 1,732,296 (32,691) 
Unique 
reflections 
269,193 (7,115) 125,249 (6,077) 106,740 (5,309) 
Multiplicity  5.0 (1.6) 6.5 (6.2) 16.2 (6.2) 
Completeness 89.2% (47.6%) 99.9% (98.1%) 100% (100%) 
Mean I/σ(I) 8.7 (0.9) 5.8 (1.6) 13.1 (2.2) 
CC1/2 1.0 (0.4) 1.0 (0.6) 1.0 (0.5) 































Large unit cell; no ligand 
electron density 
Large unit cell; no ligand 
electron density 
Poor data for MR; 
irregular intensities 
a Values in parenthesis are statistics for the highest resolution shell. Abbreviations: DMSO, 
dimethyl sulfoxide; MIB, sodium malonate: imidazole: boric acid buffer in molar ratios of 2:3:3; 
PEG, polyethylene glycol; SPG, succinic acid: sodium dihydrogen phosphate: glycine buffer in 
molar ratios of 2:7:7. 
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to 1.81 Å with unit cell dimensions of a=79.32 Å, b=113.86 Å, c=128.72 Å and two protomers in 
the ASU. I solved the structure via molecular replacement, but the resulting model had large 
portions of the chains missing. The refinement statistics (Rflags) were ≥0.38 and did not decrease 
despite progress made to the model during refinement cycles. Before proceeding, Dr Paul Brear 
attempted to refine using different crystallographic software programmes such as BALBES,290 but 
could not decrease the Rflags and progress any further. We compared the model and electron density 
after initial refinement to that of the apo model, and predictably, we did not see any electron 
density for the ligand.  
Translational noncrystallographic symmetry (NCS) arises if more than two copies of the 
same structural motif in the asymmetric unit of the crystal are present in a similar orientation.291 
This results in abnormalities in the distribution of reflection intensities in the reciprocal space and 
in difficulties in assigning correct symmetries at the data processing stage.292 Solution of these 
structures is often possible, although it usually requires a high degree of competence and 
perseverance in testing various, potentially plausible symmetry interpretations.230 Therefore, I 
consulted Professor Ben Luisi, with whom I tried expanding the symmetry operations to I2 2 2 
and P1 space groups, but the Rflags still did not decrease upon refinement in CCP4’s Refmac.  
In the I2 2 2 space group, the unit cell was again redefined with an axis of 900 Å. Twinning 
is not possible in orthorhombic space groups, but there were unusual intensity statistics in the 
dataset, and there could be several reasons for the departure of the intensity statistics from 
normality. Possible reasons include over-merging pseudo-symmetric or twinned data, intensity to 
amplitude conversion problems, as well as simply bad data quality.293 Analysing the Patterson 
function in Phenix’s Xtriage294 in the dataset revealed a significant off-origin peak that was 37.28% 
of the origin peak, which indicates pseudo-translational symmetry. The chance of finding a peak 
of this height randomly in a structure without pseudo-translational symmetry was equal to 4.39 × 
10-04, according to this analysis. The detected translational NCS was most likely also responsible 
for the elevated intensity ratio. If the structure is solved, abnormal intensity statistics can lead to 
higher R-factors (Rflags) in refinement.
286 
Crystal morphology, including various twinned forms, is often directly related to pH, but 
the irregular intensity statistics were observed across a pH range of 5.0-8.0 in the datasets of the 
ICLPa co-crystals presented here, see table 34. Still, these experiments provided a good starting 
point for future work. I was able to obtain crystals that diffracted to at least 2.0 Å in the presence 
of SB002. Diffraction to 3.0 Å and beyond provides the resolution of specific interactions 
necessary to relate these interactions to biological function. However, we could not detect SB002 
binding in the solved structures, and more advanced techniques are required for further crystal 
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optimisation. Crystallisation is a difficult and unpredictable stage of structural determination and 




In this work, I evaluated novel 2-aminopyridine compounds for their potential as dual 
inhibitors of the glyoxylate shunt in Pseudomonas aeruginosa. P. aeruginosa infections are notoriously 
difficult to treat as this species has a plethora of intrinsic resistance mechanisms, including the 
impermeable Gram-negative outer membrane. There is undoubtedly an urgent need for new 
therapeutic leads. The glyoxylate shunt has been demonstrated as essential for P. aeruginosa to 
establish an infection in vivo, and it is well understood that the glyoxylate shunt is required for the 
bacteria to thrive in conditions with poor nutrient conditions.167  
Research endeavours to find species-specific inhibitors in the equally clinically challenging 
Mycobacterium tuberculosis have yielded successes through structural-based approaches. Building on 
structural information of a critical anion-π interaction provided from these structure-based studies 
on MSMt,
242,263 Dr Sean Bartlett synthesised a collection of small molecules based off of the 
structural and electronic features of the MSMt PDKA inhibitors as well as a hit compound from a 
HTS campaign against P. aeruginosa in acetate media that could be used to verify this hypothesis. 
Of the 2-aminopyridines, only SB002 (4-Cl) and SB023 (4-CN) were capable of inhibiting P. 
aeruginosa PAO1 growth completely in minimal medium with acetate as a sole carbon source. This 
inhibition was not observed in LB medium, further validating that the glyoxylate shunt is 
conditionally expressed under carbon-poor nutrient conditions. It also verifies that these inhibitors 
were selective and cell-permeable through the Gram-negative cell envelope.  
SB002 was the only compound to display complete dual inhibition against the purified 
glyoxylate shunt enzymes. SB023 and SB026 (4-F) displayed partial dual inhibition as well, but 
among these two compounds, only SB023 was able to inhibit MSPa activity completely. I then 
expanded on the inhibition by using enzyme kinetics to determine the mode of inhibition of SB002 
and SB023 on MSPa and SB002 on ICLPa. According to the Lineweaver-Burk plots, SB002 and 
SB023 displayed mixed inhibition of MSPa with a preference towards uncompetitive inhibition 
regarding substrate glyoxylate, which was inferred by comparing calculated Ki and Ki’ values. 
SB002 and SB023 displayed mixed inhibition with a preference for competitive inhibition 
regarding co-substrate acetyl coenzyme A. This finding correlated with the analysis of MSPa 
druggability in results chapter 3.  
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 SB002 also displayed mixed/noncompetitive inhibition of ICLPa, according to the 
Lineweaver-Burk analysis, but the data from the substrate versus enzyme velocity plots showed that 
the mode of inhibition was better suited to uncompetitive inhibition. This means that SB002 binds 
with a stronger affinity to the enzyme-substrate complex than the free enzyme. According to 
Crousilles et al., there is a flexible loop between β-4 and β-5 in the ICLPa crystal structure poised 6 
Å away from the active site. The loop contains the general catalytic base, Cys222. In the ICLMt 
crystal structure, the loop is positioned inwards, closing off access to the active site, and is 
presumably involved in catalysis.174 This provides insight into a possible binding scenario. When 
isocitrate and SB002 are both present, the substrate might bind to ICLPa first, closing the active 
cleft. SB002 is left to bind to another enzyme location and halt isocitrate cleavage. 
Using ITC, I validated SB002 as a dual inhibitor by measuring the thermodynamics of 
direct binding to the target enzymes. ITC revealed that SB002 binds to MSPa with a better affinity 
than ICLPa, which correlates with the results from kinetic analyses. This is not what was reported 
in the original study that identified this compound in a high throughput screening.194 The reason 
for this difference in affinity could have to do with the activity of the protein purification batches, 
or it could be providing insight into the mechanism of action against ICLPa, but otherwise, I have 
no explanation for this. 
Extensive soaking and co-crystallisation attempts were undertaken to try and further 
validate ligand binding and to determine the binding pockets and poses of SB002 in both enzymes. 
I was successful in obtaining robust ICLPa and MSPa crystals, but I could not obtain a structure of 
either of the ligand-protein complexes. The main issue with MSPa soaking was the crystal’s 
sensitivity to DMSO. Higher solvent concentrations caused disorder in the crystal, resulting in 
crystal disintegration in the worst of cases and reduced data quality in the best of cases. SB002 
displayed solubility in other solvents, like methanol, but was not very soluble in water, physiological 
buffers, or previous crystallisation conditions, which made the SB002 concentration the limiting 
factor in soaking attempts. 
MSPa co-crystallisation was arguably even more unproductive than soaking because SB002 
appeared to prevent crystal formation. Rational attempts to acquire co-crystallisation hits using 
sparse screening were employed, including reducing the concentration of DMSO, matching the 
ligand-protein ratio guided by the ITC results, and screening for hits that were congruent with the 
physiological conditions of ligand binding, as suggested by kinetics and thermal shift experiments. 
Either SB002 was interfering with important crystallisation contacts required for crystal packing, 
or the crystallisation conditions were prohibiting ligand binding. 
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While SB002 binding to ICLPa was conducive to crystallisation, it caused abnormal 
diffraction intensities and high mosaicity in the diffraction patterns, which complicated symmetry 
calculations and resulted in a massive unit cell, predicted to have 7-8 protomers present. Because 
this was not a straightforward case, I enlisted help from more experienced crystallographers, but 
the consensus was to continue rational co-crystallisation screening to find a crystal system which 
supported ligand binding and was more conducive to data processing and downstream model 
refinement.  
According to the literature, extensive optimisation by trial and error is common when 
trying to obtain co-crystal structures.278,279,281,284,293,295 There are a few gems of wisdom (mostly from 
experienced crystallographers) that endorse the chances of obtaining a crystal structure with the 
ligand bound. One example is to understand the protein quality with which one is working (i.e. 
solubility, stability and prior hit crystallisation conditions).295 Another example is to use a high 
ligand concentrations (≥1 mM final concentration) for soaking or co-crystallisation, particular in 
cases where weaker binding (Kd in the mM range) is expected.
278 A final example is to mimic what 
is understood about the physiological binding conditions,284 but in the end, the success of a co-
crystal structure cannot be predicted and varies widely depending on the protein, the protein batch, 
and even the day.282  
 
Table 35. Physicochemical properties of 2-aminopyridines. 
 SB001 SB002a SB022 SB023 SB026 SB029 2-AP 
MW (Daltons) 415.29 370.83 404.39 361.40 354.38 394.43 128.56 
cLogP octanol/water 3.91 3.74 4.02 2.99 2.78 1.96 1.13 
H-bond donors 2 2 2 2 2 3 1 
H-bond acceptors 5 5 5 6 5 7 2 
a Values reported for SB002 also apply to isomeric SB032. Properties were calculated using 
ChemBioDraw Ultra 13.0 (PerkinElmer). Abbreviations: 2-AP, 2-amino-4-chloropyridine; 
cLogP, calculated partition coefficient; H-bond, hydrogen bond; MW, molecular weight.  
 
In the absence of a co-crystal structure to definitively support my proposed molecular 
mechanism of action, I examined the physicochemical properties of the synthesised compound 
library to attempt to correlate the structure-activity relationships (SAR). The analysis (shown in 
table 35) revealed that they are all compliant with Lipinski’s rule of five (RO5), in that they have 
a molecular weight <500 Daltons, <5 hydrogen bond donors, <10 hydrogen bond acceptors, a 
calculated octanol-water partition coefficient, cLogP, <5, and <10 rotatable bonds.296,297 
Complying with the RO5 is a useful metric of how “drug-like” a compound is. Compounds that 
conform to the RO5 are associated with 90% of orally active drugs that have achieved phase II 
clinical status in the drug development pipeline.296 The RO5 was deliberately created by Pfizer to 
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be a conservative predictor in an era where medicinal and combinatorial chemistry produced too 
many compounds with very poor physicochemical properties. This information is a decent starting 
point for understanding hit compounds and is useful in designing inhibitors to which the 
pharmaceutical industry still adheres and simultaneously rejects.298,299  
Personal communication with Prashanthi Medarametla from the University of Eastern 
Finland suggested that when subjected to general molecular docking, SB002 interacts with MSPa in 
the acetyl coenzyme A binding pocket. Because we could not confirm this through X-ray 
crystallography, the pharmacophores based on the functional groups present in SB002 and SB023 




Figure 35. Predicted ligand pharmacophores for SB002 and SB023. Functional groups are 
shown in a coloured dot surface based on atom type. Nitrogen atoms are coloured in blue and 
comprise a guanidine moiety in the centre of the structures. The two ester functional groups that 
are a part of the Boc protecting groups are coloured in red. (A) SB002’s chlorine substitution is 
coloured in green. (B) SB023’s nitrile substitution is coloured blue. 
 
2-AP showed no target nor whole-cell inhibition throughout my experiments, meaning the 
guanidine moiety and the Boc protecting groups are important for SB002 and SB023 binding to 
the target enzymes as well as penetrating P. aeruginosa’s outer membrane. Both compounds contain 
guanidine moieties, which have been associated with antibacterial activities, including the 
inhibition of P. aeruginosa.300 In fact, six out of the eight hits from Pfizer’s P. aeruginosa whole-cell 
screening campaign in acetate medium contained guanidine groups.194 Most guanidine derivatives 
are strong bases and this underpins their biological interactions. Under physiological conditions, 
the guanidine group exists mainly in its protonated form, which may afford interactions with the 
target enzymes. Another option is that it could be binding to the bacterial outer membrane on the 
negatively-charged polysaccharide layer, causing cell death.301,302 Additionally, the Boc groups could 
also be important to maintain the overall shape rather than just the chemical binding, such as 
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providing an electronegative balance to the chemical scaffold, but I could find no evidence of 
intentionally using a Boc protecting group as a part of a pharmacophore for biological activity, 
antibacterial or otherwise. 
Finally, the electron withdrawing groups at the heterocyclic 4th positions are likely 
responsible for the inhibition. They might activate the guanidine binding activity to enhance its 
interaction with any amine groups present in the cell membrane. The nitrile substituent on SB023 
is a short, polarised triple bond, resulting in a small steric demand on the molecular scaffold.303 For 
comparison, the C-N unit is 8x smaller than a methyl group.304,305 Nitriles often play a key role as 
hydrogen bond acceptors in active pharmaceuticals, and arylnitriles are one of the most common 
of these pharmaceuticals.306 SAR studies have shown that para-substituted arylnitriles in the 4th 
position were instrumental in hydrogen bonding to arginine residues and that these crystal 
structures show the nitrile projecting into narrow crevices in the binding pocket to make polar 
interactions or hydrogen bonds in a sterically congested environment.307,308 SB002, on the other 
hand, is an arylchloride, which has a weaker dipole moment on the rest of the molecule than the 
arylnitrile. This substitution (4-Cl) is very electronegative; however, and can cause the inductive 
withdrawal of electrons from the carbons in the benzene ring depending on the position of the 
halide substituent.309 
It is important to note that the dual inhibitory activity of SB023 reported in this chapter is 
incongruent with the in vitro inhibition of ICLPa to explain its observed MIC value. This indicates 
that although the predicted affinity based on the chemical scaffold was generally confirmed, the 
reasons behind the whole-cell activity of SB023 most likely lies elsewhere. I have shown that these 
compounds inhibit the glyoxylate shunt enzymes, but a more conservative explanation is that a 
direct dual or polypharmacology explain the observed MIC values by hitting other P. aeruginosa 
targets. However, it is also possible that the observed MIC values are a result of a synergistic effect 
that includes their activities against ICL and MS and on other enzymes. 
This study provided an example of how a designed, multi-targeted approach to early 
antibacterial drug discovery, particularly in a clinically important pathogen, is a good starting point 
for medicinal chemistry modifications. In the future, instead of ICL or MS, other enzymes could 
make alternative targets for the functional inhibition of the glyoxylate shunt. For instance, an 
indirect means of inhibition of the glyoxylate shunt is through inhibiting the enzymes of the 
polyhydroxybutyrate cycle since this metabolic route can produce acetyl coenzyme A in a manner 
that circumvents the link between glycolysis and the TCA cycle.310,311 Another example is inhibiting 
the CbrAB two-component system, or Crc, in P. aeruginosa, which is a post-transcriptional global 
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regulator of carbon metabolism. Inhibiting this system would block the initiation of translation 




5. Results and discussion 





A screening programme for new antibacterial compounds can result in several hits, but not 
all of them will have equally desirable qualities. It is essential to evaluate and prioritise their 
potential before settling on a single hit as suitable for development into a lead compound.313 This 
process is known as hit to lead optimisation. Antibacterial drug discovery encompasses the same 
goals as all drug discovery; to develop therapies that are efficacious and safe.81 An antibiotic hit 
must bind to its target and must be important for growth inhibition of the pathogen of interest. 
However, antibacterial drugs are unique in that they require chemistry which allows them to pass 
the cellular envelope (outer membrane, periplasm, and cell membrane) in Gram-negative 
bacteria.80 Potential antibacterial candidates must specifically kill bacterial cells while being 
innocuous to eukaryotic cells, which is determined by assessing mammalian cytotoxicity. 
 
 
Figure 36. Timeline of antibacterial drug development. The corresponding timelines and 
success rates for each stage of antibacterial drug discovery and development pipeline are shown. 
Lead optimisation is the most arduous stage. Figure modified from Payne et al., 2007.110  
 
Determining in vitro drug metabolism is a significant pharmacokinetic parameter as the 
majority of drugs are metabolised in the liver, and intrinsic clearance determined in vitro can be 
used to predict in vivo drug clearance.314,315 Significant drug-drug interactions can also arise from 
the inhibition of cytochrome P450-mediated clearance mechanisms in the liver and can negatively 
impact the clinical and commercial viability of potential medicines. This impact ranges from 
labelling requirements for relatively minor interactions to non-approval or withdrawal from the 
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market for more serious cases.316 Therefore, it is important to consider drug metabolism, as well 
as mammalian cytotoxicity, early on in development when evaluating the potential of hit 




Figure 37. The hit compounds tested in this study. SB002 and SB023 displayed potent 
inhibition against the glyoxylate shunt enzymes from Pseudomonas aeruginosa and prevented PAO1 
growth in acetate. Therefore, their potentials as antibacterial lead candidates were evaluated in this 
chapter. 2-amino-4-chloropyridine (2-AP) was used as a negative control. 
 
In this chapter, I set out with three experimental objectives. First, I hoped to elucidate 
more about the antibacterial specificity and mechanism of the hit compounds, SB002 and SB023 
(figure 37), defined in chapter 4. I attempted this by evaluating their antibacterial effects on P. 
aeruginosa grown in different carbon sources, a multidrug efflux pump mutant of P. aeruginosa, and 
on the ESKAPE pathogen panel. Second, I assessed the hit compounds for in vitro cytotoxicity 
using four human cell lines and one murine cell line. Third, I evaluated the hit compounds for in 
vitro drug metabolism and pharmacokinetics (DMPK), specifically their intrinsic metabolic 
clearance in liver microsomes of humans and preclinical species, as well as for any inhibition of 
the main human cytochrome P450 enzymes. These goals were meant to support a general 
assessment of SB002 and SB023 and their potential of satisfying the requirements for defining hit 
to lead compounds. 
 
5.2 SB002 and SB023 display bactericidal activity 
 
 First, I expanded on the antibacterial evaluation of hit compounds detailed in section 4.3 
of chapter 4 by incubating P. aeruginosa PAO1 with SB002 and SB023 and plotting turbidity 
measurements (OD600 nm) over time to observe growth kinetics. Untreated PAO1 reached 
exponential phase in M9 acetate after 4 hours and stationary phase after 10 hours (figure 38A). 
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PAO1 treated with 1.16 µg mL-1 SB002 resulted in a severe growth lag while PAO1 treated with 
2.32 µg mL-1 SB002 or 50 µg mL-1 of gentamicin, a bactericidal aminoglycoside, resulted in no 
growth. After incubation, the samples were serially diluted and added to M9 acetate agar plates to 
determine if the compounds were bacteriostatic or bactericidal. Figure 38B shows colony forming 
units after 24 hours at 37°C. Agar plates with gentamicin-treated PAO1 and 2.32 µg mL-1 SB002-





Figure 38. Growth kinetics of PAO1 inhibition by SB002. (A) Growth curves of PAO1 grown 
in acetate medium in the absence of (black) and presence of 50 µg mL-1 of gentamicin (magenta), 
1.16 µg mL-1 SB002 (powder blue), and 2.32 µg mL-1 SB002 (navy blue). (B) PAO1 viable CFUs 
from the growth curve samples. Values marked with ns are not significantly different (p>0.05; 
n=3). Abbreviations: CFU, colony forming units; NR, no recovered colonies; OD, optical density. 
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The same experiment was repeated with SB023. Untreated PAO1 again reached 
exponential phase in M9 acetate after 4 hours and stationary phase after 10 hours. In the presence 
of 2.3 µg mL-1 SB023, there was a slight lag in overall PAO1 growth when compared with the 
untreated control. There was an even larger growth lag when 18.1 µg mL-1 SB023 was added, and 
no growth was observed when either 50 µg mL-1 gentamicin or 36.1 µg mL-1 SB023 were added. 
After incubation, I serially diluted these samples and plated them on fresh M9 acetate agar plates. 
After 24 hours incubation, there were no recoverable colonies from the 36.1 µg mL-1 SB023 
sample, indicating that SB023 is also a bactericidal agent at relevant doses. When exponential-
phase PAO1 cells were challenged by adding hit compounds, there was no effect on growth or 




Figure 39. Growth kinetics of PAO1 inhibition by SB023. (A) Growth curves of PAO1 in 
minimal medium with acetate in the absence of (black) and presence of 50 µg mL-1 gentamicin 
(magenta), 2.3 µg mL-1 SB023 (maroon), 18.1 µg mL-1 SB023 (orange), and 36.1 µg mL-1 SB023 
(turquoise). (B) PAO1 viable CFUs from the growth curve samples. Values marked with ns are 
not significantly different (p>0.05; n=3). Abbreviations: CFU, colony forming units; NR, no 




Bactericidal antibiotics, regardless of their original target, commonly induce oxidative 
stress by disrupting metabolite flux into the TCA cycle and reducing the amount of NADH present 
in the cell.317 A decline in NADH fuels the formation of oxide anions (O2
-) by the cell’s electron 
transport chain. O2
- then damages iron-sulphur clusters and frees ferrous iron to be oxidised via 
the Fenton reaction, which results in the formation of hydroxyl radicals (•OH). Build-up of •OH 
culminates in damage to DNA, proteins and lipids, which eventually results in cell death.318 The 
glyoxylate shunt has been linked to oxidative stress tolerance in P. aeruginosa. Mutants deficient in 
the glyoxylate shunt displayed metabolic phenotypes favouring aerobic denitrification, which 
decreases the amount of oxygen consumption without dropping the total ATP yield.317 According 
to this finding, SB002 and SB023 inhibit the glyoxylate shunt and relinquish PAO1’s protection 
from •OH damage and cell death. 
 
5.3 SB023 exhibits broad-spectrum antibacterial activity 
 
As the glyoxylate shunt enzymes are present in many medically relevant bacteria, I assayed 
the hit compounds on the ESKAPE pathogen panel to assess their broad spectrum applications. 
Antibacterial assays were completed in Dr Päivi Tammela’s Bioactivity Screening Laboratory at 
the University of Helsinki during a research secondment. MIC assays were performed initially 
using Mueller Hinton broth (MHB) medium following the CLSI broth microdilution protocol for 
antimicrobial testing.197  
Assays were then repeated on the pathogens that displayed robust growth (Z’ values > 
0.75) in M9 minimal medium supplemented with 0.5% acetate. The ESKAPE pathogen panel is 
listed in table 36 along with the amino acid identities of the glyoxylate shunt enzymes in the 
ESKAPE pathogens compared with Pseudomonas aeruginosa PAO1. During this secondment, I 
realised the SB002 sample had lost most of its antibacterial activity, even against PAO1. This was 
presumably due to chemical degradation, which was later confirmed through NMR, the spectrum 
of which is in appendix 4. Therefore, the results presented in table 36 are the MICs for SB023 in 
MHB and M9 acetate media. SB023 could not inhibit the growth of any ESKAPE pathogen nor 
PAO1 in MHB at 27.11 µg mL-1 (75 µM), which was as expected in rich medium. Of the ESKAPE 
pathogens, S. aureus and E. faecium are Gram-positive bacteria that do not possess genes encoding 
the glyoxylate shunt enzymes.319 Absence of the shunt may relate to the specific growth conditions 
in which these species flourish and cause infection. For example, many S. aureus infections are 
associated with the blood-stream, which provides high concentrations of glucose (5 mM-50 mM) 
available for infective bacteria.320 Therefore, S. aureus and E. faecium could not grow in a medium 
where acetate was supplied as the sole carbon source. When I repeated the antibacterial assay in 
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M9 acetate, I increased the test concentrations of SB023 to 72.28 µg mL-1 (200 µM). PAO1 
inhibition was observed at 36 µg mL-1, which confirmed that PAO1 was consistently susceptible 
to SB023, even from different laboratories. E. coli was also susceptible to SB023 at a MIC of 9 µg 
mL-1, and A. baumannii was susceptible at 72.28 µg mL-1.  
 
Table 36. SB023 antibacterial activity against the ESKAPE pathogen panel.  Amino acid 
sequence identities of isocitrate lyase and malate synthase G from Pseudomonas aeruginosa PAO1 are 
compared with those present in the ESKAPE pathogen panel, along with MICs against ESKAPE 
pathogens for SB023. 
Bacterial species 
Amino acid identityb (%) SB023 MIC (µg mL-1) 
MSPa ICLPa MHB M9 Ac 
Enterobacter aerogenes 13048 25% 28% >27.11 >72.28 
Staphylococcus aureus 29213 N/A N/A >27.11 n.d. 
Klebsiella pneumoniae 700603 24% 28% >27.11 >72.28 
Acinetobacter baumannii 19606 65% 75% >27.11 72.28 
Pseudomonas aeruginosa 27853 100% 100% >27.11 >72.28 
Enterococcus faecium 35667 N/A N/A >27.11 n.d. 
Pseudomonas aeruginosa (PAO1)a  100% 100% >27.11 36.04 
Escherichia coli 25922 59% 27% >27.11 9.04 
a Pseudomonas aeruginosa PAO1 strain was from the University of Helsinki.  
bAmino acid sequence identities were determined by the protein-protein algorithm BLAST.231 
Abbreviations: Ac, acetate; MHB, Mueller Hinton Broth; MIC; minimum inhibitory 
concentration; N/A, not applicable; n.d., not determined; Pa, Pseudomonas aeruginosa PAO1. 
 
No inhibition was observed for all other microorganisms, despite growing robustly on 
acetate and hence utilising the glyoxylate shunt enzymes. For the P. aeruginosa clinical isolate, 
perhaps there was a barrier to cell entry such as active multidrug efflux pumps. For the remaining 
pathogens, E. aerogenes and K. pneumoniae, the shunt enzymes’ amino acid similarity with PAO1’s 
were no higher than 28%, which could explain the lack of inhibition, especially if SB023 binds in 
an allosteric pocket that is subject to more amino acid variability than in the conserved protein 
catalytic cores. Successful SB023 inhibition of A. baumannii and E. coli, however, expands the 
compound’s antibacterial spectrum, supports the hypothesis that the glyoxylate shunt is an 
attractive antibacterial target, and represents new ways to address the need for new antibacterial 
agents. 
 
5.4 Antibacterial activity is altered in the absence of 
multidrug efflux pumps  
 
From the MIC assays, it was clear that the hit compounds were cell permeable, but I was 
conscious of the threat of spontaneous mutations that could give rise to resistance. One of the 
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major acquired resistance mechanisms is increased drug efflux from mutations in multidrug efflux 
pumps.111 If P. aeruginosa, which is already characterised by a poorly-permeable outer membrane, 
benefits from increased efflux, then a serious risk of resistance can develop, even though the hit 
compounds have multiple targets. Pseudomonas aeruginosa YM64, a mutant strain of PAO1 lacking 
all four major mex operons encoding the Mex multicomponent efflux pumps (MexAB-OprM, 
MexEF-OprN, MexCD-OprJ, and MexXY-OprM) was used to explore any possible enhancement 
of the antibacterial activity of the hit compounds in the absence of said multidrug efflux pumps.153 
First, robust growth of YM64 was confirmed in M9 minimal medium supplemented with 0.5% 
acetate before subjecting the strain to incubation with the hit compounds. YM64 did not show a 
significant change in susceptibility to 6.25 µM (2.32 µg mL-1) SB002 when compared with PAO1 
treated with the same SB002 concentration, suggesting it is not a substrate of these efflux pump 
systems, see figure 40. 
 
 
Figure 40. Comparison of PAO1 and YM64 growth in the presence of hits. YM64 showed 
increased susceptibility to SB023 compared with PAO1, while there was no difference in growth 
between PAO1 and YM64 when exposed to SB002. Compounds were tested at 6.25 µM. Values 
marked with **** are significantly different [ns = not significant (p>0.05); **** = p<0.0001; n=4]. 
 
Conversely, YM64 showed a significantly increased susceptibility to 6.25 µM (2.26 µg mL-
1) of SB023 when compared with PAO1 treated with the same concentration of SB023. This means 
that SB023 might be a substrate for any of the four Mex multidrug efflux pumps present in P. 
aeruginosa PAO1, which could eventually confer resistance. The resistance-nodulation-division 
(RND) family of efflux pumps present in Gram-negative bacteria are thought to function as a 
detoxification mechanism for the cell from heavy metals and detergents present in the 
environment.321 MexAB-OprM and MexXY-OprM efflux pumps, in particular, contribute to the 
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intrinsic multidrug resistance in P. aeruginosa.155 The MexXY efflux system is a well-known 
determinant of aminoglycoside resistance, and MexAB system contributes to intrinsic resistance 
of fluoroquinolones, tetracycline, chloramphenicol, and carbenicillin.322  
Perhaps for SB002, there is an alternative mechanism of entering the cell that avoids the 
efflux pump systems, such as passively through porins or actively through substrate-specific β-
barrel transport systems.111 OprD and OprO are porins from the outer-membrane carboxylate 
channel (Occ) family, for example, that function as “nonspecific” entry and exit points for 
antibiotic-like molecules and are responsible for transporting neutral and basic amino acids such 
as arginine, lysine, and histidine.59,152 The guanidine moiety present in SB002 and SB023 is also 
present in the arginine side chain, so it is conceivable that these compounds could mimic arginine 
uptake. OprD expression, like many other PAO1 porins, varies based on growth media or 
exposure to metals like copper or zinc. In one instance, an in-frame deletion allowed for normal 
porin expression and arginine uptake while simultaneously conferring carbapenem resistance.148 
 
5.5 Antibacterial activity is likely achieved through “network 
pharmacology” 
 
When exposed to a variety of carbon sources, P. aeruginosa can rewire its central metabolism 
to adapt. PAO1 growth in all types of minimal media was robust whether the bacteria had access 
to acetate, glucose, succinate or propionate as the building blocks for gluconeogenesis. M9 and 
MOPS (3-(N-Morpholino) Propane-Sulfonic Acid) were both tried as bases for minimal media, 
see table 37. The full differences between the recipes of M9 and MOPS are detailed in chapter 2, 
but MOPS is comprised of a more complex nutrient profile with added minerals like iron, copper 
and zinc.323  
P. aeruginosa has a two-component CzcSR system that is activated after exposure to metals, 
which in turn, induces efflux pumps to extrude any excess metals. An increase in metals in the 
medium alters the expression of different membrane porins. For example, the presence of copper 
and zinc decrease OprD expression, iron decreases OprG and OprE expression, and magnesium 
decreases OprH. This can influence how the hit compounds gain entry into the cell.324 This may 
explain the differences in the MICs in M9 and MOPS media, particularly concerning acetate. A 
notable surprise is the fact that the compounds inhibit PAO1 growth in the presence of glucose 
equal to, if not slightly better than, acetate. This is not what was reported in Fahnoe et al.’s work, 
and I have no explanation for why this discrepancy exists, other than the fact that the hit 
compounds must have off-target effects on other metabolic enzymes. A study on P. aeruginosa 13C-
metabolic flux indicated that strains grown in glucose still exhibit significant flux through the 
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glyoxylate shunt, but this does not fully explain why the inhibition is equally potent in glucose as 
in acetate.325  
 
Table 37. MICs values of hit compounds in various carbon sources.  
Media and carbon source 
MIC (µg mL-1) 
SB002 SB023 
M9 acetate (0.5%; 60 mM) 1.16 13.52 
M9 glucose (0.5%; 15 mM) 1.16 4.51 
MOPS acetate (40 mM) 9.27 72.28 
MOPS glucose (15 mM) 9.27 72.28 
MOPS propionate (30 mM) 37.08 72.28 
MOPS succinate (30 mM) 9.27 72.28 
 
Propionate (C3) is an abundant short-chain fatty acid and is metabolised by the 
methylisocitrate pathway in P. aeruginosa, resulting in molecules of pyruvate and succinate. 
Methylcitrate synthase (PrpC) catalyses the conversion of oxaloacetate, provided from the TCA 
cycle, and propionyl coenzyme A, provided from propionate as a nutrient source, into 2-
methylcitrate and coenzyme A.326 I tested SB002 for PrpC inhibition to confirm if the inhibition 
of bacterial growth observed in MOPS propionate medium could be observed enzymatically.ii 
Inhibition of PrpC enzyme activity was measured by quantifying thiol release from propionyl-CoA 
leading to the formation of TNB from DTNB measured at 412 nm. SB002 exhibited promiscuous 
activity by significantly inhibiting (50%) of methylcitrate synthase activity at 100 µM, while SB023 
did not show significant inhibition at 100 µM, see figure 41.  
The reason for the partial inhibition of PrpC by SB002 could be a consequence of similar 
active sites between PrpC and MSPa, which have to accommodate propionyl coenzyme A and acetyl 
coenzyme A, respectively. In MSPa, the proposed binding pocket for SB002 binding is in the acetyl 
coenzyme A binding pocket. However, no crystal structure of PrpC from P. aeruginosa has been 
deposited in the PDB, and the deposited structures from bacterial species like M. tuberculosis, 
Salmonella typhimurium, and Coxiella burnetii do not have propionyl coenzyme A or coenzyme A 
present to confirm this theory. 
                                                 
 
ii I tested PrpC instead of other metabolic enzymes involved in glucose metabolism because PrpC was readily available 






Figure 41. SB002 inhibition of 2-methylcitrate synthase. Enzyme activity of methylcitrate 
synthase was determined by measuring the enzyme’s products, 2-methylcitrate and coenzyme A, 
using Ellman’s reagent, which is similar to how malate synthase activity and inhibition was 
determined. SB002 (blue) inhibited enzyme activity significantly, and SB023 (orange) did not 
inhibit enzyme activity. Values marked with * are significantly different (* = p<0.05; n=3). 
 
5.6 Cytotoxic assessment of SB002 and SB023 
 
I assessed any mammalian cytotoxicity of SB002 and SB023 using a commercial 
luminescence-based assay during a research secondment in Dr Päivi Tammela’s Bioactivity 
Screening Laboratory at the University of Helsinki. I evaluated any mammalian cytotoxicity of 
SB002 and SB023 using a commercial colourimetric-based assay in the Department of 
Pharmacology at the University of Cambridge.  
Cytotoxicity of SB002, SB023 and 2-amino-4-chloropyridine (2-AP) was measured by quantifying 
ATP after 48-hour incubation with A-375, Hs27, and BALB/c cell lines. Cytotoxicity of SB002 
and SB023 was estimated by measuring lactate dehydrogenase (LDH) release, correlating with cell 
membrane damage, after 4-hour incubation with A549 and U937. The highest concentration of 
the compounds tested was 100 µM in 0.5% DMSO. The first attempt at assessing SB002 
cytotoxicity on A-375, Hs27 and BALB/c cells during the research secondment was unproductive, 
as it was later discovered that the quality of SB002 had been compromised due to chemical 
degradation, see appendix 4. Therefore, I am grateful to Viviana Gatta from the University of 
Helsinki for repeating the cytotoxicity assay on Hs27 cells with “fresh” SB002 for me. The results 
for SB002 reported in this section for A-375, and BALB/c cells are from the first attempt with the 





Figure 42. A-375 human malignant melanoma cytotoxicity. (A) Micrographs of control and 
treated A-375 cells after a 48-hour incubation. 40x images including (in clockwise order) untreated 
A-375 cells, and A-375 cells exposed to 1.57 µM camptothecin, 100 µM SB023, and 400 µM SB002. 
(B) Dose-response curves of A-375 cytotoxicity by 10 nM-1.57 µM positive control camptothecin 
(black), 0.39-400 µM SB002 (blue), 0.39-100 µM SB023 (orange), and 0.39-100 µM 2-amino-4-
chloropyridine (2-AP) (teal). Toxicity was calculated from cell viability (n=3) relative to untreated 
controls and media only wells.  
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Microscopic images of A-375 (figure 42A), Hs27 (figure 43A) and BALB/c (figure 44A) cells 
showed >90% confluency in untreated wells. All images of cells treated with positive controls 
contained rounded, shrunken cells, which is a sign of apoptosis.224 A-375 cells incubated with 1.57 
µM camptothecin also showed reduced cell quantity compared with untreated cells (figure 42A). 
SB023-treated wells in all three cell lines displayed less confluence, as did SB002-treated Hs27 wells 
(figures 42A-44A). 
In order to determine if the observed cytotoxic effects were specific effects of the 
compounds or non-specific factors, dose-response curves were generated for the test compounds 
and positive controls on all three cell lines (figures 42B-44B). In cells treated with 100 µM SB023, 
images show reduced cell quantities, but according to the dose responses, 60-80% of those cells 
were metabolically active. Full cytotoxicity profiles of the hit compounds for all five cell lines are 
presented in table 38. 
Among the cell lines, A-375 was the most susceptible to incubation with SB023 at 100 µM, 
displaying 42% toxicity. U937 and Hs27 were the cell lines most susceptible to SB002 exposure at 
100 µM, see table 38. Hs27 was susceptible to both hit compounds but was more sensitive to 
SB002 than SB023. BALB/c and A549 cells were the most resilient to exposure towards the hit 
compounds and did not show any dose-dependent susceptibility. There was, however, baseline 
toxicity of around 20-25% for SB023 in the case of BALB/c, see figure 44B, as well as for A549 
and U937 (not shown). BALB/c cells are sensitive to contact inhibition from cell division, so they 
are an intrinsically more sensitive cell line.224 2-AP displayed no toxicity towards any cell lines, 
which was predicted because it does not have the guanidine moiety or Boc protecting groups 
present.  
Because the compounds are lipophilic, they run the risk of diffusing through the 
cytoplasmic membrane, disrupting the structure of the different layers of polysaccharides, fatty 
acids and phospholipids. Guanidines are associated with membrane perturbation, so it is possible 
that any cytotoxic or anti-proliferative effects of the compounds were due to the presence of the 




Figure 43. Hs27 human neonatal foreskin fibroblast cytotoxicity. (A) Micrographs of control 
and treated Hs27 cells after 48-hour incubation. 40x images include (in clockwise order) untreated 
Hs27 cells, and Hs27 cells exposed to 50 µM camptothecin, 100 µM SB023, and 100 µM SB002. 
(B) Dose-response curves of Hs27 cytotoxicity by 20 nM-50 µM of positive control camptothecin 
(black), 0.39-100 µM SB002, (blue), 0.39-100 µM SB023 (orange), and 0.39-100 µM 2-amino-4-
chloropyridine (2-AP) (teal). Toxicity was calculated from cell viability (n=6) relative to untreated 
controls and media only wells.  
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Table 38. Cytotoxicity profiles of hit compounds against five cell lines.  





 IC50 (µM) >400
c 105.60 ±1.14 >100 0.02 ±1.05 N/A 
Hill slope n.d. 1.20 ±0.18 n.d. 1.15 ±0.07 N/A 
%Toxicity 
at 100 µM 




 IC50 (µM) 98.42 >100 >100 3.69 ±1.12 N/A 
Hill slope n.d. 1.70 ±0.61 n.d. 0.48 ±0.03 N/A 
%Toxicity 
at 100 µM 







 IC50 (µM) >400c >100 >100 N/A 533.60 ±1.03 
Hill slope n.d. n.d. n.d. N/A 4.73 ±0.53 
%Toxicity 
at 100 µM 





 IC50 (µM) >100 >100 n.d. N/A N/A 
Hill slope n.d. n.d. n.d. N/A N/A 
%Toxicity 
at 100 µM 





 IC50 (µM) 18.18 ±1.45
 >100 n.d. N/A N/A 
Hill slope 0.23 ±0.04 n.d. n.d. N/A N/A 
%Toxicity 
at 100 µM 
56.79 31.16 n.d. N/A N/A 
a Camptothecin was used a positive control for both A-375 and Hs27 cell lines.  
b Polymyxin B was used as a positive control for BALB/c. 
c These results were of degraded SB002. Abbreviations: 2-AP, 2-amino-4-chloropyridine; 
BALB/c, BALB/c 3T3 Clone A31 cells; N/A, not applicable; n.d., not determined. 
 
The difference in susceptibilities across cells lines, particularly in the case of A-375 
compared with Hs27 and BALB/c could be due to different cellular markers expressed and 
compositions of the cellular plasma membranes as a result of their respective metabolic and 
differentiated cellular states.328 
The assays did not indicate whether cell damage is occurring through apoptosis or necrosis. 
For instance, in the LDH assay, cells that did not release LDH might still have undergone 
apoptosis. The cell viability assay only gave certainty about whether the cells are metabolically 
active, and thus, alive; it did not elaborate on the mechanism of cell death. The duration of 
incubation is also important as apoptosis markers may only be expressed transiently, and this can 
influence cytotoxic determinations like LD50.
329 Both the concentration of toxin and the duration 
of exposure contribute to the cytotoxic effect. Also, in the LDH assay, cells could be dying 
(releasing LDH) for reasons other than compound exposure, including temperature, mechanical 




Figure 44. BALB/c 3T3 Clone A31 (BALB/c) mouse embryonic fibroblast cytotoxicity. 
(A) Micrographs of control and treated BALB/c cells after 48-hour incubation. 40x images include 
(in clockwise order) untreated BALB/c cells, and BALB/c cells exposed to 50 µM camptothecin, 
100 µM SB023, and 400 µM SB002. (B) Dose-response curves of BALB/c cytotoxicity by 130 
µM-1.58 mM of positive control polymyxin B (black), 0.39-400 µM of SB002 (blue), 0.39-100 µM 
SB023 (orange), and 0.39-100 µM 2-amino-4-chloropyridine (2-AP) (teal). Toxicity was calculated 
from cell viability (n=6) relative to untreated controls and media only wells.  
127 
 
Table 39. Therapeutic indexes of SB002 and SB023.  


















A-375 1.05 n.d. n.d. 8.84 105.60 11.95 
A549 1.05 >100 n.d. 8.84 >100 n.d. 
BALB/c 1.05 n.d. n.d. 8.84 >100 n.d. 
Hs27 1.05 98.42 93.73 8.84 204.80 23.17 
U937 1.05 18.18 17.31 8.84 >100 n.d. 
a The ED50 values were obtained from dose-response inhibition of P. aeruginosa in M9 acetate 
medium. 
b Calculated by dividing LD50 by ED50. Abbreviations: ED50, dose at 50% efficacy; LD50, dose at 
50% cytotoxicity; n.d., not determined. 
 
To make a meaningful judgment about whether the compounds were cytotoxic, I aligned 
the dose-response curves illustrating toxicity towards cell lines with the dose-response curves of 
PAO1 inhibition in M9 acetate medium. This created a visual comparison of the beneficial and 
adverse effects of SB002 and SB023. The concentration of compound which produced 50% of 
the adverse effect was divided by the concentration of compound which produced 50% of the 
beneficial effect, which gave a therapeutic index (TI), presenting a relationship between the 
minimum effective dose and the maximum tolerated dose in vitro.330  
The dose-response curves of beneficial, i.e. antibacterial, and adverse, i.e. cytotoxic, effects 
of SB002 were compared using Hs27 and U937 cell lines. A black arrow indicates the area between 
the effective dose at 50% (ED50) and the lethal dose at 50% (LD50) in figure 45A and B. There 
was a wider TI for Hs27 (93.73) than U937 (17.31), see table 39. A high base absorbance signal 
(indicating >25% toxicity) among the concentrations of SB002-treated U937 cells could be 
responsible for the narrower TI. U937 is a suspension cell line, which means some cells were 
probably pipetted from the incubation plate into the assay plate, which added to the amount of 
LDH present in the assay plate. Attempts to optimise the assay included a centrifugation step, 
which I found to disrupt the cells and create mechanical cell lysis, which only increased the final 




Figure 45. Therapeutic index of SB002. (A) Comparison of dose-response curves of 
Pseudomonas aeruginosa PAO1 inhibition in M9 acetate (turquoise) and toxicity towards Hs27 normal 
human fibroblasts (red) indicates a broad therapeutic window (black arrow) of 93.73. (B) 
Comparison of dose-response curves of P. aeruginosa PAO1 inhibition in M9 acetate (turquoise) 
and toxicity towards U937 human lymphocytes (maroon) indicates a narrower therapeutic window 
(black arrow) of 17.31.  
 
The dose-response curves of the antibacterial and cytotoxic effects of SB023 were 
compared for A-375 and Hs27 cell lines. The area between the ED50 and the LD50 was analysed 
and indicated as a black arrow in figure 46A and B. There was a wider TI for Hs27 (23.17) than 
A-375 (11.95). Generally, if the dose required for the desired effect is high, the higher the exposure 
that is required to drive that effect, and the smaller the TI will be. The United States Food and 
Drug Administration defines narrow TI drugs as medicines that have less than a twofold difference 
in the minimum toxic concentration and minimum effective concentration, and which often 
require blood-level monitoring that is patient-specific.330 An ideal therapeutic index depends on 
the clinical situation but should be several-fold higher than the dose required for efficacy if the 




Figure 46. Therapeutic index of SB023. (A) Comparison of dose-response curves of 
Pseudomonas aeruginosa PAO1 inhibition in M9 acetate (turquoise) and toxicity towards Hs27 normal 
human fibroblasts (red) indicates a narrow therapeutic window (black arrow) of 23.17. (B) 
Comparison of dose-response curves of P. aeruginosa PAO1 inhibition in M9 acetate (turquoise) 
and toxicity towards A-375 human malignant melanoma (orange) indicates an even narrower 
therapeutic window (black arrow) of 11.95.  
 
Progression of drug candidates that have narrow therapeutic indexes through the 
development process for non-life-threatening indications may be justified to explore a new 
therapeutic mechanism (also known as proof-of-mechanism studies). These studies must use 
limited dose exposure durations and ideally use sensitive biomarkers to monitor target 
modulation.331 Overall, SB002 and SB023 were tested on two normal cell lines and three cancerous 
cell lines for any anti-proliferative and cytotoxic effects. Both SB002 and SB023 exerted low 
cytotoxicity on Hs27, A549, and U937 cells in concentration ranges relevant to therapeutic 
concentrations for the observed bactericidal effects. SB002 is particularly promising in the case of 
Hs27, where it has a therapeutic index of 93.73. SB023 additionally exhibited low toxicity towards 
A-375 melanoma cells and BALB/c 3T3 Clone A31 mouse embryonic fibroblasts. 2-AP exhibited 
no toxicity.  
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5.7 CYP450 metabolism of hit compounds  
 
The in vitro metabolic clearances of the hit compounds were determined in liver 
microsomes from human and preclinical species during a research secondment in the Drug 
Metabolism and Pharmacokinetics (DMPK) department at Aptuit in Verona, Italy. Cytochrome 
P450s (CYP450) are a family of isoforms concentrated in the liver that play an important role in 
the oxidative metabolism of nearly 60% of all drugs we consume.332 Relevant concentrations of 
test compounds and controls were incubated with human liver microsomes (HLM), rat liver 
microsomes (RLM) and mouse liver microsomes (MLM) to represent theoretical amounts of test 
molecules in the blood not bound to plasma proteins.  
HLM, RLM and MLM were able to metabolise all three compounds (note: SB002 was not 
tested on MLM due to the limited quantity of sample available), see figure 47. The rate of parent 
compound depletion during the microsomal incubation was plotted as the natural log of the 
percentage of analyte remaining versus time and was used to calculate the compounds’ intrinsic 
clearance, predicted hepatic clearance, and predicted in vivo hepatic clearance, see table 40. For 
SB002, 64%, and 51% of the parent compound was remaining at the end of 45-minute incubations 
with HLM and RLM, respectively. For SB023, 62%, 27%, and 30% was remaining after 45 minutes 
with HLM, RLM, and MLM, respectively. For 2-AP, 53%, 85%, and 35% was remaining after 45 
minutes with HLM, RLM, and MLM, respectively (figure 47). By contrast, both positive controls 
were completely cleared at the end of the incubation period in all species, excluding 
dextromorphan incubated with HLM (figure 47A). 
The clearance rates for the test compounds displayed interspecies variation. The values for 
intrinsic clearance (in µL min-1 mg-1) of the hit compounds incubated with HLM were 2-AP > 
SB023 > SB002. Intrinsic clearance values of hits incubated with RLM were SB023 > SB002 > 2-
AP, and in MLM, clearance values were SB023 > 2-AP see table 40. SB002 was metabolised faster 
when incubated with RLM (27.27 µL min-1 mg-1) than with HLM (17.27 µL min-1 mg-1).  
SB023 was metabolised faster when incubated with RLM (53.93 µL min-1 mg-1) and MLM 
(55.88 µL min-1 mg-1) than when incubated with HLM (19.09 µL min-1 mg-1), so SB023 was 
metabolised faster than SB002 by both HLM and RLM. For 2-AP, clearance was highest in MLM 





Figure 47. Metabolic clearance of SB002, SB023 and 2-AP in liver microsomes. All 
compounds were quantified by LC-MS/MS from 45-minute incubations with (A) human liver 
microsomes (B) rat liver microsomes and (C) mouse liver microsomes. The % analyte remaining 
at each time point was calculated by dividing the peak area by the peak area of the LC-MS/MS 
internal standard and % was determined based on the analyte remaining at time 0. % of analyte 
remaining was transformed to the natural log (ln) so that clearance could be derived from the slope 




Table 40. Calculated in vitro and predicted in vivo clearance parameters of hit compounds. 
  Slope R2 
Clint (µL 
min-1 mg-1) 













 SB002 0.009 0.91 17.27 23.31 10.96 80.50 
SB023 0.010 0.96 19.09 25.75 11.48 72.85 
2-AP 0.013 0.95 25.44 34.33 12.91 54.65 
Dex. 0.025 0.97 50.66 68.36 15.89 27.45 







SB002 0.014 0.93 27.27 62.99 36.18 50.99 
SB023 0.027 0.93 53.93 124.58 50.53 25.78 
2-AP 0.003 0.44 6.33 14.63 12.48 219.58 
Dex. 0.106 0.90 211.88 489.44 72.42 6.56 







 SB002 n.d. n.d. n.d. n.d. n.d. n.d. 
SB023 0.028 0.93 55.88 205.40 64.95 24.88 
2-AP 0.028 0.98 48.37 177.78 61.91 28.74 
Dex. 0.071 0.96 143.02 525.60 80.46 9.72 
Ver. 0.087 0.94 175.24 644.00 82.79 7.93 
Abbreviations: 2-AP, 2-amino-4-chloropyridine; Clint, calculated intrinsic clearance in liver 
microsomes; Clh, int, calculated intrinsic hepatic clearance; Clh calculated in vivo hepatic clearance; 
Dex, dextromethorphan; LM, liver microsomes; Ver, verapamil.  
 
The variation in microsomal metabolism carried through to the calculated hepatic and in 
vivo intrinsic clearances, where I considered the effect of scaling intrinsic clearance by average body 
mass and blood flow of each organism, see table 40. From the calculated hepatic clearance and 
blood flow, an extraction ratio was also determined for each compound. All compounds including 
positive controls had extraction ratios >0.70,  which means the compounds are rapidly and wholely 
cleared from the blood by the liver, and their clearance is heavily dependent on the rate of blood 
flow.333  
 
5.8 Evaluating CYP450 inhibition of hit compounds  
 
 Once I established that the hit compounds were CYP450 substrates, I also tested them for 
CYP450 inhibition in human liver microsomes during the same research secondment in Aptuit’s 
DMPK department. CYP450 inhibition points to potential drug-drug interactions that occur when 
a molecule competes with a drug for the same enzyme receptor site. The more potent molecule 
will predominate, resulting in the decreased metabolism of the other. For most drugs, CYP450 
inhibition leads to increased serum levels of their un-metabolised form, increasing the potential 
for toxicity. For drugs whose pharmacological activity requires biotransformation from a pro-drug 
form, inhibition also can lead to decreased drug efficacy.316  
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CYP450 inhibition was determined by quantifying the amounts of the CYP450 probes’ 
products via LC-MS/MS analysis when human liver microsomes were incubated with the test 
compounds, probe compounds, and known inhibitors. The dose-response curves are shown in 
figure 48, and the IC50 values from the dose-response curves are displayed in table 41. SB002, 
SB023 and 2-AP inhibited none of the isozymes, with IC50 values well above the highest 
concentration tested (100 µM). SB002 displayed a slight inhibition of CYP2C19 (figure 48D), with 
a calculated IC50 value of 126.20 µM. By contrast, all positive controls inhibited CYP450s with 
sigmoidal data distributions and with IC50 values in the nanomolar to submicromolar range (table 
41).  
 
Table 41. CYP450 inhibition. Parameters were determined from best nonlinear regressions using 
GraphPad Prism version 7.04. 




IC50 (µM) >100 >100 >100 1.55 ± 1.16 
Hill slope -0.27 ± 0.14 -0.33 ± 0.23 -0.14 ± 0.02 -0.73 ± 0.07 
2C8 
IC50 (µM) >100 >100 >100 2.28 ± 1.14 
Hill slope n.d. n.d. n.d. -1.09 ± 0.14 
2C9 
IC50 (µM) >100 >100 >100 1.47 ± 1.81 
Hill slope n.d. n.d. n.d. -0.38 ± 0.09 
2C19 
IC50 (µM) 126.20 ± 1.10 n.d. n.d. 0.54 ± 1.92 
Hill slope -0.35 ± 0.12 n.d. n.d. -0.57 ± 0.24 
2D6 
IC50 (µM) >100 >100 >100 0.09 ± 1.23 
Hill slope n.d. n.d. n.d. -0.62 ± 0.08 
3A4-
ATR 
IC50 (µM) >100 >100 n.d. 0.03 ± 1.11 
Hill slope n.d. n.d. n.d. -0.83 ± 0.07 
3A4-
NIF 
IC50 (µM) >100 >100 n.d. 0.02 ± 1.29 
Hill slope n.d. -0.22 ± 0.04 n.d. -0.52 ± 0.07 
3A4- 
MDZ 
IC50 (µM) >100 >100 >100 0.02 ± 1.16 
Hill slope n.d.  n.d. n.d. -0.75 ± 0.09 
a Positive controls; 1A2: fluvoxamine; 2C8: quercetin; 2C9: sulfaphenazole; 2C19: ticlopidine; 2D6: 
quinidine; 3A4-ATR, 3A4-NIF, and3A4-MDZ: ketoconazole. 
Abbreviations: 2-AP, 2-amino-4-chloropyridine; ATR, atorvastatin; CYP, cytochrome P450; 
MDZ, midazolam; n.d., not determined; NIF, nifedipine. 
 
The probe for CYP2C19 could not be detected in the first instance during incubations 
with SB023 and 2-AP because the constitutive expression of CYP450 genes fluctuates in the 
human population.315 When we used a new batch of liver microsomes, we detected the probe 
(diclofenac), but due to limited quantity of hit compounds available, we could not repeat the assays 





Figure 48. Dose-response inhibition of CYP450 isozymes. SB002 (blue), SB023 (orange), 2-
amino-4-chloropyridine (teal) and relevant positive controls (black) were tested for their inhibition 
of: (A) CYP1A2 (positive control: fluvoxamine), (B) CYP2C8 (positive control: quercetin), (C) 
CYP2C9 (positive control: sulfaphenazole), (D) CYP2C19 (positive control: ticlopidine), (E) 
CYP2D6 (positive control: quinidine), (F) CYP3A4 binding site 1 (ATR) (positive control: 
ketoconazole), (G) CYP3A4 binding site 2 (NIF) (positive control: ketoconazole), (H) CYP3A4 




Biochemically, the lack of inhibitory activity simply meant that the hit compounds were 
not able to bind irreversibly to any of the CYP450s to inhibit oxidation of the known substrates. 
We know from the previous section that the hit compounds are metabolised by CYP450s, so these 
results indicate the hits did not bind CYP450s with a similar affinity as the known substrates and 
therefore did not offer competitive inhibition. Pharmacologically, however, the absence of 
CYP450 inhibition means that the probability of causing drug-drug interactions is markedly 




The two primary reasons behind the failure of hit to lead candidates in drug discovery and 
development are lacking efficacy and safety profiles.82 This study is the first to report SB002 and 
SB023 in the context of hit to lead optimisation as putative antibacterial compounds for 
Pseudomonas aeruginosa. SB002 and SB023 displayed bactericidal activity towards P. aeruginosa, which 
is congruent with the glyoxylate shunt’s function to protect against oxidative stress. When I 
expanded the pathogen screening, SB023 was not effective against a P. aeruginosa clinical isolate or 
K. pneumoniae, and showed limited inhibition of A. baumannii. This could have to do with the 
difference in the regulation of the glyoxylate shunt in these organisms, or it could be a permeability 
issue. Comparing the genomes between PAO1 and ATCC 27853, the differences are due to the 
accessory genes from prophages and genomic islands that suggest biofilm maturation and 
virulence-related genes in the clinical isolate.335 The YM64 mutant did not show increased 
susceptibility to SB002, yet was more susceptible to SB023, which means that an up-regulation in 
any of the major Mex efflux pumps could decrease the intracellular SB023 concentration. 
SB002 and SB023 also showed variability in their efficacy when carbon sources were 
altered, which could be that off-target effects or a more complex network are behind inhibition. 
A slight inhibitory activity was observed in minimal medium supplemented with propionate, so I 
tested the hits against 2-methylcitrate synthase, one of the enzymes in the 2-methylcitrate pathway 
that allows bacterial growth on C3 sources, like propionate.
326 This experiment confirmed that the 
inhibition of bacterial growth in propionate was partially occurring as a result of direct interaction 
with one of the enzymes in the pathway and that the compounds were displaying a degree of 
promiscuity. The promiscuity could be intrinsic to the compounds’ antibacterial efficiency. 
Antibacterial compounds have been an exception to Lipinski’s RO5 and occupy a unique 
chemical space. They typically deviate from the rules towards higher molecular weights and 
increased polarities, which reflect the requirement to penetrate the outer membranes of Gram-
negative bacteria.149 An analysis of the physicochemical properties of 147 compounds active 
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against Gram-negative bacteria revealed that compared with the average properties of compounds 
in the Comprehensive Medicinal Chemistry (CMC) database, the average MW, H-bond donors, 
and H-bond acceptors of antibacterial agents were higher, while the cLogP was lower.149 The 
calculated physicochemical properties of SB002, SB023 and 2-AP are listed in table 42, along with 
the averages from the study for reference. Approved antibacterial drugs effective against 
Pseudomonas aeruginosa revealed an even narrower physicochemical range, with molecular weights 
below 600 Da and a lipophilicity average well below 0. This is nearly 4-fold more polar than SB002 
and SB023.  
 
Table 42. Comparison of physicochemical properties of hits and antibiotics.  
 CMC Gram- SB002 SB023 2-AP 
MW (g mol-1) 338 414 370.8 361.4 128.6 
cLogP octanol/water 2.7 -0.1 3.7 3.0 1.1 
H-bond donors 1.6 5.1 2 2 1 
H-bond acceptors 4.9 9.4 5 6 2 
Properties were calculated using ChemBioDraw Ultra 13.0 (PerkinElmer). CMC and Gram-
negative properties were obtained from O’Shea, 2008.149 
Abbreviations: 2-AP, 2-amino-4-chloropyridine; CMC, Comprehensive Medicinal Chemistry 
database; Gram-, Gram-negative antibiotics; H-bond, hydrogen bond; cLogP, calculated partition 
coefficient; MW, molecular weight. 
 
The likelihood of binding to multiple targets doubles above the value of  
cLogP = 3.75.297,336 Lipophilicity represents the molecular desolvation when transferring from 
aqueous phases to cell membranes and protein sites, which are hydrophobic in nature.297 
Promiscuity is the number of hits where >30% inhibition was found at a concentration of 10 µM, 
and promiscuity is controlled by lipophilicity and ionisation state of the drug.297  
It is important to understand the pharmacophore of the hit compounds for medicinal 
chemistry optimisation, which is a crucial step in hit to lead optimisation. The structure-activity 
relationships of the hit compounds are not yet confirmed by co-crystal structures with the target 
enzymes, but were rationally discussed in chapter 4. 2-AP showed no target nor whole-cell 
inhibition in these studies, meaning the guanidine moiety and/or the Boc protecting groups most 
likely are important for binding to the target enzymes as well as getting through P. aeruginosa’s outer 
membrane. Although rare, there are instances of approved drugs containing a guanidine moiety, 
including the aminoglycoside, streptomycin.337 Despite this rarity, there are several examples in the 
literature of guanidine-containing compounds that exhibit antibacterial activity.301,327,338–341 Indeed, 
six out of the eight hits from Pfizer’s P. aeruginosa whole-cell screening campaign contained 
guanidine groups.194 Another example is a rational approach to improve aminoglycoside antibiotics 
conducted by modifying the chemical scaffold and replacing the amine or hydroxy groups with 
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guanidine groups. This resulted in guanidine-modified amikacin with improved affinity and a lower 
MIC for P. aeruginosa.342 In 2018, a patent was filed for a guanidine-derivative that displayed potent 
inhibition against P. aeruginosa and low toxicity to A-549 lung epithelial cells.300 Another example is 
the muraymycin compounds, which have a lipophilic side chain and a guanidine group that are 
required to inhibit the peptidoglycan biosynthesis pathway in P. aeruginosa.343   
Most of the biological properties of guanidine derivatives are related to their strong basicity 
in water with a pKa of 13.8.344 Under physiological conditions, the guanidine group exists mainly 
in its protonated form, which may allow for interaction with the target enzymes.345 Another option 
is that it could be responsible for binding to the bacterial outer membrane on the negatively-
charged polysaccharide layer, causing cell death.346 The electron-withdrawing groups present in the 
hit compounds might enhance guanidine’s binding activity with phosphate and sulphate groups 
present on the cell membrane through charge pairing and hydrogen bonds.347 
Despite the successful performance of the compounds overall, there were issues with 
chemical stability during this study. I observed a total loss of antibacterial activity on a degraded 
sample of SB002. Removal of the Boc protecting groups was most likely responsible for the loss 
of activity and most likely occurred by protonation from the residual water present in DMSO (a 
hygroscopic solvent), which was accelerated by heat during my attempts to improve compound 
solubility (personal communication with Dr Sean Bartlett). In fact, it has been published that Boc 
protecting groups can be removed using H2O and a microwave (170°C) in 2-3 minutes.
348 It is a 
requirement of drugs, in general, to remain stable for prolonged periods due to administration 
requirements based on the dosing window,321 so this is a major drawback when considering the 
potential of SB002 and SB023 as antibacterial lead compounds. 
The next stage in hit to lead optimisation is to improve upon the medicinal chemistry of 
the hits. An obvious chemical modification to perform on SB002 and SB023 is to replace the Boc 
protecting groups with a functional group that behaves similarly either chemically or sterically. 
Possible chemical shape modifications are being explored using in silico methods by Prashanthi 
Medarametla from the University of Eastern Finland. She is currently conducting a shape screening 
study on my MSPa crystal structure (PDB entry 5AOS), which is a virtual screening methodology 
that considers the shape and steric chemistry of a molecule, which could be important depending 
on the shape and amino acids in the binding pocket of interest.349 
The other requirement for a lead candidate is safety. Lipinski’s RO5 are meant to be 
guidelines based on successful lead candidates that reach Phase II in the drug development pipeline 
and display good murine bioavailability. By definition, RO5-compliant lead candidates have already 
passed rigorous toxicology and clinical safety hurdles.296 This was promising as SB002 and SB023 
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were RO5-compliant. SB002 and SB023 did not exhibit profound cytotoxicity towards any of the 
mammalian cells I tested, but compared side-by-side with the antibacterial dose-response curves, 
revealed a narrow potential therapeutic range (<100), according to preclinical development 
standards.331 
There are approved antibiotics with narrow TIs that require patient monitoring when 
administered, including the aminoglycosides, gentamicin and amikacin, or the lipopeptide, 
vancomycin, as well as polymyxin B.350 This indicates that the candidate’s safety is considered on 
a case by case basis when there is a clear efficacy with drug-like, physicochemical properties.  
SB002 and SB023 were metabolised by CYP450s in human liver microsomes with 
moderate half-lives of 81 and 72 minutes, respectively. The results indicate that SB002 and SB023 
are direct substrates of CYP450 isozymes. Analysing in vitro metabolic clearance does not indicate 
which isozyme is responsible for the compound’s metabolism; however, the clearance rates 
themselves and the in vivo considerations are important for progressing in the drug development 
pipeline. The in vivo predictions should be approached with caution, though, because whenever 
pooled liver microsomal activities are measured, the assumption is that every enzyme represents 
the average population’s activity.351 I observed differences in hit compounds’ metabolism between 
HLM and RLM/MLM, which gives insight into future in vivo work, specifically that using murine 
models as pharmacokinetic/pharmacodynamic representations for human models might not be 
accurate.315  
2-AP itself is a chemical fragment of SB002 and SB023, and CYP450-mediated N-
hydroxylation of the primary amine in the ortho position would theoretically be more stable and 
therefore slower to metabolise than its meta or para counterparts. Slower metabolism is linked to 
increased accrual in the liver and likely increases the chances for toxicity in vivo.352 2-AP is a 
precursor for the manufacture of a select few drugs on the market, including Sulphapyridine, a 
sulphonamide antibiotic that is no longer prescribed for human treatment due to bacterial 
resistance.353 The hit compounds are metabolised by CYP450s in liver microsomes but do not 
inhibit CYP450s compared with known inhibitors. This is a routine test for in vitro DMPK studies 
and is indicative of potential drug-drug interactions.  
Despite the advantages, in vitro models have an important downside in that the host 
immune system is ignored during antibacterial evaluation. For instance, in an in vitro 
pharmacodynamic study, ticarcillin performed better at reducing log CFU of Pseudomonas aeruginosa 
than in a murine thigh infection model.354 In animal models, the action and efficacy of the drug 
can be evaluated at the place of infection, and the reaction of the immune system can be 
monitored, which delivers more precise results, provided a realistic human pharmacokinetic profile 
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is present. Free drug concentrations need to sometimes remain above the MIC level for this type 
of assessment, which is why assessing cytotoxicity is so important.355 
Overall, SB002 and SB023 display promise as potential lead candidates for antibacterial 
development. Further work will involve chemical optimisation, as well as testing a range of doses 
for in vivo pharmacodynamics in preclinical species. The methodology required in moving from hit 
to lead candidate selection depends on the screening technology used to identify the hit 
compounds. Hit evolution is a technique for hit optimisation where analogues of the original hits 
are synthesised and tested for potency or an improved lead-like profile. Structure-activity 
relationship (SAR) studies are then used for chemical optimisation and lead selection.313 The work 
presented here provides data for proof-of-principle studies, but there will be a substantial challenge 






The adaptation of Pseudomonas aeruginosa to its environment is responsible for a significant 
proportion of hospital-acquired infections worldwide. These infections are notoriously difficult to 
treat because they often exhibit resistance to one or more antibiotics. Despite the critical need for 
new antibiotics to mitigate these hospital-acquired infections, the pharmaceutical industry has 
struggled to replace antibiotics as they inevitably become obsolete due to antibiotic resistance. P. 
aeruginosa can thrive in diverse infection scenarios by rewiring its central metabolism, and a 
prominent example of this is in the airways of cystic fibrosis patients, where the bacterium uses 
the glyoxylate shunt to metabolise fatty acids (degraded from lung surfactant into acetyl coenzyme 
A) for biomass production.356 It has been proven that without a functional glyoxylate shunt, P. 
aeruginosa is unable to grow on fatty acids or acetate that are the main nutrient sources in the CF 
airways.357 
The glyoxylate shunt has potential as a new antibacterial target in P. aeruginosa. The 
glyoxylate shunt is a part of central metabolism and therefore, conditionally important for the 
bacteria. There is also evidence to support that, besides carbon fixation, the glyoxylate shunt has 
been implicated in virulence and is essential for establishing pulmonary infections in mammalian 
systems. There are no known mammalian orthologues of the glyoxylate shunt, meaning the target 
is selective. Additionally, successfully targeting the glyoxylate shunt could be possibly broad 
spectrum as it is present in many pathogenic bacteria. Finally, the glyoxylate shunt contains two 
enzymes: isocitrate lyase and malate synthase G, which targeting simultaneously could provide an 
antibacterial agent that theoretically delays the development of resistance. Being able to create new 
strategies of antibacterial intervention for P. aeruginosa infections would greatly improve a patient’s 
prognosis.  
Appreciating the conditional importance of the glyoxylate shunt in establishing and 
sustaining P. aeruginosa infection scenarios, the first objective of this study was to characterise the 
second enzyme of the glyoxylate shunt, malate synthase G, from Pseudomonas aeruginosa and assess 
its suitability as a target for drug discovery and development. Recent work has demonstrated the 
tractability of this enzyme as a drug target in other pathogens, but remarkably little has been 
documented about its biochemistry in P. aeruginosa. I overexpressed and purified MSPa and 
determined the first X-ray crystal structure at 1.62 Å resolution. I found that the secondary 
structures were very similar between malate synthases from other pathogens, which led to highly 
similar tertiary structures among pathogenic bacteria as well. 
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 Data derived from a computational analysis of the crystal structure revealed two sites in 
the enzyme that were theoretically promising for binding of drug-like molecules. One site was 
highly hydrophobic and was buried deep in the protein, while the other site was more hydrophilic 
and spanned the entrance of the active site, which contained the amino acids responsible for acetyl 
coenzyme A binding. Another computational analysis mapped the likely physiological hydration 
network within the protein and illustrated the thermodynamic properties of the predicted 
hydration sites. This examination further supported the “druggability” of malate synthase, as it 
elaborated on the energetically favourable and unfavourable hydration sites within the predicted 
drug binding sites. I also found that the events in the enzyme’s active site could be monitored non-
invasively using intrinsic tryptophan fluorescence as a probe. I quantified magnesium binding as a 
co-factor and confirmed its necessity as a co-factor in enzyme catalysis. The structural and 
mechanistic information deriving from this study will support the design of improved inhibitors 
of malate synthase G in P. aeruginosa.  
The second objective of this study was to identify dual inhibitors of the glyoxylate shunt 
in P. aeruginosa. Compounds were synthesised that combined the structural features of a known 
family of π-anion inhibitors of malate synthase G in Mycobacterium tuberculosis, and a 2-aminopyridine 
hit from a high throughput screening campaign against P. aeruginosa grown in acetate. This resulted 
in eight novel 2-aminopyridine derivatives, which I screened for their potential as dual inhibitors 
using enzyme kinetics and bacterial MIC assays. From this investigation, a hit compound was 
confirmed, SB002, which inhibited P. aeruginosa PAO1 growth in acetate medium, as well as 
abolished the enzyme activities of both shunt enzymes with low micromolar potencies. A second 
hit compound emerged from this study; SB023, a cyano derivative of SB002. SB023 inhibited 
PAO1 growth and MSPa activity completely, and which partially inhibited ICLPa activity with MICs 
and IC50 values in the low micromolar range. These experiments confirmed the hypothesis that 
these designed inhibitors were selective and cell-permeable. However, the other 2-aminopyridine 
derivatives underperformed as inhibitors, which did not follow initial predictions that their 
potencies would increase as the electronegativity of their aromatic substitutions increased.  
The precise molecular mechanism of the two hit compounds was not yet clear, but I 
elucidated more information about the mechanism of inhibition upon further kinetic analysis. Both 
SB002 and SB023 displayed mixed inhibition of malate synthase, with a preference towards 
uncompetitive inhibition regarding substrate glyoxylate and competitive inhibition regarding co-
substrate acetyl coenzyme A. SB002 displayed uncompetitive inhibition of isocitrate lyase. I 
validated SB002 as a dual inhibitor using isothermal titration calorimetry, which resulted in 
dissociation constants equal to 28 nM and 1 µM for malate synthase and isocitrate lyase, 
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respectively. ITC also revealed that the thermodynamics driving inhibitor binding was different 
for both shunt enzymes. The favourable energy of binding was strongly driven by entropy for 
malate synthase. While releasing less heat, the binding of SB002 to isocitrate lyase was driven more 
equally by enthalpy and entropy.  
Although I could not obtain co-crystal structures to determine the exact binding poses and 
confirm the structure-activity relationships of the inhibitors, SB002 and SB023, I proposed an 
alternative analysis based on ligand chemistry. The hit compounds contain unique functional 
groups, such as guanidine groups and Boc protecting groups that were not present in the negative 
control, which illustrated that these functional groups were important for binding to the target 
enzymes as well as cellular uptake P. aeruginosa’s outer membrane. Guanidine groups are well 
known for their biological properties. At physiological pH, guanidine exists as a protonated, highly 
stable cation, which allows for many biological interactions, particularly forming hydrogen bonds 
with negatively-charged ions, like the phosphates in the cell’s polysaccharide layer. Despite this 
conjecture, the molecular mechanism by which SB002 and SB023 are interacting with both 
glyoxylate shunt enzymes remains unanswered. This study resulted in the identification of novel 
dual inhibitors of the glyoxylate shunt and highlighted intriguing differences in the mechanisms 
behind their inhibition.  
The final objective of this study was to evaluate the hit compounds to determine their 
potential as lead antibacterial candidates for Pseudomonas aeruginosa infections in the context of the 
pharmaceutical discovery and development pipeline. The first requirement for a successful 
antibacterial candidate is efficacy, so more insight about the antibacterial action of the hit 
compounds was elucidated. SB002 and SB023 exhibited bactericidal activity, which corresponds 
with the notion that the glyoxylate shunt serves to protect against oxidative stress in P. aeruginosa.317  
When I expanded the pathogen screen to include the ESKAPE pathogen panel, SB023 
was not effective against a P. aeruginosa clinical isolate or K. pneumoniae, but did reduce A. baumannii 
and E. coli growth, further expanding its activity spectrum. The incongruity of inhibition among 
these pathogens might be due to the different regulation of the glyoxylate shunt in these organisms, 
which, in turn, affects their expression levels and available binding sites.166 Another possibility for 
reduced activity, particularly in the P. aeruginosa clinical isolate could be decreased permeability 
derived from increased efflux pump expression or decreased porin expression. A mutant of P. 
aeruginosa deficient in the genes encoding the four major Mex multidrug efflux pumps did not show 
increased susceptibility to SB002, yet was more susceptible to SB023, which means that SB023 is 
a likely substrate for one of these efflux pumps. Up-regulation of any of the efflux pumps could 
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rapidly decrease the intracellular SB023 concentrations and reduce its efficacy, which is an 
important consideration if the compound were to progress in its current chemical form. 
SB002 and SB023 also showed variability in their antibacterial efficacies when I altered the 
carbon sources in the growth media. This indicated that off-target effects were present, or that a 
more complex network was responsible for the inhibition. For example, inhibitory activity was 
observed in medium supplemented with propionate for both compounds, so I tested the hits on 
2-methylcitrate synthase, which is one of the enzymes in the 2-methylcitrate pathway that allows 
bacterial growth on propionate. I tested on 2-methylcitrate synthase to confirm that the inhibition 
was occurring as a result of direct interaction with the enzymes in the pathway. SB002 displayed 
promiscuity by partially inhibiting 2-methylcitrate synthase, but it seemed that the promiscuity was 
intrinsic to the compounds’ therapeutic efficiency as SB002 consistently performed better than 
SB023. 
The other requirement for a lead candidate is that it must be safe for eukaryotic cells. From 
the cytotoxicity evaluation, SB002 and SB023 did not exhibit cytotoxicity towards any of the 
mammalian cells, but when the toxicity data were compared side-by-side with the antibacterial 
dose-response curves, they revealed a relatively narrow potential therapeutic range according to 
preclinical development standards. There are approved antibiotics with narrow therapeutic indices, 
which indicates that safety is considered as a case by case basis when the compounds exhibit clear 
efficacy.  
SB002 and SB023 were metabolised by CYP450s in human liver microsomes with 
moderate half-lives of 81 and 72 minutes, respectively. These results indicated that SB002 and 
SB023 were direct substrates of CYP450 isozymes. The hit compounds also exhibited no 
irreversible inhibition of CYP450s compared with known inhibitors, which decreases the 
likelihood of drug-drug interactions in the future. The hepatic clearance rates and the in vivo 
extrapolations are important considerations for progressing in the drug development pipeline 
before subjecting the hit compounds to in vivo efficacy testing. I also observed differences in the 
hit compounds’ metabolism between human liver microsomes and the liver microsomes of 
preclinical species, which gives insight into how the inhibitors might behave in future in vivo work. 
Specifically, using murine models as pharmacokinetic/pharmacodynamic representations for 
human models might not be totally accurate.  
Consequently, the hit compounds performed successfully in the in vitro efficacy and safety 
assessments. Despite this success, there were issues with chemical stability during this study. I 
observed a total loss of antibacterial activity on a degraded sample of SB002. Removal of the Boc 
protecting groups through protonation from residual water present in DMSO, especially in the 
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presence of heat, is what most likely occurred. Evidence of stability issues leads into the next stage 
in the hit to lead optimisation, which is to improve upon the medicinal chemistry of the hits. An 
obvious chemical modification to perform on SB002 and SB023 is to replace the Boc protecting 
groups with a functional group that either interacts similarly, chemically or sterically.  
Overall, this work provided a proof of concept for the glyoxylate shunt as a target for 
antibacterial intervention in Pseudomonas aeruginosa. MSPa was biochemically characterised and 
delivered structural and mechanistic information that will support the design of MS inhibitors in 
the future. SB002 and SB023 were identified and validated as selective and cell-permeable 
inhibitors of the glyoxylate shunt in Pseudomonas aeruginosa, and both hit compounds displayed 
promise in in vitro safety and efficacy analyses. Continuing work should endeavour to chemically 
optimise the compounds to improve their stability, solubility, and to define structure-activity 
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Appendix 1: Extracted information from MSPa PDB deposition 
 The percentile ranks, Ramachandran plot, Polygon chart, and data collection and 






Table 43. Summary of data collection and refinement statistics for MSPa. 
Data Collectionα 
X-ray source DLS MX-I03 
wavelength (Å) 0.97625 
resolution range (Å) 71.17-1.62 
# total reflections 556009 (9988) 
# unique reflections 96326 (3151) 
multiplicity 5.8 (3.2) 
completeness (%) 94.5 (69.9) 
mean I/σ(I) 11.75 (1.47) 
Rsym 0.066 (0.912) 
Rmeas 0.079 (1.080) 
CC1/2 1 (0.5) 
space group  P212121 
unit cell 
 a (Å) 71.17 
 b (Å) 81.20 
 c (Å) 137.57 
α = β = γ (°) 90 
# molecules per asymmetric unit 1 
Refinement 
Rwork (%) 16.7 
Rfree (%) 19.6 







bond lengths (Å)  0.0008 
bond angles (°)  0.897 
Wilson B factor (Å2) 19.6 








Ramachandran analysis   
favoured (%) 98 
allowed (%) 12 
outliers (%) 0.1 
rotamer outliers (%) 0.3 
MolProbity Clashscore 5 
PDB entry 5OAS 




Appendix 2: Thermodynamic parameters of MSPa from WaterMap. 
 
Table 44. Full thermodynamic parameters of hydration sites from WaterMap. WaterMap 
hydration sites and thermodynamic parameters for the water molecules shown in figure 18B and 
C: enthalpy (H), entropy (-TS) and Gibbs free energy (G). 
 
Site number ΔH -TΔS ΔG 
8 -25.40 5.94 -19.46 
82 0.68 4.05 4.73 
135 0.60 3.38 3.98 
140 -0.91 3.47 2.56 
156 -4.42 3.39 -1.03 
218 1.62 2.85 4.47 
406 1.19 2.53 3.72 
407 3.35 2.40 5.75 
568 0.35 2.00 2.35 
736 -1.23 1.53 0.30 
832 -0.40 1.35 0.95 
1039 -3.50 1.47 -2.03 
1092 0.59 1.04 1.63 
1279 5.75 1.09 6.84 
1286 5.40 1.14 6.54 
1434 4.34 0.88 5.22 





Appendix 3: ICLPa purification and activity. 
 
Analysis after purification of His6-tagged ICL indicates that it corresponds to the estimate 
molecular mass (59 kDa) compared with the molecular mass ladder. Kinetic analysis of purified 
ICL revealed that 1) the protein was enzymatically active and 2) that it behaved as a Michaelis-









Appendix 4: NMR spectra of SB002. 
 
The Department of Chemistry NMR service analysed a sample of SB002 (40mM) for signs 
of chemical degradation. SB002 was previously dissolved in DMSO and was vortexed and heated 
(60°C) to increase solubility. Stocks were then kept at -20°C. The DMSO caused solvent 
swamping, as the hydrogens in DMSO influenced the NMR signal in the 1-3 ppm region, which 
is just where the hydrogen atoms in the methyl groups on the Boc groups would appear. The 
bottom graph illustrates the intensity of the chemical shifts over time, indicating that the chemical 
structure did not change after 48 hours at 25°C. It had already degraded, as indicated by the loss 
of antibacterial activity. 
 
 
